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Abstract 
Human papillomaviruses (HPVs) are present in 99.7% of all cervical cancers and HPV type 16 
(HPV-16) is the major cause of cervical cancer. Expression of the viral capsid gene L1 and L2 
can be detected only in the terminally epithelial cells and we speculate that inhibition of HPV-16 
late gene expression in the early stage of the life cycle is probably a prerequisite for persistence 
of infection. The products of the late genes, L1 and L2, are highly immunogenic and expression 
of these proteins in the lower layers of the cervical epithelium could lead to clearance of the 
virus. Therefore, it is of interest to understand how HPV late gene expression is regulated. The 
goal of this thesis was to examine the regulation of late genes in HPV-16. To this end we wished 
to generate reporter plasmids based on the HPV-16 genome with the L1 gene replaced by an 
easily measurable reporter gene, such as chloramphenicol acetyltransferase (CAT), green 
fluorescent protein (GFP), secreted alkaline phosphatase (SEAP) or luciferase, and to establish 
reporter stable cell lines useful for large scale screening of small molecules or cellular factors 
that influence RNA processing events during late gene expression. CAT and GFP proved to be 
functional surrogate markers of late gene expression and their expression was dependent on the 
levels of known inducers of HPV-16 late gene expression such as adenovirus E4orf4 protein 
(E4orf4), polypyrimidine tract binding protein (PTB), arginine/serine-rich SRp30c protein 
(SRp30c) or alternative splicing factor/splicing factor 2 (ASF/SF2). Functional stable cell lines 
with CAT reporter plasmids, separately integrated into the HeLa cellular genome, were also 
generated allowing the identification of a number of small molecules capable of modulating 
CAT expression. Phorbol 12-myristate 13-acetate (TPA), valproic acid and tannic acid were 
identified as inducers of HPV-16 late gene expression. Further experiments identified the TPA-
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inducible, hnRNP A2/B1 protein as a novel regulator of HPV-16 late gene expression. 
Immunohistochemical analysis of this protein in cervical epithelium at the different stages of the 
development of cervical cancer demonstrated that hnRNP A2/B1 is highly expressed in normal 
cervical epithelium and low-grade squamous intraepithelial lesion (LSIL) and decreased in high-
grade squamous intraepithelial lesion (HSIL) and squamous cell carcinoma (SCC). In 
conclusion, the HPV-16 reporter plasmids and reporter cell lines described herein are functional 
and can be used for the investigations of HPV-16 late gene expression. 
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1. Chapter 1 - Introduction 
 
1.1 Viruses 
A virus is a microscopic particle consisting of a core of nucleic acid, DNA or RNA, surrounded 
by a protein shell called a capsid; some viruses have an envelope of lipids that surrounds the 
protein coat when they are outside a cell. Viruses are typically not considered living organisms 
because they are unable to replicate without a host cell, but inside of a living cell are capable of 
taking over the cells metabolic machinery for the production of new virus particles called 
virions. Viruses are the most abundant biological entities that exist in nature and generally are 
classified by the organisms they infect (animals, plants, or bacteria) (Suttle, 2007). They are 
responsible for many diseases with different symptoms. 
The first viral agent to be discovered was the tobacco mosaic virus in 1892 by Dmitry Iosifovich 
Ivanovsky while he was investigating a disease affecting tobacco (Levine, 2001). He 
demonstrated that this virus is capable of permeating filters that restrain bacteria. These particles 
were only classified definitively as viruses by Martinus Willem Beijerinck in 1898. He 
demonstrated that the tobacco mosaic was caused by an infective agent much smaller than 
bacteria (Levine, 2001). Most viruses are about one hundred times smaller than bacteria.  
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1.2 Papillomavirus 
Papillomaviruses are small, non-enveloped DNA viruses that belong to the Papillomaviridae 
family (Bernard, 2005). A papillomavirus (PV) was first described as the responsible agent for 
papillomas in the cotton-tail rabbit by Richard Scope in 1933 (Lowy & Howley, 2001). Despite 
the lack of an appropriate cell-culture system, papillomaviruses continued to be studied 
intensively. 
They are ubiquitous and can infect many mammals, including humans, and are absolutely 
species-specific. Papillomaviruses are epitheliotropic viruses with a predilection for infection of 
either cutaneous or internal squamous mucosal surfaces. Approximately 130 papillomavirus 
types have been completely described so far (Bernard, 2005) and among all the papillomaviruses 
the most studied is the Human Papillomavirus (HPV). The 130 HPV types are subdivided in 5 
groups distinguished by a letter of the Greek alphabet: Alpha, Beta, Gamma, Mu and Nu (Fig. 
1.1) (Bernard, 2005). The largest group of HPVs, containing approximately 60 members, 
comprises the Alpha papillomavirus, which infect the genital/mucosal area. HPV types from the 
Beta, Gamma, Mu and Nu groups primarily infect cutaneous surfaces (Doorbar, 2006). The 
Alpha papillomaviruses can be classified as high-risk, low-risk and cutaneous types depending 
on the frequency they cause cervical cancer (Table 1.1). The cutaneous viruses, such as HPV-2, 
cause common warts and very rarely cause cancer (Tate, 2004). The low-risk types can cause 
genital HPV infections, which are believed to be the most common sexually transmitted viral 
infection in many countries. Low-risk HPVs, such as HPV-11, are very seldom associated with 
cancer (de Villiers et al., 2004). The high-risk type can lead to cancers of the cervix, vulva, 
vagina, anus, oesophagus (Collins et al., 2005) and larynx (Tsutsumi et al., 1993) in women or 
less common cancers of the anus and penis in men. HPV infections are widely spread and in fact 
 13 
more than the 70% of women are infected by the virus during their lifetime. HPV-16 is the most 
common high-risk type and is present in approximately 50% of all cervical cancers (Munoz et 
al., 2003). 
 
 
Figure 1.1 Human papillomavirus family tree 
HPVs are subdivided into five evolutionary groups. The Alpha group infects the cervix. HPV 
types from the Beta, Gamma, Mu and Nu groups primarily infect cutaneous sites (Doorbar, 
2006). 
  
 
 
 14 
 
Risk group HPV types 
High-risk                                16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73 and 82   
Low-risk 6, 11, 42, 43, 44, 55, 81, 83 
Cutaneous 3, 7, 10, 28, 29, 40, 43, 77, 78, 91, 94 
 
Table 1.1 Risk groups of αHPV types (risk relates to the risk of developing cervical cancer). 
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1.3 HPVs and Cervical cancer 
Cervical cancer remains the second most common malignancy and second most common cause 
of cancer-related death in women worldwide (Fig. 1.2) (WHO, 2006). 
 
 
 
 
Figure 1.2 Cervical cancer incidence worldwide 
Incidence of cervical cancer and deaths related to cervical cancer in the developed and 
developing world. The pie charts are colour-coded according to relative prevalence. (N.J. 
Maitland, modified from IARC website (www.iarc.fr)). 
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Most recent estimates suggest that each year there are more than 500,000 new cases of cervical 
cancer and over 250,000 deaths from the disease (Wheeler, 2007). 
The most important risk factor in the development of cervical cancer is a persistent infection 
with a high-risk strain of human papillomavirus, in fact high-risk HPV strains are responsible for 
more than 99.7% of cervical cancer worldwide (Walboomers et al., 1999). Most cases of cervical 
cancer are attributable to sexually acquired HPV infection (Bosch et al., 2002).  
HPVs infections are normally cleared within 12-18 months after infection, but high-risk types 
may persist in the infected host and lead to cancer (Baseman & Koutsky, 2005) (Fig. 1.3). The 
interval between the acquisition of HPV infection and malignant progression usually takes at 
least 10 years and is frequently longer (Snijders et al., 2006).  
 
 
 
 
Figure 1.3 The major steps in cervical carcinogenesis 
HPV infection followed by clearance by the immune system or progression to precancer and 
invasion. (Schiffman & Kjaer, 2003). 
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Cervical cancer arises from non invasive pre-malignant lesions known as cervical intraepithelial 
neoplasias (CINs). These lesions are divided into three groups that represent the different stages: 
CIN 1 for mild dysplasia; CIN 2 for moderate dysplasia and CIN 3 for both severe dysplasia and 
carcinoma in situ (Fig. 1.4). CIN lesions are also graded as low-grade squamous intraepithelial 
lesion (LSIL) or high-grade squamous intraepithelial lesion (HSIL) (Fig. 1.4). LSIL is the 
indication of mild cervical dysplasia seen on Papanicolaou (Pap) cytology testing and generally 
corresponds to the histological classification of CIN 1, whereas HSIL indicates moderately to 
severely abnormal-appearing cells on a Pap smear and corresponds to the histological 
classification of CIN 2 or 3 (Fig. 1.4). CIN lesions can be detected by screening programs before 
cancer develops. In developed countries, regular cervical cancer screening with Pap and HPV 
tests have been shown to decrease the incidence of cervical cancer by 70% (Kitchner et al., 
2006). In less-developed countries, where sufficient resources for high-quality cervical cancer 
screening are not available, the risk of developing cervical cancer from CIN 3 is estimated to be 
80% (Wright et al., 2002). The recent introduction of a vaccine against HPVs is an important 
development in the fight against cervical cancer. Early studies show that HPV vaccination, 
recommended for young women and men between 9-26 years old, not exposed to HPV prior to 
immunization, has the potential to significantly reduce the rate of cervical cancer worldwide and 
the burden of precancerous cervical lesions in women (Paavonen, 2009). Gardasil (CDC, 2010; 
Lowy & Schiller, 2006; NCI, 2011) and Cervarix (Hitti, 2006; Kresge, 2006) are the vaccines 
currently available, which prevent cervical dysplasia from the HPV types 16, 18, 6 and 11 and 
types 16 and 18, respectively. This effect has lasted 6 years after vaccination for Gardasil and 
more than 8 years for Cervarix (Harper et al., 2008). To date, it seems that booster vaccines will 
not be necessary (Committee opinion no. 467, 2010). Both vaccines are subunit virus-like 
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particle (VLP) vaccines composed of the viral L1 protein, which is the major structural protein of 
the virus and includes the immunodominant neutralization epitopes of the virus. When expressed 
in eukaryotic cells, L1 is capable of self-assembly into VLPs (Kirnbauer et al., 1993) that can 
induce high levels of neutralizing antibodies (Roden, 1996; Rose et al., 1994). 
 
 
 
Figure 1.4 Representation of cervix epithelium pre- and post-infection 
Normal cervix and different grade of squamous intraepithelial lesions: low-grade squamous 
intraepithelial lesion (LSIL) and high-grade squamous intraepithelial lesion (HSIL); a small 
percentage of cases progresses to cervical cancer that, if left untreated, will invade surrounding 
tissues. The histology grade of cervical intraepithelial neoplasia is also shown: CIN 1 for mild 
dysplasia; CIN 2 for moderate dysplasia and CIN 3 for both severe dysplasia and carcinoma in 
situ (Ciaran et al., 2007). 
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1.4 The cervix 
The cervix is the cylindrical lower portion of the uterus that protrudes into the vagina (Junqueira 
& Carneiro, 2005) (Fig. 1.5). Two narrow openings are present in the cervix called the internal 
and external os. The internal os is located on the topmost portion of the cervix and opens into the 
uterus (Stevens & Lowe, 2005). The external os is located at the minor portion of the cervix and 
opens into the vagina (Ross & Pawlina, 2006). The passageway between the external os and the 
uterine cavity is called endocervical canal or canal of the cervix which can change in width and 
length. The cervix is divided in endocervix, the portion proximal to the uterus and ectocervix 
proximal to the vagina. The endocervix has a fusiform shape and is composed of a single layer of 
mucous-secreting simple columnar epithelium. The ectocervix has a convex, elliptical surface 
and is composed of nonkeratinized stratified squamous epithelium (Arends et al., 1998) which 
comprises diverse layers: basal, parabasal, intermediate and superficial. The basal layer is 
composed of a single row of cylindrical cells where mitosis takes place. Above the basal cell 
layer lie the parabasal and intermediate layers which together constitute the prickle cell layer. 
The superficial layer is made up of the most mature cells and varies in thickness, depending on 
the degree of estrogen stimulation (Fig. 1.6). The portion adjacent to the edge of the endocervix 
and ectocervix is known as the transformation zone (TZ) (Ross & Pawlina, 2006), or squamo-
columnar junction (Stevens & Lowe, 2005), in which columnar epithelium is converted to 
squamous epithelium by a process called squamous metaplasia. The TZ is the area where most 
abnormal change occurs and is susceptible to carcinogens and diseases.  
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Figure 1.5 The uterus 
Diagram of the uterus indicating location of the cervix, the internal and external os and the 
cervical canal (from Martini & Bartholomew, 2007).  
 
 
superficial layer
intermediate layer
parabasal layer
basal layer
connetive tissue  
Figure 1.6 Structure of the ectocervix 
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1.5 HPV life cycle 
HPVs infect primitive basal keratinocytes (Lowy & Howley, 2001) through micro-wounds that 
expose the cells to the incoming viruses (Doorbar, 2005). The HPV-16 viral life cycle is strictly 
linked to the differentiation of these cells (Fig. 1.7). The virus enters the cell by binding to 
different receptors on the surface of the cell (Evander et al., 1997; Giroglou et al., 2001; Joyce et 
al., 1999). Glycosaminoglycans (GAGs), especially heparan sulphate, have been suggested as 
initial attachments receptors for HPV VLPs (Drobni et al., 2003; Joyce et al., 1999). Another 
candidate receptor for HPV, laminin-5 in the extracellular matrix (ECM) has been suggested 
(Culp et al., 2006a; Selinka et al., 2007), with an affinity even higher than heparan sulfate; 
however infectious transfer from the ECM seems to also require heparan sulfate binding (Culp et 
al., 2006b; Giroglou et al., 2001; Selinka et al., 2007). A second receptor, α6-integrin, has been 
shown to be involved in HPV infection, but its role is rather controversial (Culp et al., 2006b; 
Sapp & Day, 2009). Once the virus has entered the basal epithelial cells and migrated to the 
nucleus, the viral genome starts its replication producing approximately 50-100 episomes of viral 
DNA per cell (Stunberauch & Laimins, 1999). At this stage only low levels of the early E1 and 
E2 genes are expressed, along with the early oncogenes E6 and E7, whereas expression of the 
late genes is suppressed.  
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Figure 1.7 Representation of the different layers in the epithelium and HPV gene 
expression in infected cells 
The different cell layers present in the epithelium are indicated on the left. HPVs infect the basal 
cell layer of the squamous epithelium through micro-wounds and its replication is dependent on 
a differentiating epithelium. Infection results in expression of the early viral proteins, E6 and E7, 
in the lower and upper epithelial layers.  Late genes are expressed only in the upper layers of the 
epithelium.  
 
 
 
When the infected basal epithelial cell replicates into two daughter cells the viral DNA is divided 
between them. One of the daughter cells migrates to the suprabasal layers and undergoes 
differentiation, whereas the other remains in the basal layer to continue proliferating 
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(Stunberauch & Laimins, 1999). Once the cell migrates to the upper layers, the viral DNA 
replicates to several thousand copies and the late promoter is activated inducing expression of the 
late genes L1 and L2, which encode for the capsid proteins. At this stage the viral genomic DNA 
is packaged into capsids in the nucleus and the newly formed viruses are released as the 
superficial layers of the epithelia are sloughed off (Doorbar, 2005). 
 
 
1.6 The HPV genome 
The HPV genome is a double stranded, circular DNA, 7904 base pairs (bp) in size, with all genes 
located on the same strand (Lowy & Howley, 2001). It can be divided into three domains: a long 
control region (LCR), an early and a late region (Fig. 1.8 A and B). The early and late gene 
regions are both protein-encoding whereas the LCR is a non-encoding sequence (Park et al., 
1995). The LCR is approximately 800-1000 base pairs (bp) long, located adjacent to the E6 ORF 
and it contains many cis-regulatory elements necessary for viral transcription and replication 
(Turek, 1994). The early region is approximately 4 Kb in size and contains six open reading 
frames (ORFs), E6, E7, E1, E2, E4 and E5; however it has been shown that HPV-31 contains 
also an E8 ORF (Stubenrauch et al., 2000). The late region is approximately 3 Kb and contains 
L1 and L2 genes which encode two capsid proteins, the L1 major capsid protein, and L2, the 
minor capsid protein. 
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Fig 1.8 Genomic organisation of HPV-16 
(A) The HPV-16 genome circular, double stranded (Burk et al., 2009). (B) Linear representation 
of the HPV-16 genome. The early and late viral promoters, p97 and p670, and the early and late 
polyadenylation signals pAE and pAL are shown. Boxes indicate protein-coding regions: E 
represents the early genes and L represents the late genes. The long control region (LCR) is also 
indicated. Black circles indicate splice donors (5’ splice sites) and white circles indicate splice 
acceptor (3’ splice sites). Numbers refer to nucleotide positions in the HPV-16 sequence. 
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Expression of L1 and L2 is detected only in the upper layers of the epithelium (Zheng & Baker, 
2006). Two major promoters are present on the HPV genome; one early promoter (p97) located 
upstream of the E6 coding region, which drives expression of the early genes and a late promoter 
(p670) located on the E7 coding region, which drives expression of the late genes (Howley & 
Lowy, 2001; Longworth & Laiminis, 2004). The late promoter is activated only in the 
differentiating part of the epithelium (Cumming et al., 2003). The genome also contains two 
polyadenylation signals: the early polyadenylation signal (pAE) that is located between the early 
and late region and the late polyadenylate signal (pAL) located in the late region (Zheng & 
Baker, 2006; Schwartz et al., 2007). All early mRNAs are polyadenylated at the pAE, and the 
late mRNAs can be polyadenylated at the pAE or pAL (Fig. 1.8). 
 
1.6.1 E1 and E2 proteins 
E1 and E2 have a pivotal role in viral replication. The E1 gene product is a 68 kilodalton (kDa) 
nuclear protein, highly conserved among papillomaviruses. E1 is expressed at very low levels 
and has been shown to bind to the viral Ori, located in the proximal end of the LCR. The affinity 
of this binding is very weak and in order to be efficiently increased requires the presence of E2 
(Dixon et al., 2000; Frattini & Laimins, 1994). E2 associates with E1 primarily through its N-
terminus and binds to DNA as a dimer through its C-terminus (Moscufo et al., 1999; Sarafi & 
McBride, 1995). The complex E1-E2 binds to DNA with high affinity and can unwind the DNA. 
It also been shown that E1 forms a specific protein complex with the catalytic p180 subunit of 
DNA polymerase-α to activate DNA replication (Liu et al., 1995). 
The E2 protein is approximately 48 kDa and also has functions in transcriptional regulation 
(Longworth & Laiminis, 2004). In the undifferentiated cells, the E2 protein acts at low 
 26 
concentration as a viral transcriptional trans-activator to stimulate transcription whereas at high 
levels it acts as a repressor by interfering the binding of transcriptional factors such as Sp1 and 
TFIID to their recognition sequences (Longworth & Laiminis, 2004). In differentiated cells, 
when the late promoter is activated the E2 repressive function of transcription is arrested, 
resulting in a rapid increase in the level of E1 and E2 expression (Hebner & Laiminis, 2006). 
During the integration of the viral genome into chromosomes the E2 gene is broken and has been 
observed that the loss of E2 expression contributes to the progression from low-grade to high-
grade cervical neoplasia (Schneider-Maunoury et al., 1987).  
 
 
1.6.2 E4 and E5 proteins 
The E4 ORF does not contain the AUG start codon and so the E4 protein is formed by a single 
splice from E1 ORF to E4 ORF, indicated as E1^E4 protein. The full length of this fusion protein 
is 17 kDa and contains the first 5 amino acids of the E1 ORF and the last 85 amino acids of the 
E4 ORF (Doorbar et al., 1986). It is abundantly expressed in all different stages during epithelial 
cell differentiation and is distributed primarily in the cytoplasm. It has been shown that E4 
proteins are associated with the keratin cytoskeleton, causing the collapse of the cytokeratin. 
This suggests that E4 protein may allow virion particles to exit the cell. 
The E5 proteins of human papillomaviruses are small hydrophobic proteins that are expressed in 
the early and late stages of the viral life cycle; however, their role in HPV pathogenesis is not 
clearly understood. It is about 5 kDa in size and is localized predominantly in the endoplasmic 
reticulum and Golgi apparatus, but is also present in the plasma membrane (McMurray et al., 
2001). HPV E5 is known to interact with growth factor receptors and gap junction proteins and is 
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believed to play a role during the initiation of neoplasia (Leechanachai et al., 1992; Martin et al., 
1989). 
 
1.6.3 E6 and E7 proteins 
Expression of the viral oncogenes, E6 and E7, has been shown to lead to an increased 
proliferation of suprabasal epithelial cells (Doorbar, 2006). The E6 oncoprotein is approximately 
17 kDa and is present in the nucleus and cytoplasm. It is expressed at the early stage of HPV life 
cycle and is capable of binding to p53. p53 is a tumor suppressor protein that, when cellular 
DNA is damaged, induces cell cycle arrest or apoptosis (Fig. 1.9). E6, particularly from high-risk 
HPV subtypes, binds to p53 through the E6-associate protein (E6AP) ubiquitin ligase. This new 
E6-E6AP-p53 complex leads to degradation of p53 therefore preventing growth arrest and/or 
apoptosis (Scheffner et al., 1993). It has been shown that low-risk E6 can also bind to p53 but 
with lower affinity (Li & Coffino, 1996). 
The HPV-16 E6 can activate telomerase via upregulation of human telomerase reverse 
transcriptase (hTERT) at transcriptional level (Veldman et al., 2001). Telomerase is an enzyme 
that prevents the loss of important DNA sequences from the end of chromosomes and the 
shortening of telomere (Fehrmann & Laiminis, 2003). Expression of telomerase prevents 
senescence of cells. HPV-16 and HPV-18 E6 proteins contain a carboxyl terminal PSD-95/discs 
luarge/zonaocculdens 1 (PDZ) domain (Dell & Gaston, 2001). Many PDZ proteins are involved 
in signal transduction and they are found within cellular protein complexes located in the tight-
junctions in epithelial cells (Longworth & Laiminis, 2004). The PDZ domain interacts with 
proteins such as MUPP-1, hDLG and hSCRIB which can be targeted by E6 protein (Fehrmann & 
Laiminis, 2003). This binding to E6 protein leads to E6-AP mediated ubiquitation and 
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proteolysis (Hebner & Laiminis, 2006). Binding to p53, activation of hTERT expression and 
binding of PDZ proteins are fundamental ways for E6 proteins to immortalize human cells 
(Hebner & Laiminis, 2006; Veldman et al., 2001). 
E7 is a nuclear protein approximately 12 kDa in size. It has been shown to be the major viral 
protein expressed in cervical cancers and cancer-derived cell lines containing HPV-16 or HPV-
18 DNA, and in some cervical cancers only the E7 DNA is retained (Wilczynski et al., 1988).  
The HPV-16 E7 protein can form a specific complex with members of the retinoblastoma (Rb) 
family (Dyson et al., 1989), which are involved in cell cycle regulation. Three proteins belong to 
this family: Rb, p107 and p130. They prevent excessive cell growth by inhibiting cell cycle 
progression through G1 into S phase. The binding of E7 with one of the member of the Rb tumor 
suppressor family leads to an inactivation of Rb protein and a consequent cell cycle progression 
into S phase (Munger & Phelps, 1993). In addition, it has been shown that inactivation of the 
cyclin-dependent kinase inhibitors (CKIs) such as p21 and p27, by the E7 oncoprotein is 
necessary to inhibit cell cycle arrest in human epithelial cells (Demers et al., 1994; Helt et al., 
2002) (Fig. 1.9).  
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Figure 1.9 p53 and Rb pathway 
The tumor suppressor protein, p53, can activate DNA repair and apoptosis. It also regulates cell 
cycle, through the retinoblastoma (Rb) pathway. The Rb function depends on the level of 
phosphorylation of Rb which is achieved by cyclin-dependent kinase (CDK) and cyclin D1 
complex. When Rb is in its hypophosphorylated state is active and binds to E2F inhibiting cell 
cycle progression. In its phosphorylated state Rb is inactive and releases E2F that, in turn, 
activates factors like cyclins which push the cell through the cell cycle (from Brambilla & 
Gazdar, 2009). 
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1.6.4 L1 and L2 proteins 
L1 and L2 genes are both transcribed from the late promoter (p670) (Stunberauch & Laimins, 
1999) and are dependent on epithelial differentiation (Oberg et al., 2003). L1 and L2 are highly 
immunogenic structural proteins, and their production in the lower layers of the infected 
epithelium is strongly suppressed, possibly to prevent detection by the host immune system 
(Schwartz et al., 2007). The L1 protein is around 55 kDa in size and encodes for the major 
capsid protein. L1 proteins are capable of self-assembly into virus-like particles (VLPs) when 
expressed as a eukaryotic recombinant protein and the immunisation with these particles can 
produce an immune response in the infected host (Inglis et al., 2006). The L2 protein is around 
50 kDa in size and encodes the minor capsid protein. The function of L2 protein is still elusive 
but it is thought that it can be important in HPV capsid assembly and DNA binding (Zhou et al., 
1994). Both L1 and L2 proteins contain nuclear localization signals (NLS) necessary for transfer 
into the nucleus after synthesis that occurs in the cytoplasm (Zhou et al., 1991). 
 
 
1.7 DNA integration 
The HPV DNA is usually extrachromosomal or episomal in benign cervical precursor lesions. 
However, in many cervical cancer cells the HPV DNA is integrated in the cellular genome (Park 
et al., 1995). In cervical cancer the HPV DNA could be either episomal or integrated at the same 
time, although integration appears to occur more frequently in HPV-18-associated cervical 
cancer than in HPV-16-associated cervical cancer (Crusius et al., 1997). Viral integration sites 
seem to be randomly distributed among all chromosomes with a clear preference for 
chromosomal breakpoints and genomic fragile sites. In fact viral DNA sequences have been 
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mapped to different chromosomal loci in independent cervical cancer cell lines (Durst et al., 
1987; Popescu et al., 1987).  
During HPV DNA integration, the viral genome usually breaks in the E1/E2 region resulting 
usually in the loss of the E1 and/or E2 regions. The functional inactivation of E2, which acts as a 
transcriptional repressor of the E6 and E7, leads to an uncontrolled and increased expression of 
the transforming genes E6 and E7. This continuous expression of the viral gene E6 and E7 is the 
major cause of malignant transformation of the host cells and tumor formation (Bosch et al., 
1992; Doorbar et al., 1991; Phelps et al., 1988). The integration of HPV DNA into the host DNA 
appears to increase cellular proliferation and the risk of malignancy (Scheurer et al., 2005). 
 
1.8 Regulation of gene expression 
RNA processing is the pivot of regulation of gene expression, delivering a number of 
modifications in mRNA molecular features. In eukaryotic cells, the first transcript from a DNA 
template is called pre-mRNA. It is made in the nucleus by RNA polymerase II (RNA pol II) and 
it is not directly exported to the translation machinery in the cytoplasm. First it must undergo 
three major processing events to become a mature and stable mRNA. These three events are 
capping, splicing and polyadenylation and they can occur co-transcriptionally (Proudfoot et al., 
2002) (Fig. 1.10). 
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Figure 1.10 RNA processing  
In eukaryotes a gene is transcribed from DNA to pre-mRNA. mRNA is then made from pre-
mRNA by RNA processing, which includes the capping, splicing and polyadenylation of the 
transcript. It is then transported from the nucleus to the cytoplasm for translation. (Orpahnides, A 
unified theory of gene expression. Cell, 2000). 
 
 
1.8.1 Capping 
Capping consists on the addition of 7-methyl guanosine groups (mRNA "cap") to the 5′ -ends of 
the new synthesized pre-mRNA and occurs after about 20-30 nucleotides of the molecule have 
been transcribed. The 5′ -triphosphate is removed from the first nucleotide of the pre-mRNA by 
RNA triphosphatase, leaving two terminal phosphates. Guanosine mono-phosphate (GMP) is 
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added to the terminal phosphates by RNA guanylyl transferase. The 7-nitrogen of guanine is then 
methylated by methyltransferase (Shatkin, 1976). The 5′ cap then binds to the cap binding 
complex (CBC). The new formed complex helps to protect the mRNA from premature 
degradation and also facilitates binding of ribosomes to the mRNA during translation. 
 
 
1.8.2 Splicing  
Almost all synthesized eukaryotic pre-mRNAs contain coding sequences called exons and non-
coding sequences called introns. Pre-mRNA splicing is a process that removes introns and 
retains exons in the transcript that can be then translated into proteins. Each intron contains all 
consensus sequences necessary for splicing: a 5′ splice site (5′ ss), a branch point sequence (BPS) 
and a 3′ splice site (3′ ss) containing a polypyrimidine tract (PPT). The 5′ ss is identified by the 
consensus sequence AG | GURAGU (R, purine) where the line | represents the junction between 
the first exon and the adjacent 5′ end of the intron. The consensus sequence of the branch point 
sequence is YNYURAC (the A is the adenosine conserved in all genes which lies between 18 
and 37 nucleotides upstream from the 3′ ss). The consensus sequence of the 3′ss is YnAG|RNNN 
(Y, pyrimidine; N, variable nucleotides) where Yn represents the polypyrimidin tract and the line 
represents the junction between the 3′ end of the intron and the second exon (Fig. 1.11 and 1.12). 
In the 3′ splice site, the AG is normally preceded by a polypyrmidince tract of variable length 
(Y10-20) and sequence and if it is long and uninterrupted, the 3′ splice site is strong.  
The pre-mRNA splicing is carried out by the spliceosome via a 2 step trans-esterification 
mechanism. In the first step, the 2′ OH group of the conserved A residue in the BPS binds to the 
5′ ss and cleaves the phosphodiester bond at this site. This reaction produces a lariat shaped 
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intron and releases the 5′ exon. In the second step, the 3′ OH group at the end of the 5′ exon 
attacks the phosphodiester bond at the 3′ ss releasing the lariat shaped intron and joining the 
flanking exons (Cooper & Hausman, 2007). 
The spliceosome is formed from five ribonucleoprotein subunits, termed uridine-rich small 
nuclear ribonucleoproteins (snRNPs), transiently associated to non-snRNPs splicing factors 
(small nuclear RNA (snRNA), SR splicing factors, etc...) (Brown, 2002). Spliceosomes are 
highly dynamic machines, building anew on each pre-mRNA and their assembly occurs in a 
stepwise manner. In the first step, U1 snRNP binds to the 5′ ss and U2 snRNP to the BPS via 
RNA:RNA interactions between snRNA and pre-mRNA. A pre-formed U5-U4-U6 triple-snRNP 
then binds to this new complex forming an immature spliceosome. This immature spliceosome 
complex undergoes a series of rearrangements to form a fully functional spliceosome. Several 
splicing factors are involved in the removal of introns and the process often continues post-
transcriptionally (Bentley, 2005). 
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Figure 1.11 Splicing 
The structure of the pre-mRNA and splicesome is shown (from Dredge et al., 2001). 
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1.8.3 Polyadenylation 
Polyadenylation is an important process for the nuclear export, translation and stability of 
mRNA. It consists on the addition of a poly(A) tail at the RNAs 3′ end (Fig. 1.12). First the pre-
mRNA is cleaved by the cleavage and polyadenylation specificity factor (CPSF) at the 
cleavage/polyadenylation site, that usually is the AAUAAA sequence located 10-30 nucleotides 
upstream of the polyadenylation site. This binding is very weak and is stabilized by binding of 
the cleavage stimulation factor (CstF) which binds specifically to the GU-rich elements 20-40 
nucleotides downstream of the polyadenylation site (Colgan & Manley, 1997). The cleavage 
factors I and II (CFI and CFII) allow the cleavage of the RNA. Before the cleavage occurs the 
poly(A) polymerase (PAP) associates with this complex allowing the rapid addition of adenosine 
at the cleavage site of mRNA. After the first 12 adenosines synthesis, poly(A) binding II (PABII) 
binds to the poly(A) tail, allowing the synthesis of a full length poly(A) by PAP. When the 
poly(A) tail is approximately 200 nucleotides long the polyadenylation stops. 
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Figure 1.12 The structure of the pre-mRNA and RNA processing 
The structure of the pre-mRNA is shown. Schematic representation of the three RNA processing 
events: capping, splicing and polyadenylation. 
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1.8.4 Alternative splicing 
Alternative splicing is an important process to generate diversity and to regulate gene expression. 
This is particularly important in HPV gene expression where transcription of all mRNAs is 
regulated through the use of splicing and polyadenylation signals (discussed in detail below). Six 
basic modes of alternative splicing have been recognized: constitutive, exon skipping, mutually 
exclusive exons, intron retention, alternative donor site and alternative acceptor site (Fig. 1.13). 
The selection of the splice site depends on the strength of each splice site. The presence of 
splicing enhancer and silencer elements in exon and introns can increase or inhibit respectively 
the usage of weak splice site (Srebrow & Kornblihtt, 2006). Viruses efficiently exploit 
alternative splicing to produce many functional mRNAs from small genomes. About 70% of all 
human genes in the human genome undergo alternative splicing (Venter et al., 2001). Alternative 
splicing can result in the addition or loss of coding sequences, a frame shift, or the presence of a 
premature stop codon. It is known that about 80% of alternative splicing can alter the encoded 
protein due to the addition or removal of many regulatory elements controlling translation, 
mRNA stability, or localization (Mondrek & Lee, 2002). Even thought it is still unclear, different 
studies have demonstrated a correlation between alternative splicing and cancer (Faustino & 
Cooper, 2003; Krawczak et al., 1992; Srebrow & Kornblihtt, 2006; Venables, 2004) and many 
splicing factors are up-regulated in cancer cells, suggesting that it would be opportune to have a 
better understanding of the diverse mechanisms by which disrupted splicing and splicing 
regulation contribute to human disease and cancer.  
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Figure 1.13 Schematic representation of alternative splicing 
Different types of alternative splicing are illustrated. For a singular pre-mRNA different 
alternative exons often show diverse types of alternative-splicing patterns (from Cartegni et al., 
2002). 
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1.9 Regulation of HPV gene expression 
HPV gene expression is regulated at the transcriptional level by the use of the two major 
promoters activated at different stages of cell differentiation (Lambert et al., 1999). Cellular 
factors, such as TEF-2, Oct1, AP-1 have been shown to have an essential role in HPV 
transcriptional regulation by regulating promoter activity (Chong et al., 1991). It has been 
demonstrated that also the viral E2 protein is involved in transcriptional regulation through the 
interaction with 4 binding sites located in the LCR (Zur Hausen, 1996). Since HPVs have only 
one strand active, transcription occurs in only one direction (Zur Hausen, 1996). Most HPV 
mRNAs are polycistronic (Favre et al., 1997), and some of them carry 3 or more messages on 
one mRNA (Longworth & Laiminis, 2004). During transcription all mRNAs are regulated 
through the use of splicing and polyadenylation signals. For HPV-16 20 transcripts have been 
identified (Fig. 1.14), of which 14 are produced from the early promoter to the early 
polyadenylation signal (Zheng & Baker, 2006). In HPV-16 11 splice sites have been identified, 
10 located in the early region and only 1 in the late region (Fig. 1.14) (Doorbar et al., 1990). 
Splice Donor 226 (SD226) is used exclusively by early mRNAs and is followed by 3 distinct 
splice acceptors (SAs). This disposition allows the production of 4 different mRNAs, E6*I, 
E6*II, E6^E7 and when no splicing occurs E6E7 (Zheng & Baker, 2006). However in order to 
reach a correct and proportionate concentration of E6 and E7 proteins, a balance in these splicing 
events is required. E6 and E7 mRNAs are also spliced directly from SD880 to SA3358 (Fig. 
1.14) (Baker & Calef, 1997). 
Splicing from SD226 to SD742 in HPV-16 is required also for production of E1 mRNAs (Hubert 
& Laimins, 2002). Splicing directly to SA2582 and SA2709 result in production of E2 mRNAs 
and directly to SA3358 is likely to produce E5 mRNAs (Baker & Calef, 1997). 
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The E4 mRNA is one of the most abundant HPV-16 mRNAs produced and is generated from 
SD880 to SA3358. The SA3358 is the most efficient splice site used in HPV-16. In fact it is used 
for production of E6, E7, E4, L1 and L2 mRNAs and also indirectly blocks HPV-16 late gene 
expression. It has been shown that an AC-rich splicing enhancer at SA3358 in HPV-16 promotes 
usage of SA3358 and polyadenylation at pAE, thereby indirectly suppressing HPV-16 late gene 
expression (Rush et al., 2005). Late mRNAs are transcribed from the late promoter and are 
presumably spliced from SD880 to SA3358 and from SD3632 to SA5639 or directly from 
SD880 to SA5639 (Fig. 1.14). SD3632 and SA5639 are used exclusively by late mRNAs and are 
under control of multiple adjacent splicing silencer elements that suppress these splice sites 
therefore inhibiting late gene expression (Rush et al., 2005; Zhao et al., 2007). It has been shown 
that late gene expression is also inhibited in mitotic cells because of a competition between 
SA3358 and late splice sites (Rush et al., 2005). In fact inactivation of the E4 enhancer and the 
L1 splicing silencers in a subgenomic HPV-16 plasmid showed production only of L1 mRNA 
(L1i) but not E4 mRNA production (Rush et al., 2005; Schwartz et al., 2007).  
Alternative splicing seems to be necessary to produce L1 since the 3′ end of L2 and the 5′ end of 
L1 overlap. Late viral mRNAs are expressed only in differentiating cells and it has been shown 
that posttranscriptional events are highly involved in late gene regulation (Zheng & Baker, 
2006). Viral RNA elements and cellular RNA binding factors have therefore a pivotal role in 
HPV-16 gene regulation (Mole et al., 2009a; Mole et al., 2006; Schwartz et al., 2007). Thus it is 
of interest to elucidate the mechanism of HPV-16 gene regulation.  
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Figure 1.14 HPV-16 genome and transcription map  
Schematic representation of the HPV-16 genome and transcription map. The early and late viral 
promoters, p97 and p670, and the early and late polyadenylation signals pAE and pAL are 
shown. Boxes indicate protein-coding regions. Black circles indicate splice donors (5’ splice 
sites) and white circles indicate splice acceptor (3’ splice sites). Numbers refer to nucleotide 
positions in the HPV-16 sequence. All 20 different RNA transcripts are shown. The coding 
potential of each mRNA is shown on the right.  
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1.10 HPV-16 late gene expression 
As already mentioned, the HPV late genes are expressed only in differentiated cells and also it is 
known that late HPV-16 genes are not expressed in cervical cancer containing HPV-16 DNA 
(Doorbar, 2005). They encode for the highly immunogenic structural proteins, L1 and L2, and 
their production in the lower layers is strongly suppressed, possibly to prevent detection from the 
host immune system (Schwartz et al., 2007). The SD3632 and SA5639 are used exclusively by 
the late mRNAs and the presence of an adjacent splicing silencer that actively suppresses the use 
of these splice sites has been shown to inhibit late gene expression (Rush et al., 2005; Zhao et 
al., 2004; Zhao et al., 2007). Late gene expression is also indirectly inhibited by RNA elements 
that stimulate early mRNA splicing (Rush et al., 2005) and polyadenylation (Oberg et al., 2003; 
Oberg et al., 2005; Terhune et al., 1999; Zhao et al., 2005). Recent studies show that 
overexpression of a number of proteins, such as adenovirus E4orf4 (E4orf4), polypyrimidine 
tract binding protein (PTB) and alternative splicing factor/splicing factor 2 (ASF/SF2), induce 
late gene expression in subgenomic HPV-16 expression plasmids (Somberg & Schwartz, 2010; 
Somberg et al., 2009; Somberg et al., 2008). Another member of the serine-arginine rich family 
(SRp30c) has been shown to regulate splicing (Raffetserder et al., 2003) and it also has a role in 
late gene expression (Somberg et al., 2011).  
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1.11 SR proteins  
In humans, the SR protein family is encoded by nine genes, named ASF/SF2, SC35, SRp20, 
SRp40, SRp55, SRp75, SRp30c, 9G8, and SRp54 which have a common structural organization 
(Fig. 1.15), containing either one or two amino-terminal RNA-binding domains (RNA 
recognition motifs (RRM)) and a variable-length RS domain rich in arginine (R) and serine (S) 
amino acid residues at their carboxyl terminus (Shepard & Hertel, 2009). As the name implies 
the RRM provides RNA-binding specificity through a wide range of interactions, whereas the 
RS-domain functions as a protein interaction domain that promote recruitment of the 
spliceosome, splicing and shuttling between the nucleus and cytoplasm (Caceres et al., 1998; 
Graveley & Maniatis, 1998; Wu & Maniatis, 1993). In addition, the RS domain can function as a 
nuclear localization signal by mediating the interaction with of the SR protein with the nuclear 
import receptor, transportin-SR (Cáceres et al., 1997; Lai et al., 2000). The SR proteins play an 
important role in mRNA export, translation, stability and both activation and repression of 
constitutive and alternative splicing of pre-mRNA (Shepard & Hertel, 2009; Sanford et al., 2005; 
Long & Caceres, 2009). They mostly bind exonic splicing enhancer (ESE) therefore enhancing 
splicing of pre-mRNA into messenger RNA (mRNA).   
SR proteins take part in many steps during the splicing reaction (Chew et al., 1999; Fu, 1993; Ge 
& Manley, 1990; Krainer et al., 1990; Zahler et al., 1992) and require phosphorylation for 
efficient splice site recognition and dephosphorylation for splicing catalysis (Mermoud et al., 
1994; Mermoud et al., 1992).  
SF2/ASF and SC35 are two of the best characterized among the nine human SR proteins 
identified to date. They interact with U1-70K and U2AF by RS domain-mediated protein-protein 
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interactions and the RRMs of these two proteins are responsible for their unique substrate 
specificities (Chandler et al., 1997; Mayeda et al., 1999). 
 
 
 
 
Figure 1.15 Human SR proteins family 
The structural organization of the nine human SR proteins is shown. RRM, RNA recognition 
motif; RRMH, RRM homology; RS, arginine/serine-rich domain; Zn, Zinc knuckle (from 
Shepard & Hertel, 2009). 
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(i) ASF/SF2  
ASF/SF2 (alternative splicing factor/splicing factor 2), also called splicing factor, 
arginine/serine-rich 1 or SFRS1, is encoded in humans by the SFRS1 gene. This protein of 
approximately 30 kDa binds to pre-mRNA transcripts and components of the spliceosome, and 
can either activate or repress splicing depending on the location of the pre-mRNA binding site. 
ASF/SF2 contains an arginine-serine rich region (RS domain), and two RNA recognition motifs 
(Fig. 1.15). It interacts with RNA and other splicing factors through the RRMs (Ngo et al., 2008; 
Hagopian et al., 2008) and binds directly to RNA at the branchpoint to promote pre-spliceosomal 
assembly (Shen & Green, 2004; Shen et al., 2004). 
It is well-known that ASF/SF2 is a proto-oncogene and it has also been shown that knockdown 
of this gene inhibits tumor growth in vitro and in vivo (Karni et al., 2007). ASF/SF2 expression 
is up-regulated in a number of tumors such as breast, liver, colon, kidney, pancreas, lung (Zerbe 
et al., 2004) and cervix (Fay et al., 2009). ASF/SF2 and heterogeneous nuclear ribonucleoprotein 
A1 (hnRNP A1) act antagonistically to modulate splice site selection. Levels of ASF/SF2 along 
with hnRNP A1 have been shown to be altered in neoplastic lung cells and ASF/SF2 has shown 
to be localized in cytoplasm and/or nuclei while hnRNP A1 appeared prevalently within tumor 
nuclei (Zerbe et al., 2004).  
It has been shown that ASF/SF2 regulates one of the most used splice sites in HPV-16, the splice 
acceptor SA3358, specifically binding to exonic sequences located between SA3358 and 
SD3632 (Somberg & Schwartz, 2010). In particular ASF/SF2 enhances splicing to SA3358 and 
inhibits usage of splice donor SD3632 (Somberg & Schwartz, 2010). 
This SR protein also interacts with U2AF, which binds to the negative regulatory element (NRE) 
that is located in the late 3′ untranslated region of HPV-16 (McPhillips et al., 2004). In addition, 
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it seems that in epithelia infected by high-risk HPV, ASF/SF2 expression is up-regulated by the 
virus transcription and replication factor E2 (McPhillips et al., 2004). 
 
(ii) SRp30c 
SRp30c is one of several highly conserved serine/arginine-rich (SR) proteins that are involved in 
both constitutive and alternative splicing in eukaryotic cells. It has been shown to have a role in 
the alternative splicing of hnRNP A1 by repressing the use of a 3′ splice site (Simard & Chabot, 
2002). However, SRp30c has been shown to regulate alternative splicing of cellular mRNAs as 
an inducer and suppressor. SRp30c displays 74% amino acid similarity with ASF/SF2 although 
no consensus mechanism of action for these two splicing factors has been identified. As shown 
in figure 1.15 it contains two RRM (RNA recognition motif) domains. 
Selection of alternative splice sites can be affected by interaction with SRp30c and also its 
overexpression is involved in the shuttling of the Y-box protein-1 (YB-1) into the nucleus 
(Raffetseder et al., 2003). Presence of nuclear YB-1 is a strong averse survival factor in human 
breast cancer (Dahl et al., 2009). 
It has been shown that SRp30c is required for alternative splicing of the glucocorticoid receptor 
(GR) pre-mRNA to form mRNA encoding GRβ (Xu et al., 2003). Several studies indicate that 
GR resistance has been associated with increased expression of GRβ, therefore upregulation of 
SRp30c contributes to the GR resistance in several inflammatory cell types (Xu et al., 2003; Jain 
et al., 2011). 
SRp30c has been shown to induce HPV-16 late L1 gene expression in subgenomic HPV-16 
plasmids by binding to sequences between SA3358 and SD3632 and specifically interfering with 
splicing enhancers downstream of SA3358 in an RS-domain independent manner (Somberg et 
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al., 2011). SRp30c also interferes with splicing inhibitory RNA elements in an RS-domain 
dependent manner activating splicing of late splice site SD3632 leading to production of L1 
mRNA (Somberg et al., 2011).  
 
(iii) SC35 
Serine/arginine-rich splicing factor 2, also called SC35, belongs to the splicing factor SR family. 
It contains 1 RRM (RNA recognition motif) domain and 1 RS (arginine/serine-rich domain) (Fig. 
1.15). 
In vitro it self-associates and binds to ASF/SF2, SNRNP70 and U2AF1 but not U2AF2. SC35, 
like other members of the SR family of splicing factors, may take part in splice site selection by 
functioning as a bridge between components bound to the 5' and 3' splice sites (Wu & Maniatis, 
1993; Kim et al., 2011; Tronchère et al., 1997).  SC35 leads to both an exon inclusion and an 
intron excision in the 3' untranslated region of its mRNAs. It is required for formation of the 
earliest ATP-dependent splicing complex and for ATP-dependent interactions of both U1 and U2 
snRNPs with pre-mRNA. 
Sureau et al. reported that endogenous SC35 mRNA levels in HeLa cells are decreased when 
SC35 is overexpressed. They also demonstrated that SC35 accumulation is correlated to changes 
in the splicing pattern regulating its expression by promoting alternative splicing events changing 
the stability of its own mRNAs (Sureau et al., 2001).  
SC35 protein plays a critical role in terminal differentiated mature cardiomyocytes in mice and 
controls cell proliferation during pituitary gland development (Xiao et al., 2007). 
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Zheng et al. demonstrated with DNA microarrays that SC35 expression is induced by the small 
molecule 12-O-tetradecanoylphorbol-13-acetate (TPA), in leukemia cell lines (Zheng et al., 
2002).  
 
 
1.12 hnRNP family 
Heterogeneous nuclear ribonucleoproteins (hnRNPs) are a group of RNA-binding proteins first 
discovered in 1956 during the observation of lampbrush chromosomes in amphibian oocytes 
(Gall, 1956).  These proteins have molecular masses of 34-120 kDa and play a critical role as 
trans-factors in regulating gene expression, in processing heterogeneous nuclear RNAs 
(hnRNAs) into mature mRNAs, in DNA repair and telomere regulation. 
These RNA-binding proteins are among the most abundant proteins in the nucleus. The hnRNP 
proteins generally consist of multiple domains such as RNA recognition domain (RRM), and 
KH, K homology domain (Fig. 1.16); they are connected by a linker of varying length. Even 
though the RNA recognition domain is the most common it is not present in all hnRNPs. RRMs 
have two different structures (Hoffman et al., 1991), which the most prevalent is characterized 
by a β1-α1-β2-β3-α2-β4 structure and two RNP consensus sequences called RNP-1 and RNP-2 
useful for the interaction with RNA (Birney et al., 1993). The hnRNPs bind to pre-mRNA with 
sequence specificity to high-affinity binding sites consisting of sequences that code for 5´- and 
3´splice sites, polyadenylation elements and the polypyrimidine tract (PPT) (Ghetti et al., 1992). 
It is known that there is a correlation between carcinogenesis and some of these proteins such as 
hnRNP A2/B1 and hnRNP A1 in lung cancer (Tockman et al., 1997; Tockman et al., 1988; 
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Zerbe et al., 2004; Zhou et al., 1996) hnRNP K in esophageal cancer (Hatakeyama et al., 2006) 
and in oral squamous cell carcinoma (Roychoudhury & Chaudhuri, 2007). 
 
 
 
 
Figure 1.16 Schematic representation of the hnRNP family structure  
RRM, RNA recognition domain, KH, K homology domain; RNA binding domain structurally 
distinct from RRM. (Adapted from Han et al., 2010). 
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(i) hnRNP A2/B1 
Heterogeneous nuclear ribonucleoprotein (hnRNP) A2/B1 belongs to the hnRNPs A/B family 
that comprises RNA-binding proteins important for alternative splicing. They are also involved 
in many stages of RNA metabolism and play crucial roles in RNA processing, mRNA 
trafficking, and telomere maintenance (Krecic & Swanson, 1999; Dreyfuss et al., 2002; Smith, 
2004; He & Smith, 2009).  
The hnRNP A/B paralogs are structurally similar, but differ especially in their alternative 
splicing patterns. As shown in figure 1.17 hnRNP A2/B1 is alternatively spliced to produce the 
transcripts B1, A2, A2b, and B1b (Han et al., 2010). The A2/B1 isoforms have different 
intracellular localization patterns and expression levels vary between tissue types and across 
developmental and cell cycle stages (Kamma et al., 2001; Kamma et al., 1999; Matsui et al., 
2000; Hatfield et al., 2002; Maggipinto et al., 2004; He et al., 2005). The hnRNP A2/B1 group 
have been associated with the binding and elongation of single stranded telomere repeats 
TTAGGGn (McKay & Cooke, 1992). 
It has been shown that the splicing factor hnRNP A2/B1 is overexpressed in glioblastomas and is 
correlated with poor prognosis (Golan-Gerstl et al., 2011). There have been also some 
speculations about the role of hnRNP A2/B1 as a presumed proto-oncogene due to the fact that 
overexpression of hnRNP A2/B1 in immortal cells led to malignant transformation and 
knockdown of hnRNP A2/B1 in glioblastoma cells inhibited tumor formation in mice (Golan-
Gerstl et al., 2011).  
Different studies have shown that hnRNP A2/B1 is overexpressed in breast and lung tumors 
(Tockman et al., 1997; Tockman et al., 1988; Zhou et al., 1996) whereas the hnRNP A2/B1 
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proteins showed decreased expression or no change in tumors of the colon, thyroid, small 
intestine and kidney (Karni et al., 2007). 
It has been demonstrated that hnRNP A2/B1 levels are increased by the small molecule TPA in 
leukemia cell lines (Zheng et al., 2002), whereas in human neuroblastoma cell lines its 
expression level is down-regulated by retinoic acid (Liang et al., 2011). 
 
 
. 
 
 
Figure 1.17 Structure of hnRNPs A2/B1 and transcript in the mouse 
Transcripts B1, A2, A2b, and B1b produced by alternatively spliced are shown. Each numbered 
rectangle represents an exon, with lengths adjusted to align homologous exons. Vertical dashed 
lines highlight the structural similarity in terms of exon lengths, the correspondence of exons to 
functional protein domains, and the location of alternative exons relative to the entire mRNA. 
Below are shown the different splicing of alternative exons can occur in hnRNPs A/B in mouse. 
Exons are represented with boxes and introns with black horizontal lines. Blue lines represent 
major splicing patterns and green lines represent minor splicing patterns. Note that exon 9 in 
A2/B1 is generally included whereas exon 2 is excluded. (Adapted from Han et al., 2010).  
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(ii) PTB 
Polypyrimidine tract-binding protein (PTB), called also hnRNP I, is a 58 kDa protein. PTB is a 
RNA-binding protein and has a regulatory role in alternative splicing. When PTB binds to the 
RNA it blocks the binding of E2AF to the polypyrimidine tract (Spellman & Smith, 2006). It 
binds both intronic splicing silencers (ISS) and exonic splicing silencers (ESS) and in particular 
the ESSs have multiple PTB binding sites regulating the 3′ splice site (Garcia-Blanco et al., 
1989). The UCUU in a pyrimidine-rich context is an optimal binding site for PTB (Patton et al., 
1991). 
As it can been seen in figure 1.16 the structure has four weakly conserved RRMs (Oh et al., 
1998), of which the most prevalent is characterized by a βαββαβ structure and an N-terminal 
domain involved in nuclear localization and export. It contains also a hinge region between RRM 
2 and 3 of different length depending on the alternative splicing of the PTB transcript itself. The 
RRMs have been associated with the ability of PTB to oligomerize, bind to RNA, and possibly 
interact with other proteins. 
Recent studies showed that PTB is highly upregulated in cervical cancer cells, whereas in the 
superficial levels of the cervical epithelium is down regulated (Fay et al., 2009). It has been 
shown that PTB induces HPV-16 late gene expression in subgenomic HPV-16 expression 
plasmids acting on the inhibitory elements located immediately upstream of SD3632 (Somberg 
et al., 2008). 
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1.13 E4orf4 
Adenoviral E4orf4 (AdE4orf4) is a protein encoded by adenoviruses which are double stranded 
DNA viruses that, like HPV, has a  life cycle that is characterized by an early and a late phase. 
E4orf4 protein of human adenovirus plays important roles in the adenoviral life cycle, including 
the switch from early to late gene expression (Akusjärvi, 2008). It is a 14 kDa protein which it 
has been shown to induce p53-independent apoptosis, promoting cell death and viral spread. 
When expressed alone, E4orf4 kills transformed cells but not normal human cells (Roopchand et 
al., 2001). At the molecular level it has been shown to interact with the cellular protein 
phosphatase P2 (PP2A), thereby dephosphorylating SR-proteins (Kanopka et al., 1998; Kanopka 
et al., 1996). In subgenomic HPV-16 expression plasmids, overexpression of E4orf4 protein has 
been shown to overcome the negative effect of the splicing silencer adjacent to either splice sites, 
SD3632 and SA5639, inducing late gene expression (Somberg et al., 2009). 
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1.14 Transient and stable transfection 
The artificial uptake of new nucleic acid by mammalian cells, called transfection, was first 
described in 1965 by Vaheri and Pagano and had a substantial impact on biomedical research. 
Since then transfections have been widely used in laboratories to analyze gene expression and 
different methodologies have been developed to enhance the efficiency of delivered nucleic acids 
directly into the cytoplasm. These include calcium-phosphate transfection technique (Graham & 
van der Eb, 1973), electroporation (Andreason & Evans, 1988), cationic lipid-mediated 
transfection (Felgner et al., 1993) and other reagents composed of cellular protein and 
polyamine. In particular one reagent, based on a nontoxic cellular protein and a small amount of 
a novel polyamine, is GeneJuice®Transfection reagent, which ensures maximal transfection 
efficiency and minimal cytotoxicity in both stable and transient transfection of eukaryotic cells.  
The passage of foreign DNA into the nucleus is primarily mediated by cellular processes 
(Colosimo et al., 2000; Salman et al., 2001) and once into the nucleus part of the exogenous 
DNA can be degraded or lost through successive cell divisions (Liang & Jasin, 1996).  
Transfected nucleic acids can either be transiently expressed or permanently expressed; unlike 
transient transfection, in which introduced DNA persists in cells for few days, stable transfection 
guarantees long term gene expression due to integration of exogenous DNA into the cellular 
genome and the inheritance of the cells progeny. Foreign DNA integrates in the chromosomal 
DNA randomly at one or very few sites (Murnane et al., 1990) and site integration influences the 
transcription rate of the gene of interest (Wurm, 2004). Cellular DNA in the nucleus is combined 
with proteins to prevent damage, to control gene expression, DNA replication and to reduce the 
volume to fit in the nucleus. This compact structure is called chromatin and is found in two 
forms: euchromatin and heterochromatin (Elgin, 1996). Euchromatin is the active form of 
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chromatin. It is lightly packed allowing RNA polymerase and gene regulatory proteins to bind to 
DNA sequence therefore delivering gene transcription. The heterochromatin is the compact form 
that, with his tight structure of packed DNA, impedes the binding of protein factors and RNA 
polymerase complexes to bind the DNA inhibiting gene expression. Therefore integration of 
exogenous DNA into active euchromatin generally leads to transgene expression, whereas 
integration into inactive heterochromatin results in very little or no transgene expression.  
Even though integration of foreign DNA into the cellular genome generally does not cause 
damage to its integrity (McFarlane & Wilson, 1996), it can sporadically have deleterious 
consequences for the endogenous DNA, leading to different rearrangement at the site of 
integration (Covarrubias et al., 1987; Kato et al., 1986; Robins et al., 1981; Wilkie & Palmiter, 
1987), such as deletions, duplications and translocations (Hamada et al., 1993; Mahon et al., 
1988; Mark et al., 1992) or can interfere with coding sequences (Rijkers et al., 1994). Therefore, 
alteration of chromatin structure and functions leads to gene inactivation and genomic instability. 
However, it seems that in the endogenous genome there are “integration hotspots”, where DNA 
integration is more likely to occur (Rijkers et al., 1994). 
The development of genome manipulation and the establishment of stable cell lines is one main 
achievements of molecular biology which allows the analysis of large scale protein production 
(Wurm, 2004), gene function and regulation (Grimm, 2004), gene therapy and drug discovery 
(Glover et al., 2005). 
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1.15 Small molecules used in this study 
 
(i) TPA 
TPA (12-O-tetradecanoylphorbol-13-acetate), also called PMA (phorbol-12-myristate-13-
acetate), is a small molecule drug, the most commonly used phorbol ester. It was first found in 
the Croton tiglium, commonly called croton, a shrub of the Euphorbiaciae family native to 
Southeast Asia. It is extensively used as a tumor promoter in cancer research (Furstenberger et 
al., 1981; Scribner & Boutwell, 1972). It binds and activates protein kinase C (PKC), causing 
numerous effects in cells and tissues (Blumberg, 1988; Blumberg, 1980; Castagnag et al., 1982; 
Niedel et al., 1983; Rebois & Patel, 1985) although at maximal or submaximal concentration 
elicits down-regulation of PKC in response to continuous stimulation (Blobe et al., 1996; Liu, 
1996). The activation of protein kinase C by TPA is due to its resemblance with diacylglycerol. 
Weinberg has shown that in the presence of TPA human leukemia cell lines HL-60 differentiate 
to nondividing macrophage-like cells. These differentiated cells are cytotoxic for tumor cells in 
vitro, including untreated HL-60 cells (Weinberg, 1981). In 1998 TPA was reported as a 
therapeutic drug for patients with leukemia (Han et al., 1998; Strair et al., 2002). Intravenous 
administration of TPA alone or in combination with other drugs in patients with myelocytic 
leukemia has been demonstrated to reduce the number of myeloblasts in blood and bone marrow 
(Han et al., 1998). It has been reported that this small molecule can regulate Bcl-x alternative 
splicing in glioma cells but not in leukemia cells (Li et al., 2004). Bcl-x, a Bcl-2-related gene, is 
an apoptosis regulator that can function as pro- or anti-apoptotic, depending on the rate of 
alternative splicing in two distinct Bcl-x mRNAs: the Bcl-xS isoform, which promotes apoptosis, 
or the Bcl-xL isoform, which is a potent inhibitor of cell death (Boise et al., 1993). BclxS 
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induces apoptosis in caspase- and BH3-dependent manner (Chang et al., 1999; Lindenboim et 
al., 2000). In addition, it has been shown that Bcl-xS induces apoptosis via Bak activation and 
induction of apoptosis is merely dependent on Bak but not on Bax (Lindenboim et al., 2005). 
Different pathways have been reported for the regulation of apoptosis by Bcl-xL suggesting that 
there may be involved multiple mechanisms. Recently, it has been demonstrated that Bcl-xL 
inhibits apoptosis by binding to CED-4-like molecules such as Apaf-1 preventing the activation 
of downstream caspases (Hu et al., 1998; Pan et al., 1998), or by the heterodimerization with 
BH3-containing death agonists such as Bax and the ability to form a sustained ion channel (Minn 
et al., 1999). Bcl-xL is over-expressed in several types of cancers and promotes resistance to 
chemotherapy in tumors in vivo (Liu et al., 1999). 
Interestingly, DNA microarray analysis of TPA treated cells have identified several genes, whose 
expression is altered by this substance; in particular TPA has shown to induce expression of a 
number of genes that are involved in splicing, such as SC35 (serine/arginine-rich splicing factor 
2) and hnRNP A2/B1 (Zheng et al., 2002).  
In 1992 Meyers et al. demonstrated that TPA induces HPV-31 late gene expression and that 
production of the L1 proteins occurs simultaneously with the induction of keratin 10 and 
filaggrin synthesis (Meyers et al., 1992). 
 
 
(ii) Emetine 
Emetine is the principal alkaloid of ipecac root (Wiegrebe et al., 1984). Initially emetine was 
used as an expectorant and emetic (Grollman, 1966).  
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In 1968 Grollman demonstrated that emetine inhibits both ribosomal and mitochondrial protein 
synthesis and interferes with the synthesis and activities of DNA and RNA (Grollman, 1968). 
This inhibition is caused by the binding of emetine to the 40S subunit of the ribosome (Jimenez 
et al., 1977). It is also known that it can inhibit viral RNA synthesis in poliovirus-infected HeLa 
cells (Grollman, 1968) and selectively inhibits mitochondrial protein synthesis in mouse liver 
(Lietman, 1970).  
Treatment with emetine has been shown to be effective in the therapy of leukemia (Jondorf et al., 
1970) and to induce apoptosis in cancer cells (Boon-Unge et al., 2007). In fact, it has been 
shown that emetine modulates the regulation of the apoptotic factors Bcl-x, downregulating Bcl-
xL and upregulating Bcl-xS (Boon-Unge et al., 2007). Moreover, it is known that treatment of 
Jurkat cells with emetine up-regulates a number of genes such as CASP8 (caspase 8), CASP9 
(caspase 9), BAK1, DAXX (death-associated protein 6), GZMB (granzyme B) AKT1, MST1, 
TNFRSF6, TNFRSF11B, and TNFSF13 and downregulates BCL2, EGFR (epidermal growth 
factor receptor) and TNF (tumor necrosis factor) (Moller et al., 2007). 
 
 
(iii) Cycloheximide 
Cycloheximide is a glutarimide antibiotic which was isolated from the bacterium Streptomyces 
griseus. It was first discovered in 1947 by Leach et al., and it has been defined as an inhibitor of 
protein biosynthesis in eukaryotic organisms. Grollman has shown that cycloheximide and 
emetine share certain structural properties around two nitrogen atoms that are essential for their 
activity and they have a similar site and mode of action for inhibition of protein synthesis 
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(Grollman, 1966) and just like emetine, cycloheximide regulates alternative splicing of exon 2 in 
the Bcl-x gene (Boon-Unge et al., 2007).   
Due to its heavy toxic side effects, including DNA damage, teratogenesis, and other reproductive 
effects it is not suitable for human use as a therapeutic compound. 
 
 
 
(iv) Ceramide 
Ceramides (sphingolipids) are composed of sphingosine and a fatty acid and were first described 
in 1874 by Thudichum (Thudichum, 1874). Ceramides are found in high concentrations within 
the cell membrane and they were believed to be merely structural elements but over the years it 
has been discovered that this compound plays many others important functions in the cell. It has 
been proposed as a novel lipid second messenger with specific roles in mediating 
antiproliferative responses including apoptosis and cell cycle arrest. In fact, numerous reports 
have demonstrated that Bcl-x alternative splicing can be regulated by ceramide in cancer cells 
(Chalfant et al., 2002; Massiello et al., 2006; Massiello et al., 2004). It has been shown that 
endogenous ceramide generated through the action of the CoA-dependent ceramide synthase is 
implicated in regulating the alternative splicing of caspase 9 but not Bax or caspase 2 pre-
mRNAs (Chalfant et al., 2002). Other studies reported that ceramide dephosphorylates a certain 
number of SR-proteins such as SRp70, SRp55, SRp40, and SRp30 in leukemia cell lines 
(Chalphant et al., 2001).  
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(v) Amiloride  
Amiloride belongs to a class of drugs known as potassium-sparing diuretics (Bull & Laragh, 
1968). First used in 1967 for hypertension and congestive heart failure, it is now considered as a 
novel drug in cancer therapy. In fact it has been shown that amiloride modulates the alternative 
splicing of a number of cancer genes, such as Bcl-x, HIPK3, and BCR/ABL, affecting the 
phosphorylation state of serine-arginine–rich (SR) proteins (Chang et al., 2011). Chang et al. 
reported that treatment of cells with amiloride resulted in hypo-phosphorylation of splicing factor 
ASF/SF2 and levels of SRp20 and two other un-identified SR proteins were decreased (Chang et 
al., 2011). It is also known that amiloride decreases phosphorylation of AKT, ERK1/2 and PP1, 
increases phosphorylation of p38 and JNK (Chang et al., 2011), promotes TRAIL-induced 
apoptotic death through Akt dephosphorylation and activates caspase-3 and -8 in HeLa and 
LNCaP cells lines (Cho et al., 2005). 
It has been demonstrated that prolonged injections of amiloride in rats significantly decrease the 
incidence of gastric cancers (Tatsuta et al., 1993).  
 
 
 
(vi) Scriptaid 
Scriptaid belongs to a well-known class of hydroxamic acid-containing histone deacetylase 
(HDAC). They cause accumulation of hyperacetylated nucleosome core histones in most regions 
of chromatin affecting the expression of a small subset of genes, leading to transcriptional 
activation of some genes and repression of others, modulating the regulation of gene 
transcription. HDAC inhibitors have become a new class of drugs for treatment of a variety of 
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cancers (Marks & Jiang, 2005). Scriptaid has many similarities with trichostatin A but it has 
lower toxicity. 
Treatment of breast cancer cell lines with scriptaid it has been shown to inhibit cell growth and 
to increase estrogen receptor α mRNA transcript (Clancy et al., 2003). Scriptaid has been also 
used in vivo on a mouse model bearing MDA-MB-231 tumors showing an inhibition of tumor 
growth following scriptaid treatment (Clancy et al., 2003). 
 
 
(vii) Valproic acid 
VPA is a histone deacetylase inhibitor. In 1882 Beverly S. Burton was the first to synthesize 
valproic acid as an analogue of valeric acid, found naturally in valerian and initially was used as 
an organic solvent (Burton, 1882). It is widely used to treat bipolar disorder, epilepsy, 
schizophrenia, migraine headaches and also major depression but recent studies have reveled that 
valproic acid can be used for treatment of HIV (Jennings & Romanelli, 1999; Moog et al., 1996; 
Albrecht, 2005; Lehrman et al., 2005) and various cancers such as multiple myeloma (Schwartz 
et al., 2007), glioma (Admirant et al., 2006) melanoma (Valentini et al., 2007) and breast cancer 
(Munster et al., 2007).  
Valproic acid has been demonstrated to affect the expression of a number of splicing factors such 
as ASF/SF2 and hnRNPA1: in particular it seems to increase the expression of ASF/SF2 and 
decrease hnRNPA1 levels (Kusuma Harahap et al., 2011). Brichta  also demonstrated that VPA 
up-regulates the SR-proteins ASF/SF2, SRp20 and Htra2-b1 which in particular overexpression 
of Htra2-β1 but not ASF/SF2 or SRp20 have been shown to lead to restoration of the splicing 
pattern of SMN2 transcripts (Britcha et al., 2003; Hofmann et al., 2000; Hofmann & Wirth, 
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2002). Alternative splicing and a consequent number of SMN2 copies are primarily related to the 
severity of a common neuromuscular disorder, the spinal muscular atrophy (SMA) disease 
(Burghes, 1997; Feldkotter et al., 2002), suggesting that VPA is a candidate drug for SMA.  
Since January 2011 the salt magnesium valproate is in phase III trials for cervical cancer and 
ovarian cancer. It has been shown that valproic acid induces apoptosis in HeLa cervical cancer 
cells by inhibition of gene expression of Akt1 and Akt2 mediated by the caspase-dependent 
pathways (Chen et al., 2006). 
 
 
(viii) Tannic acid 
Tannic acid is a commercial form of tannins and was first recorded in 1836. Tannins are plant-
derived polyphenols and are divided into two groups of hydrolyzable and condensed tannins 
(proanthocyanidins) (Hagerman, 2002). Hydrolyzable tannins are derivatives of gallic acid 
(3,4,5-trihydroxyl benzoic acid) in which a variable number of gallic acids are esterified to a core 
phenol. The simplest hydrolyzable tannins are gallotannins that are polygalloyl esters of glucose. 
The prototypical gallotannin is tannic acid or 1,2,3,4,6-penta-O-b-D-glucose. Tannins are rich in 
nuts, red wine, tea and coffee, but hydrolyzable tannins including tannic acid are not rich in tea 
(Hamilton-Miller, 1995; Yam et al., 1998) or red wine (Cozzolino et al., 2008). Nevertheless, 
red wine can extract phenolic compounds like tannic acid from aging in oak wine barrels. In fact, 
tannic acid is found in the bark and wood of oaks and other plants such as Tara pods 
(Caesalpinia spinosa), gallnuts from Rhus semialata or Quercus infectoria or Sicilian Sumac 
leaves (Rhus coriaria). It is light brown to yellow in colour powder and is highly soluble in 
water. It is used also as a process aid in beer and wine clarification and as a colour stabilizer.  
 64 
According to Cornell University Department of Animal Science, the primary function of tannic 
acid is to bind and precipitate proteins. It has been shown that tannic acid also acts as a potent 
inhibitor of phorbol ester-induced nitric oxide generation in rat hepatocytes (Srivastava et al., 
2000) and stimulates glucose transport (Liu et al., 2005). In 2009 Bian reported that tannic acid 
increases the levels of polypyrimidine tract binding (PTB) protein by activating its promoter 
region (Bian et al., 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 65 
1.16 RNAi pathway 
Expression of a specific gene can be reduced and silenced by the expression of short-hairpin 
RNA (shRNA), which is a short sequence of RNA that makes a tight hairpin turn. This process is 
called RNA interference (RNAi). First evidence of RNAi system was reported by Napoli et al. in 
1990. The original purpose was to introduce a chimeric petunia CHS gene to overexpress 
chalcone synthase (CHS) in pigmented petunia petals but instead they recorded the loss of 
expression of a pigmentation gene (Napoli et al., 1990). Only few years later RNAi was first 
used in the nematode Caenorhabditis elegans proving that, with the introduction of RNA into 
cells, was possible to regulate gene expression (Fire et al., 1998). Nowadays this innovative 
technology of introduction of viral vectors into cells is widely applied in vitro and through the 
years is developing and advancing safety and specificity in order to be designated as a safe and 
plausible therapeutic tool (Blow, 2007; Giering et al., 2008; Castanotto & Rossi, 2009; Zhanga et 
al., 2008).  
RNAi occurs naturally in plants, fungi and animals and can be induced by the introduction of 
"naked" shRNA or via a viral vector into the cell (Fig. 1.18 and 1.19) and transcription of 
shRNA after vector integration is performed by either RNA pol II or pol III promoter. 
RNA silencing is initiated with the cleavage of double-stranded RNA (dsRNA) into ~20 short 
interfering RNAs (siRNAs) by an enzyme called Dicer in an ATP-dependent manner (Bernstein 
et al., 2001; Hamilton & Baulcombe, 1999). The hairpin is cleaved from the stem following 
nuclear export in a Ran-GTPase dependent manner.   
5' phosphorylated siRNA incorporates into the RNA-induced Silencing Complex (RISC) which 
unwind the siRNA allowing the binding to target mRNAs. siRNAs that lack a 5' phosphate are 
promptly phosphorylated by an endogenous kinase. The activated RISC complex terminates the 
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reaction with mRNA cleavage and degradation (Hammond et al., 2000; Zamore et al., 2000; 
Pham et al., 2004) (Fig. 1.18).   
Lentiviruses are commonly used to deliver siRNAs to cells in order to block the expression of a 
specific gene through the RNA interference (RNAi) pathway. They are used to introduce a gene 
product into in vitro systems or animal models to replace or knock out mutated genes that causes 
disease or are functioning improperly. This novel technology is useful for a better understanding 
of the effects of a given gene in a model system and represents one of the most promising 
discoveries in molecular biology (Fig. 1.19). 
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Figure 1.18 RNAi mechanisms 
Three individual ways to knock-down target gene expression are shown: siRNA, shRNA 
Plasmid, shRNA Lentiviral Particle. siRNA refers to small interfering or short interfering RNA. 
shRNA Plasmid is a plasmid encoding short-hairpin RNA (shRNA). Both require transfection 
with a lipid-based transfection reagent for delivery into a cell and are useful for a transient 
knock-down. shRNA Lentiviral Particle are viruses carrying a shRNA that are delivered into the 
cells through transduction and stably integrate in the cellular genome. Useful for either transient 
or stable knock-down of a target gene. siRNA Dicer and complex RISC are shown in the figure.  
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Figure 1.19 shRNA Lentiviral particle delivery 
shRNA delivered into the cells through transduction of Lentiviruses and following integration in 
the cellular genome. Useful for either transient or stable knock-down of a target gene. 
Transcription of shRNA by the cellular machine. siRNA Dicer and complex RISC are shown in 
the figure. The association of the RISC complex with target mRNA and following cleavage is 
shown. 
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1.17 Immunohistochemistry  
 
Immunohistochemistry is the process in which antigens or proteins are localized in tissue 
sections exploiting the usage of labeled antibodies that bind specifically to antigens in biological 
tissues. The interaction of the antibody-antigen is visualized by an enzyme such as peroxidase, 
that can catalyse a colour-producing reaction or alternatively different fluorescent dyes are 
available, as for example FITC, rhodamine or Texas Red. In 1941 Coons was the first to 
introduce a direct fluorescent method in order to localise substances in tissues (Taylor et al., 
2006). To improve detection sensitivity different methods were then developed such as the 
horseradish peroxidase, the peroxidase anti-peroxidase technique (Lee, 2010) and the use of the 
Avidin-Biotin complex (Hsu et al., 1981) but the basic procedure has not changed since its 
invention. In immunohistochemistry preservation of antigen and lack of background staining are 
standard conditions required (Polack & Van Noorden, 1997). 
Formalin or other aldehyde fixation can alter protein biochemistry and form protein cross-links 
which mask the antigenic sites in that tissue, causing faint or false negative staining. Two 
methods are used to unmask the antigens and epitopes in formalin-fixed and paraffin embedded 
tissue sections: enzymatic and heat-mediated (also known as heat-induced epitope retrieval, or 
HIER) methods: the first consists of the application of an enzyme solution, including trypsin, 
chymotrypsin, pronase and protease, directly to the tissue and the second of boiling the sections 
in solutions of heavy metal salts in microwave ovens or pressure cookers. Currently citrate 
buffer, EDTA buffer or Tris-EDTA Buffer are widely used for antigen retrieval enhancing 
staining intensity of antibodies.  
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1.17.1 Avidin-Biotin Conjugate (ABC) Method 
 
Avidin-Biotin Conjugate (ABC) method is a standard IHC technique extensively used for 
immunohistochemical staining.  Biotin, a low molecular weight vitamin, can be conjugated to the 
primary or the secondary antibody so that immunohistochemistry can be performed either as 
direct or an indirect method. In the indirect method the primary antibody binds first to the 
antigen and then the biotinylated secondary antibody reacts with the first antibody introducing a 
large mass of biotin into the section at the location of the primary antibody. The avidin-
biotinylated enzyme complex (ABC) is then added and binds to the biotinylated secondary 
antibody. Avidin is a glycoprotein that can be labeled with peroxidase or fluorescein and has a 
great affinity for biotin. The peroxidase is then developed by 3,3-Diaminobenzidine (DAB) or 
other substrate to produce different colorimetric end products (Fig. 1.20).  
 
 
 
Figure 1.20 IHC Methods 
(A) Indirect method of immunohistochemical staining; the first antibody against the antigen 
being probed for, and a second labelled antibody against the first. (B) Avidin-Biotin Conjugate 
(ABC) Method secondary antibodies are conjugated to biotin and function as links between 
tissue-bound primary antibodies and an avidin-biotin-peroxidase complex.  
A B 
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1.17.2 Tissue Microarray 
Tissue microarrays allow the high throughput analysis of distinct tissue samples by having 
multiple tissue samples on a single slide. They consist of different tissue samples collected from 
several tissue blocks and rearranged into a singular paraffin block in an array pattern (Fig. 1.21). 
The use of tissue microarray slides has many advantages compared to individual tissue section 
slides: since the analysis happens on a single slide containing different samples the conditions of 
the treatment, such as incubation time, reagent concentration, washing conditions and other 
factors remain the same therefore yielding uniform analysis.  Many samples from different 
patients can be analyzed simultaneously and using less reagents resulting in a wider and cost 
effective analysis. 
 
 
 
Figure 1.21 Representation of tissue microarrays  
(A) Tissue microarray paraffin block (B) Tissue microarray slide. 
 
 
 
 
A B 
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1.17.3 p16INK4a 
p16INK4a, a prototypic INK4 protein, has been identified as a tumor suppressor in many human 
cancers. It has been shown that the p16INK4a gene is altered by various mechanisms in a vast 
range of human cancers (Ruas & Peters, 1998) such as melanoma, gastric adenocarcinoma, 
Hodgkin and non-Hodgkin lymphomas (O’Neill & McCluggage, 2006). It is a member of the 
CDK inhibitor family of proteins and it has been shown to arrest the progression of the cell cycle 
and to be dramatically increased in cells undergoing senescence (Ohtani et al., 2004). Under 
normal condition cell cycle initiation and progression is controlled through a complex 
mechanism involving many regulatory pathways within the cell, including several classes of 
cyclin-dependent kinases (CDKs) and the Retinoblastoma protein (pRB). To initiate cell cycle 
progression pRB is phosphorylated by a holoenzyme complex containing cyclin D and a cyclin-
dependent kinase (CDK4 or CDK6). p16INK4a binds and induces an allosteric conformational 
change in CDK4/CDK6 inhibiting the binding of ATP to the CDK complex. This antagonizes 
activation of CDK and cyclin binding, therefore preserving pRB in its hypophosphorylated state 
leading to G1 cell cycle arrest (Fig. 1.22) (Sherr & Roberts, 1999). p16INK4a is a useful 
biomarker for the identification of cervical intraepithelial lesions because it is a surrogate 
measure of active HPV gene expression. Its over-expression is associated with the oncogenic 
transformation caused by persistent high-risk HPV infection (Benevolo et al., 2008). In fact, 
under normal conditions pRB inhibits the transcription of p16INK4a but inactivation of pRB by 
HPV E7 results in the accumulation of p16INK4a.   
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Figure 1.22 p16INK4a pathway 
Mechanism of action of p16INK4a as a cell cycle inhibitor causing G1 arrest (from Natarajan et 
al., 2005). 
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1.18 Aims 
Overarching Aim 
Elucidate the mechanism of HPV-16 gene regulation, primarily regulation of late gene 
expression 
 
Individual Aims 
 Generate reporter plasmids based on HPV-16 genome with the L1 gene replaced by an 
easily measurable reporter gene  
 Generate stable cell lines with the reporter plasmids integrated in the cellular genome to 
ensure long term gene expression 
 Identify small molecules that can induce late gene expression and that could potentially 
be used to treat persistent HPV infections 
 Identify novel cellular factors involved in regulation of HPV-16 late gene expression. 
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2. Chapter 2 - Material and Methods  
 
2.1 Generation of subgenomic HPV-16 reporter plasmids 
2.1.1 Plasmid constructions  
pBEL and pBELM, have been described previously (Fig. 2.1) (Zhao et al., 2004). In order to 
construct the reporter plasmids PCR was first performed using the plasmids, annealing 
temperatures, primers, components and general PCR cycling conditions as outlined in Table 2.1, 
2.2, 2.3 and 2.4. For example the poliovirus IRES sequence was PCR amplified from 
pKSPOLIO:S at 59°C annealing with oligonucleotides IRESs and IRESa. The IRES set primers 
have at each 5′ end restriction sites useful for cloning into pBEL and pBELM and subsequently 
insertion of a reporter gene. The IRES sense has a restriction site for BamHI and the IRES 
antisense primer has a short polylinker with restriction sites for XhoI, MluI and HpaI restriction 
enzymes (Table 2.1). The PCR fragment was subcloned into pCR2.1-TOPO according to the 
manufacturers protocol (Invitrogen) and transformation into E. coli and analysis of recombinant 
was carried out. The IRES sequence was then transferred as a BamHI-XhoI fragment into pBEL 
and pBELM generating pBEL-IRES and pBELM-IRES (Fig. 2.2 A), respectively. The 
chloramphenicol acetyltransferase (CAT) sequence was first PCR amplified at 65°C annealing 
with primers CATs and CATa (Table 2.1, 2.2, 2.3 and 2.4). CATs and CATa primers have at 
each 5′ end MluI and XhoI restriction sites, respectively (Table 2.1). The CAT PCR product was 
first cloned into pCR2.1-TOPO, the cloning reaction transformed and recombinant plasmids 
analyzed. The CAT sequence was excised from TOPO vector with MluI and XhoI and inserted 
downstream of the IRES sequence in pBEL-IRES and pBELM-IRES to generate pBEL-IRES-
CAT and pBELM-IRES-CAT, renamed pBELCAT and pBELMCAT for simplification (Fig. 2.2 
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B). pBspliceCAT and pBspliceMCAT (Fig. 2.3 A) were generated by digestion of pBELCAT 
and pBELMCAT, respectively with BssHII and SalI followed by filling in of overhangs with T4 
DNA polymerase and religation. To construct pMt1sdCAT (Fig. 2.3 A), a HindIII-ApaI fragment 
from plasmid pMt1sd (Somberg et al., 2008) was inserted into pBELMCAT.  
 
 
 
 
Figure 2.1 pBEL and pBELM plasmids 
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Figure 2.2 Representation of the reporter plasmids generated in this study 
(A) pBEL-IRES, pBELM-IRES (B) pBELCAT, pBELMCAT, (C) pBELMGFP (D) pBELSEAP, 
pBELMSEAP. 
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Figure 2.3 Representation of the reporter plasmids carrying only 2 splice sites SD3632 and 
SA5639 
(A) pBspliceCAT, pBspliceMCAT, pMt1sdCAT (B) pMt1sdSEAP. 
 
 
In order to construct pBELM-IRES-GFP (Fig. 2.2 C), pUC57/tat/LTR/GFP and pBELM-IRES-
CAT plasmids were digested with MluI and XhoI restriction enzymes and religated. As a 
positive control for GFP the pdE1-sp1AhCMV EGFP plasmid was used (7923bp). 
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To generate pBEL-IRES-SEAP and pBELM-IRES-SEAP the SEAP reporter gene was first PCR 
amplified at 60.2°C using SEAPs and SEAPa primers. SEAPs and SEAPa primers have at each 
5′ end MluI and XhoI restriction sites, respectively (Table 2.1), useful for insertion into pBEL-
IRES and pBELM-IRES. The PCR product was inserted into pCR2.1-TOPO (Invitrogen) and 
then transformation and analysis of recombinant plasmids was performed. The SEAP sequence 
from TOPO vector was digested with MluI and XhoI and inserted downstream the IRES 
sequence in pBEL-IRES and pBELM-IRES resulting in pBEL-IRES-SEAP and pBELM-IRES-
SEAP, which hereafter will be called pBELSEAP and pBELMSEAP, respectively (Fig. 2.2 D). 
To generate pMt1sdSEAP (Fig. 2.3 B), pMt1sdCAT and pBELMSEAP were digested with 
HindIII and ApaI restriction enzymes and religated.  
The LacZ gene was PCR amplified at 59°C using LacZ primers with the Expand long template 
PCR system kit according to the protocol of the manufacturer (Roche). The LacZ primers both 
have a restriction site for XhoI enzyme at the 5′ end. The PCR product was cloned into pCR2.1-
TOPO vector and then transformation and analysis of recombinant plasmids was performed. 
Plasmids pCMVE4orf4 (Somberg et al., 2009), pCMVPTB (Somberg et al., 2008), 
pCMVSRp30c (Somberg et al., 2011) and pASF/SF2 (Somberg & Schwartz, 2010) express 
E4orf4, PTB, SRp30c and ASF/SF2 respectively and have been described previously.  
 
 
 
 
 
 
 80 
 
Plasmid Primers Annealing temp. PCR product Cloning enzymes 
1/10000 pKSPOLIO:S IRESs/IRESa 59°C 752 bp BamHI, XhoI, 
MluI, HpaI 
1/50000 pcSEAP SEAPs/SEAPa 60.2°C 1530 bp MluI, XhoI 
1/2000 pCMVsport β-gal LacZs/LacZa 59°C 3141 bp XhoI, XhoI 
1/2000 pCCKH1DXK CATs/CATa 65°C 660 bp MluI, XhoI 
Table 2.1 Plasmids dilution, primers pairs, annealing temperature, PCR product and 
restriction enzymes used for the cloning steps. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 81 
Oligonucleotide Sequence (5’-3’) 
IRESs                                      GGGATCCTTAAAACAGCTCTGGGGTTG    
IRESa   CCTCGAGTTAACACGCGTAGGTAATTCCAATAGGTGTGAGTG 
SEAPs AACGCGTGAAATGCTGCTGCTGCTGCTGCTGCTGGGCC 
SEAPa CCTCGAGTTAACCCGGGTGCGCGGCGTCGGTGGTGCCGG 
LacZs CCTCGAGATGTCGTTTACTTTGACCAAC 
LacZa CCTCGAGTTTTTGACACCAGACCAACTG 
CATs GACGCGTACCATGAGTAAAGGAGAAGAACTTTTCACTGGA 
CATa CCTCGAGCTATTTGTATAGTTCATCCATGCC 
GFPs ATTCTCGTGGAACTGGATGG 
GFPa CACTGCACGCCATAAGAGAA 
Table 2.2 Sequences of oligonucleotides used in this study for PCR 
 
Solution Concentration 1x 
DNA - 1µl 
Primer mix 100ng/µl 1µl 
dNTPs 10mM 0.5µl 
PCR buffer (10mM Mg++) 5x 5µl 
Taq polymerase 5u/µl 0.2µl 
H20 - 17.3µl 
Total  25µl 
Table 2.3 PCR reaction mix 
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Temperature Time Cycles 
95°C 5 min 1 
95°C 30 sec 35 
Annealing temperature required (Table 2.1) 30 sec 35 
72°C 1 min 35 
72°C 5 min 1 
Table 2.4 PCR cycling condition  
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2.1.2 TOPO TA Cloning  
2.5μl of fresh PCR product was mixed with 1μl of salt solution. 1μl of TOPO vector and 1.5μl of 
H2O. The reaction was mixed gently and incubated for 5 min at room temperature. 
 
 
2.1.3 Transformation into TOP10 Chemically competent E. coli 
2.5μl of the TOPO®Cloning reaction was added into a vial of One Shot® Chemically Competent 
E. coli and mixed gently. After incubation on ice for 25 min the cells were heated-shocked for 30 
sec at 42°C and then placed for 2 additional minutes on ice. 250μl of S.O.C. medium was added 
and the tube was let shake horizontally (225 rpm) at 37°C for 1 hour. 200μl from transformation 
was spread on a pre-warmed selective agar plate (Appendix I) containing 40μl of 40mg/ml X-gal 
in dimethylformamide (DMF) and then the plates were incubated at 37°C overnight.  
 
2.1.4 Purification of PCR product and vector reactions 
10-15μl of pBEL and the PCR product of interest inserted into TOPO vector were digested in the 
same reaction tube with 1μl of each restriction enzyme required, 2.5μl of Buffer and H2O up to 
25μl. After incubation for more than 3 hours at the required temperature a phenol/chloroform 
purification was performed. 25μl of H2O was added into the tube and mixed. 50μl of 
phenol/chloroform/isoamyl alcohol was added and mixed for 5 sec. After centrifugation at 14000 
rpm for 30 sec the aqueous phase was removed to a fresh tube and 50μl of chloroform was added 
and the mixture was vortexed. After an additional centrifugation at 14000 rpm for 30 sec the 
aqueous phase was removed to a fresh tube and 5μl of 5M NaCl and 120μl of 100% ethanol were 
added. The mixture was vortexed and incubated at -70°C for 10 min. After centrifugation at 
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14000 rpm for 15 min the supernatant was aspirated and 200μl of ice cold 70% ethanol was 
added. An additional centrifugation at 14000 rpm for 5 min was performed and the supernatant 
was aspirated and the pellet was air-dried completely.  The pellet was then resuspended in 8μl of 
H2O and ligation was performed. 
 
 
2.1.5 Ligation Reaction 
The ligation was performed using the Rapid DNA Dephos & Ligation Kit according to the 
protocol of the manufacturer (Roche). 2μl of DNA dilution Buffer was added into the tube 
containing 8μl of purified reaction and mixed thoroughly. Then 10μl of T4 DNA Ligation buffer 
and 1μl of T4 DNA ligase were added and mixed thoroughly. The reaction was incubated for 5 
min at room temperature and 2.5μl was then transformed into One Shot® Chemically Competent 
E. coli as described above. 
 
 85 
2.1.6 Analysis of recombinant plasmids 
Single colonies were picked from the agar plate and inoculated into 3ml LB medium (Appendix 
I) containing 3µl of ampicillin and incubated overnight at 37°C in an orbital incubator. 1.5ml of 
the overnight culture was poured into tubes and centrifuged at 14000 rpm for 3 min. The 
supernatant was aspirated and the pellet resuspended in 100µl of solution I (Appendix I), then 
200µl of solution II (Appendix I) was added and the mixture was incubated at room temperature 
for 5 min. 150µl of solution III (Appendix I) was added, vortexed and incubated on ice for 5 min, 
then centrifuged at maximum speed for 5 min. 400µl of the supernatant was transferred into a 
fresh tube containing 400µl of phenol/chloroform/isoamyl alcohol (Appendix I), and the mixture 
was vortexed and centrifuged for 30 sec. Then the aqueous (top) phase was transferred into a 
fresh tube and 400µl of chloroform was added. After vortexing and centrifugation for a further 
30 sec the aqueous phase was transferred into a fresh tube containing 800µl of 100% ethanol 
(Merck). The mixture was then vortexed and incubated on ice for 5 min. The tubes were 
centrifuged at maximum speed for 5 min to pellet the DNA and the supernatant was aspirated. 
1ml of cold 70% ethanol (Appendix I) was then added and centrifuged at maximum speed for 5 
min. The supernatant was carefully aspirated and the pellet let to air-dry. 25µl of TE buffer 
(Appendix I) containing RNase A (22µg/ml) (Appendix I) were added.  
 
2.1.7 Restriction of mini preparation plasmid DNA 
In order to identify the recombinant plasmid of interest each mini preparation plasmid was 
subjected at restriction. 10µl of plasmid was mixed with 1.5µl Buffer solution, 0.25µl of each 
restriction enzyme (Table 2.1) and milliQ-water up to 15µl according to the protocol of the 
manufacturer (Roche). The mixture was incubated at the required temperature of each restriction 
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enzyme for at least 2 hours and then analyzed with electrophoresis on a 1% agarose gel with 
ethidium bromide staining (0.5µg/ml ethidium bromide dissolved in gel). 
 
2.1.8 Isolation of high quality plasmid 
Isolation of purified plasmid DNA from bacterial cultures was carried out using the High Pure 
Plasmid Isolation kit (Roche). The bacterial culture with the plasmid of interest was grown 
overnight at 37°C in 8ml LB medium containing 8µl of 100mg/ml ampicillin. 3ml of overnight 
culture were poured into a tube. After centrifugation at 6000 × g for 30 sec the supernatant was 
discarded and the pellet was resuspended with 250µl suspension buffer containing RNase and 
mixed well. 250µl of Lysis buffer was added and mixed gently, the mixture was then incubated 
for 5 min at room temperature. 350µl of chilled Binding buffer was added and mixed gently and 
incubated on ice for 5 min. The tube was then centrifuged for 10 min at 13000 x g. The 
supernatant was then transferred into a high pure filter tube, previously inserted into a collection 
tube, and it was then centrifuged for 1 min at 13000 x g. The flowthrough liquid was discarded 
and 500µl of Wash buffer I was added to the filter tube. After centrifugation at maximum speed 
for 1 min the flowthrough was discarded and 700µl of Wash buffer II were added to the filter 
tube followed by centrifugation for an additional minute at maximum speed. The filter tube was 
then inserted into an eppendorf tube. 100µl of Elution buffer was added and the tube was 
centrifuged 1 min at maximum speed. 10µl of purified plasmid DNA was first subjected at 
restriction (Table 2.1) and bands analyzed with electrophoresis on a 1% agarose gel with 
ethidium bromide staining and then sent for sequencing. 
In order to prepare purified plasmid DNA in large quantities all plasmids were purified with the 
Genopure Plasmid Midi kit (Roche). The bacterial culture with the plasmid of interest was grown 
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overnight at 37°C in 100ml LB medium containing 100µl ampicillin, with vigorous shaking 
(approx. 200 rpm). To pellet the bacteria the culture medium was centrifuged for 10 min at 3000 
× g at 4°C and then the supernatant was discarded. The pellet was let air-dry for few minutes and 
thereafter carefully resuspended in 8ml Suspension buffer containing RNase. 8ml Lysis buffer 
was added and mixed gently by inverting the tube and the mixture was then incubated 2-3 min at 
room temperature. 8ml chilled Neutralization buffer were added and mixed immediately by 
inverting gently until a homogenous mix and then incubated 5 min on ice. The bacteria lysate 
was first cleared by filtration and then loaded into a column and let empty by gravity flow. The 
flowthrough was loaded into the column once more and then it was discarded. The column was 
thereafter washed with 4ml of Wash buffer and let to flow through. This step was repeated 2 
times more. The column was then inserted into a collection tube capable of withstanding high 
speed centrifugation and 2,5ml of pre-warmed Elution buffer (50°C) were added and let to empty 
by gravity flow. This step was repeated one more time and then 3,6ml of isopropanol was added 
into the tube to precipitate the eluted plasmid. The plasmid DNA was centrifuged for 30 min at 
15000 × g at 4°C. The supernatant was then carefully discarded and the plasmid DNA was 
washed with 3ml of chilled 70% ethanol and centrifuged for an additional 10 min at 15000 × g at 
4°C. The supernatant was then carefully removed and the tube was then let to air-dry for about 
10 min. The DNA plasmid pellet was then re-dissolved in 50µl TE buffer and stored at -20°C.  
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2.2 Analysis of the reporter genes 
 
2.2.1 Cell culture and transfections  
HeLa cells were cultured in RPMI-1640 medium containing 10% fetal bovine calf serum, 
glutamine and penicillin-streptomycin. Transfections were carried out by using 
GeneJuice®Transfection reagent according to the protocol of the manufacturer (Novagen). In 
short, 2x106 HeLa cells were plated per well into 35mm plates the day before transfection and 
incubated at 37°C. 3µl of GeneJuice®Transfection reagent and 100µl of serum-free RPMI-1640 
medium were mixed and incubated for 5 min. Then the required amount of plasmid DNA was 
added, and the mixture was incubated at room temperature for 10 min. Thereafter, the mixture 
was added drop-wise into each well at approximately 70% confluence, and incubated at 37°C for 
24 hours.  
 
 
2.2.2 CAT ELISA assay 
Cells were harvested 24 hours post-transfection, lysed, and the CAT levels were determined 
using a CAT ELISA assay based on the sandwich ELISA principle according to the protocol of 
the manufacturer (Roche). Briefly, cells were lysed in 1ml lysis buffer and the cell extract 
containing the CAT enzyme was centrifuged at 13000 x g for 10 min at 4°C. 200µl of cell extract 
was added per well into a coated microplate and incubated for 1h at 37°C. The wells were rinsed 
5 times with a washing buffer and an Anti-CAT-DIG working dilution was added and incubated 
for 1h at 37°C. After the washing steps an Anti–DIG-POD working dilution was added in each 
well. After 1 hour at 37°C the wells were washed 5 times and a POD substrate was added into 
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each well and incubated at room temperature. Absorption was measured at 405nm using a 96-
well microplate ELISA reader (Labsystems Multiskan®Plus).  
 
2.2.3 SEAP assay 
The medium from the transfected cells was analyzed based on the SEAP Assay Protocol 
(Roden/Bossis). The medium was heat inactivated at 65°C for about 10-15 min to reduce 
background and 200µl was then poured into a 96-well microplate. 20µl of 0.05% CHAPS 
(Appendix I) in PBS was added to each well and then 40µl of substrate (Appendix I) was added 
and incubated at room temperature in darkness and measured at 405nm in a 96-well microplate 
ELISA reader (Labsystems Multiskan®Plus). 
    
2.2.4 GFP assay 
For the analysis of CMVGFP and pBELMGFP expression plasmids, a cover slip was placed into 
each well of a 35mm plate and then 2x106 cells were added. Transfection was carried out as 
previously described. After 24 hours the cells were washed twice with PBS and the cover slip 
was removed from the well and mounted on a slide. GFP fluorescence intensities were detected 
and quantitated with a fluorescence microscope from the living cells (CELL^F software, 
Olympus Soft Imaging solutions GmbH).  
.  
 
2.2.5 β-galactosidase assay 
A second reporter vector, pCH110, was included in all transfection experiments and assayed so 
that the expression of the experimental reporter gene may be normalized. The normalizing cells 
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were transfected with each plasmid in a minimum of three independent experiments with similar 
results. β-Galactosidase was assayed by adding 150µl of 2x assay buffer (200mM sodium 
phosphate buffer, pH7.3, 2mM MgCl, 100mM β-ME, 1.33mg/ml ONPG) to 150µl of cell 
extract. The mixture was incubated at 37°C for 3 hours and the reaction was stopped adding 
500µl of 1M sodium carbonate. The absorbance was monitored at 420nm in a spectrophotometer 
using plastic cuvettes.  
 
 
2.3 Establishment of stable cell lines 
2.3.1 Stable transfection and clones selection 
2x106 HeLa cells were plated per well into 35mm plates and incubated overnight at 37°C. 1.5µg 
of DNA reporter plasmid was co-transfected respectively with 0.25µg of pSVNEO into cells and 
24 hours post-transfection cell were transferred into 100mm dishes. Stable clones were selected 
with 200µg/ml of G418 and after approximately 3 weeks individual clones were picked and 
plated in new culture dishes. For DNA extraction the cells were trypsinised, pelleted and 
resuspended in 200µl of Phosphate-buffered saline (PBS). The cells were lysed with 300µl of 
cell lysis solution (Appendix I). 100µl of a 10M ammonium acetate solution was then added to 
precipitate the proteins followed by vortexing for 15 sec. The mixture was centrifuged for 5 min 
at 13000 x g and 300µl of isopropanol was added to the supernatants followed by centrifugation 
for 5 min to pellet the DNA. The DNA pellets were washed with 300µl of 70% ethanol and 
resuspended in 25µl TE buffer (10mM Tris.Cl pH8.0, 1mM EDTA). The DNA was subjected to 
PCR amplification with CATs and CATa primers (Table 2.2) for CAT stable cell lines or GFPs 
and GFPa (Table 2.2) for pBELMGFP stable cell line. A further PCR amplification was 
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performed with IRESs and IRESa primers (Table 2.2) in both CAT and GFP positive clones to 
confirm the integration of the entire sequence. 15µl of each PCR product were analysed on a 1% 
agarose gel.  
 
 
 
 
 
2.3.2 RNA extraction and reverse transcription (RT)-PCR 
 
(i) RNA extraction 
Total RNA was isolated using the High pure RNA isolation kit according to the protocol of the 
manufacturer (Roche). The cells were trypsinised and centrifuged at 1500 x rpm for 3 min. The 
pellet was washed with PBS and centrifuged for 5 additional minutes. The cells were 
resuspended with 200μl of PBS and 400μl of Lysis/-Binding Buffer was added. After vortexing 
for 15 sec the entire sample was transferred into the upper reservoir of the filter tube inserted in 
one collection tube. The tube was centrifuged for 15 sec at 8000 × g and the flowthrough liquid 
discarded. 500µl of Wash Buffer I was added to the upper reservoir of the filter tube and 
centrifuged for 15 sec at 8000 × g.  
After discarding the flowthrough 500µl of Wash Buffer II was added. After a centrifuge for 15 
sec at 8000 × g 200µl of Wash Buffer II was added and the tube centrifuged at maximum speed 
for 2 additional minutes. The RNA was then eluted with 80µl of Elution Buffer and the tube 
centrifuge for 1 min at 8000 × g. 
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(ii) RT-PCR 
Total RNA was then reverse transcribed at 42°C by using Superscript II and gene specific 
primers (Table 2.5) according to the manufacturer’s instructions (Invitrogen). In short, 2µg of 
total RNA was added into a RNase free tube. Then 1μl (100ng) of gene-specific primer (GSP), 
1μl of dNTP Mix (10mM each) and RNase free water up to 10μl were added. The mixture was 
heated at 65°C for 5 min and quick chilled on ice. The content of the tube was collected by brief 
centrifugation and a reaction mix of 4μl of 25mM MgCl2, 2μl of 5X First-Strand Buffer, 2μl of 
0.1M DTT and 1μl of RNaseOUT™ (40 units/μl) was added into the tube and mixed gently. The 
tube was incubated at 42°C for 2 min and then 1μl of SuperScript™ II RT was added and mixed 
by pipetting gently up and down. The tube was then incubated at 42°C for 50 min and the 
reaction was inactivated by heating at 70°C for 15 min. From the synthesised cDNA 2µl was 
taken and PCR-amplified in a 25µl reaction volume using oligonucleotides listed in Table 2.1. 
An annealing temperature of 55°C was used to PCR amplify cDNAs with 757s and E4a primers, 
whereas an annealing temperature of 57°C was used with 757s and L1a primers or 757s and 
L1Ma primers. cDNA synthesized with oligonucleotide CATa was PCR amplified at 68°C with 
primers 757s and CATa (Table 2.5).  
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Oligonucleotide Sequence (5’-3’) 
CATa CCTCGAGCTATTTGTATAGTTCATCCATGCC 
757s GTCGACGGTATCGATCGGTTGTGCGTACAAAGCACACACG 
E4a CCGCGCGCTGCCTAATAATTTCAGGAGAGG 
L1a  CCGTGCTTACAACCTTAGATACTGGGACAG 
L1Ma  CGCTGGGCAGCCACAGGC 
Table 2.5 Sequences of oligonucleotides used in this study for RT-PCR 
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2.4 Treatment with small molecules drug 
2.4.1 Stable transfection with small molecules drugs 
2x106 cells from derived stables cell lines were plated per well into 35mm plates containing 2ml 
RPMI-1640 medium. Next day medium was replaced with 2ml complete medium containing 
different concentrations of small molecules: TPA (phorbol 12-myristate 13-acetate, Sigma), 
emetine (emetine dihydrochloride hydrate, Sigma), cycloheximide (Sigma), ceramide (N-
Hexanoyl-D-sphingosine, Sigma), valproic acid (Sigma), scriptaid (Sigma), amiloride (Sigma) or 
tannic acid (Sigma). Cells were then incubated at 37°C and harvested at different time points and 
analysed.  
 
2.4.2 Transient transfection with small molecules drugs 
2x106 HeLa cells were plated per well into 35mm plates containing 2ml RPMI-1640 medium. 
Transfections were carried out by using GeneJuice®Transfection reagent according to the 
protocol of the manufacturer (Novagen). 0.5µg of plasmid DNA was added, and the mixture was 
incubated at room temperature for 10 min. Thereafter, the mixture was added drop-wise into 
each well and incubated at 37°C. 24 hours posttransfection medium was replaced with 2ml 
RPMI-1640 medium containing 0.5µl H2O, 800ng TPA, 0.5mM valproic acid or 10µM tannic 
acid and cells were incubated at 37°C for further 24 hours.  
 
2.5 Protein analysis 
2.5.1 Protein extraction 
Cells were lysed from the 6 well-plate directly with the lysis buffer from the CAT ELISA KIT or 
by trypsination as follows: cells were harvested with 200µl trypsin and then 800µl of complete 
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medium was added in each well. After centrifuging the cells in media for 3 min at 1500 rpm at 
room temperature, the supernatant was aspirated off and the pellet resuspended in 1ml of cold 
PBS. After a further centrifugation at 1500 rpm for 5 min, the PBS was aspirated off and cells 
were resuspended in 40-80μl RIPA buffer and vortexed vigorously. The mixer was incubated on 
ice for 20 min with occasional mixing followed by centrifugation at 14000 rpm for 30 min at 
4°C. The supernatant was transferred into a fresh tube and protein concentration was measured in 
duplicate with Bradford assay using a BSA standard curve. Samples were stored at -80ºC.  
 
2.5.2 Western blot 
15µl of each sample was heated at 95°C for 5 min and then was loaded with 5µl of 4x Laemmli 
sample buffer onto on an SDS-PAGE minigel (Appendix I). Gels were let run at 100V for 3 
hours (dye about the bottom of the gel).  
Proteins were then transferred onto a nitrocellulose membrane. All components of the blot were 
pre-wet in cold transfer buffer pH 8.3 (Appendix I) and the entire stack was placed in the transfer 
apparatus with cold transfer buffer using an ice-pack to cool down the apparatus. Transfer was 
carried out at 100V for 60-70 minutes. 
After successful transfer, the membrane was blocked in 5% non-fat dry milk for 1 hour at room 
temperature on a shaker. The membrane was then washed with TBS + 1% Tween20, 5 times for 
5 minutes.  
A dilute solution of primary antibody (for specific dilutions see Table 2.6) was incubated with 
the membrane at 4°C for 16 hours on a nutator shaker under gentle agitation. After 5 washes in 
TBS + 1% Tween20 for 5 min the membrane was then incubated with secondary antibody for 1 
hour at room temperature in 10ml 1x TBS + 5% milk + 0.1% Tween20 on a shaker under gentle 
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agitation. The membrane was then washed 5 times for 5 min each in ~20ml 1xTBS + 0.1% 
Tween20.  
Protein detection was carried out with the ECL (enhanced chemiluminescence) kit. ECL 
solutions were mixed in a 1:1 ratio and poured onto membranes for 5 min. The ECL solutions 
were drained and membrane was exposed to film. 
 
 
Antibody Dilution Low fat Milk solution Molecular weight 
PTB 1:1000 5% milk + 0.1% Tween 20 61-64 kDa 
ASF/SF2 1:500 5% milk + 0.1% Tween 20 34 kDa 
hnRNP A2/B1 1:1000 5% milk 37 kDa 
β-actin  1:5000 5% milk + 0.1% Tween 20 42 kDa 
Table 2.6 Antibodies used in this study for Western blot 
 
 
 
2.6 Apoptosis-program 
2.6.1 Serum deprivation  
2x106 cells were seeded per well into 35mm plates and incubated overnight at 37°C with 
complete medium. Next day medium was removed and cells washed once with serum free 
medium and then incubated in medium with or without serum for 24, 48 and 72 hours. Cells 
were harvested for CAT at all time points.  
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2.6.2 Heat shock 
2x106 cells were plated per well into 35mm plates and incubated overnight at 37°C with 
complete medium. Medium was then discarded and replaced with medium preheated to 45°C. 
Cells incubated at 37°C were also included in the experiment as a control for all time points. 
Cells were analysed after 30min, 1, 2 and 3 hours. 
 
 
 
2.7 Infection of cells with Lentiviruses expressing SiRNA-GFP constructs  
2.7.1 Transduction 
5x105 cells were plated in the 35mm culture dishes and incubated overnight. After 24 hours the 
medium was replaced with 0.5ml serum free medium and cells were infected at different 
multiplicity of infection (MOI) (Table 2.7) with each lentivirus carrying short hairpin RNA 
(shRNA) ASF/SF2, PTB or scramble. 4 hours post-transduction 1.5ml of complete medium was 
added to the well and then cells were incubated at 37°C for 48 hours. Selection for infected cells 
was carried out with 1µg/ml puromycin (Sigma) for further 5 days.  
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Lentiviruses 
Number of 
Cell/well 
TU/µl MOI Time (h) 
Puromycin 
µg/ml 
ASF/SF2 5x105 3.38x105 0.3, 1, 2, 5, 10 48 1 
PTB 5x105 4.32x105 0.3, 1, 2, 5, 10 48 1 
scramble 5x105 3.75x105 0.3, 1, 2, 5, 10 48 1 
Table 2.7 Lentiviruses used in this study  
 
 
 
2.7.2 Detection of GFP fluorescence 
Cells were plated in 35mm Glass Bottom Culture Dishes and cultured in 1.5ml complete RPMI-
1640 medium. The next day the complete medium was removed and replaced with medium 
without serum. GFP fluorescence intensity was detected with a confocal laser scanning 
microscope, Zeiss LSM 510. 
 
 
2.8 Tissue microarray preparation and analysis 
2.8.1 Samples collection and tissue microarray preparation 
Cervical samples were collected from the Rotunda Hospital (samples sent between 2005 and 
2007). Ethical approval was obtained from the Rotunda Hospital to collect patient information 
and formalin fixed paraffin embedded (FFPE) cervical tissue samples, and from Dublin Institute 
of Technology Ethics Committee. Samples were arbitrarily numbered to maintain confidential all 
patient information.  
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Tissue microarrays (TMA) were prepared using a tissue arrayer (Beecher Instruments Manual 
Tissue Arrayer MTA-1) following the instructions of the manufacturer. Cores of 1.0mm in size 
were produced using MP10 needles, produced by Beecher Instruments. Each tissue microarray 
contains 4 cases of non-neoplastic cervical epithelium, 12 cases of low-grade squamous 
intraepithelial lesion, 12 cases of high-grade squamous intraepithelial lesion and 12 cases of 
cervical carcinoma. Each case was sampled in duplicate for a total of 80 cores per TMA.  
 
2.8.2 Immunohistochemistry (Avidin-Biotin Complex Immuno-peroxidase 
method) 
Five micrometer thick cervix TMA was cut from formalin-fixed paraffin embedded tissue blocks 
and melted in the oven at 56°C for 1 hour. The tissue microarray slides were then dewaxed in 
xylene for 10 min and rehydrated in absolute alcohol for 10 min and further 5 min in spirit. To 
remove alcohol slides were washed in water for 1 min.  
Slides were then submerged in 10mM/l Citrate Buffer (pH 6) (Appendix I) and heated in the 
microwave for 12 minutes. After antigen retrieval the slides were allowed to cool in the citrate 
buffer for a further 20 min.  
After fixation with 3% methyl hydrogen peroxide for 5 min, the sections were rinsed 3 times in 
phosphate buffered saline (PBS) pH 7 and then stained using the PK-6200 universal 
VECTASTAIN ABC kit as follows. Normal horse serum was applied to the sections for 5 min. 
Sections were washed with PBS three times and approximately 300µl of specific primary 
antibody was applied and incubated at room temperature for 1 hour. hnRNP A2/B1 and 
p16INK4a were used as primary antibodies (see Table 2.8 for dilutions). Following three 
washing with PBS the biotinylated secondary antibody was applied and allowed to conjugate for 
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15 min. Sections were washed three times with PBS and then covered with ABC reagent for 15 
min. Peroxidase labeling was visualized using 0.02% hydrogen peroxide and 0.2%  2,4-
diaminobenzidine. Mayer’s hematoxylin was applied to the slides for 40 sec and the slides were 
then blued in warm water for 3 min. The tissue arrays were then dehydrated in spirit and absolute 
alcohol through xylene. A cover slip was mounted on the slide using distrene plasticiser xylene 
(DPX). 
 
 
Antibody Dilution Company Raised in 
hnRNP A2/B1 1:1000 Abcam Mouse 
P16INK4a 1:500 Abcam Mouse 
Table 2.8 Antibodies used in this study for IHC 
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3. Chapter 3 - Results  
Generation and validation of HPV-16 late gene reporter constructs 
 
The life cycle of HPV-16 is strictly associated with the differentiation program of the infected 
cells (Doorbar, 2005). At the molecular level, a persistent HPV infection is characterised by 
continued expression of the early viral genes, and a complete shut-down of the late viral genes 
encoding the highly immunogenic viral structural proteins L1 and L2. Similarly high grade, 
premalignant lesions containing HPV-16 primarily express early viral genes, and not L1 or L2. 
Inhibition of HPV-16 late gene expression in the early stage of life cycle is probably a 
prerequisite for persistence of infection, therefore activation of L1 and L2 late gene expression in 
the persistently infected cells would alert the immune system of the host of the presence of the 
virus and it might clear the infection. As the L1 RNA is difficult to detect it would be useful to 
generate a novel and easy system to facilitate the investigation of HPV-16 late gene regulation. 
 
3.1 Generation of reporter plasmids 
In order to generate a simple and reliable bioassay to study HPV-16 late gene expression two 
previously described plasmids, named pBEL and pBELM, were used (Fig. 3.1) (Zhao et al., 
2004). Both plasmids carry viral early and late genes, except E6 and E7 and the weak viral 
promoters are replaced by the strong human cytomegalovirus (CMV) immediate early promoter. 
Early and late splice sites are present in the plasmid allowing the examination of the splicing 
events that can occur in HPV-16. Similar to the HPV-16 genome during an infection, pBEL 
transfected into proliferating cells expresses high level of the early genes, primarily E4, whereas 
expression of late genes is undetectable. In pBELM, the splicing silencer elements adjacent to 
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the SA5639 have been mutated to reduce the silencing on this splice acceptor therefore activating 
late gene expression (Fig. 3.1) (Zhao et al., 2004). 
This study aimed to examine the regulation of HPV-16 L1 gene by replacing it with an easily 
detectable reporter such as CAT, GFP, SEAP, Luciferase and β-galactosidase. In order to 
achieve this, the plasmids pBEL and pBELM were modified to incorporate the poliovirus IRES 
and reporter gene as described in figure 3.2 and 3.3.  
 
 
 
 
 
 
Figure 3.1 Schematic representation of the subgenomic HPV-16 expression plasmids, pBEL 
and pBELM, and the major potential mRNAs that can be produced 
The position of the human cytomegalovirus immediate early (CMV) promoter is shown. 
Numbers refer to nucleotide positions of 5’ splice sites (black circles), 3’ splice sites (white 
circles). The mutation site in pBELM (M) is indicated. The early and late polyadenylation 
signals pAE and pAL are indicated. Major potential mRNAs produced by pBEL and pBELM are 
indicated below plasmids. 
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Figure 3.2 Schematic representation of cloning steps for insertion of IRES sequence and 
reporter gene into pBEL plasmid 
To release the first part of L1 gene, pBEL was digested with BamHI and XhoI restriction 
enzymes at position 6150nt in HPV-16 L1 and position 7272nt in the HPV-16 late UTR. The 
IRES sequence from the poliovirus plasmid was PCR amplified using IRESs and IRESa primers 
(Table 2.2) and cloned into TOPO followed by insertion as a BamHI/XhoI fragment into pBEL 
using T4 DNA ligase. The polylinker present in the IRES sequence was used for insertion of 
reporter genes into the plasmid. Each step was reproduced for the cloning of IRES into pBELM.  
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Figure 3.3 Generation of reporter plasmids 
Chloramphenicol acetyltransferase (CAT), green fluorescent protein (GFP), secreted embryonic 
alkaline phosphatase (SEAP), Luciferase and β-galactosidase (LacZ) were selected as reporter 
genes to be inserted into pBEL and pBELM plasmids downstream the IRES sequence. All 
restriction sites used for the cloning steps are shown in the figure. Numbers refer to nucleotide 
positions of 5’ splice sites (black circles), 3’ splice sites (white circles). 
 
 
 
 
 
The L1 region in pBEL and pBELM has unique restriction sites for BamHI and XhoI enzymes 
necessary for the cloning. When electrophoresed on an agarose gel the uncut plasmid showed a 
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supercoiled band. The plasmid digested with BamHI or XhoI resulted on a linearised band of 
10004 bp and cut with BamHI and XhoI together it released a 1 Kb fragment of L1 (Fig. 3.4).  
Cutting with BamHI or XhoI at position 6150 and 7272, respectively, will release L1 from 
nucleotide 514 and allow insertion of the IRES and reporter sequences. 
 
 
 
 
Figure 3.4 Restriction enzymes in pBEL plasmid 
10 Kb DNA ladder (M), lane 1 undigested pBEL plasmid, lane 2 pBEL plasmid digested with 
BamHI restriction enzyme (10004 bp), lane 3 pBEL plasmid digested with XhoI restriction 
enzyme (10004 bp), lane 4 pBEL plasmid digested with BamHI and XhoI restriction enzymes.   
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The first 514-nucleotides of the L1 coding sequence contain RNA elements that regulate splicing 
to the 3′ -splice site named SA5639. These sequences therefore must be present on the reporter 
plasmids and since this L1 sequence contains the L1 ATG and multiple internal methionines, the 
poliovirus 2A internal ribosome entry site (IRES) is required upstream of the reporter gene to 
ensure that the reporter gene expression is a true measure of late mRNA levels. A serial dilution 
of the pKSPOLIO:S plasmid (initially approximately 1µg/µl) containing the IRES sequence was 
carried out and PCR amplification was performed at 59°C annealing as described in Material and 
Methods, with IRESs and IRESa primers (Table 2.2, 2.3 and 2.4). The PCR product resulted in a 
752 bp band (Fig. 3.5).    
 
 
 
Figure 3.5 PCR amplification of IRES sequence with IRES set primers 
10Kb DNA ladder (M), lane 1 PCR amplification of 1/10 pKSPOLIO:S plasmid, lane 2 1/100 
pKSPOLIO:S plasmid, lane 3 1/1000 pKSPOLIO:S plasmid, lane 4 1/10000 pKSPOLIO:S 
plasmid, lane 5 blank. 
 107 
The oligonucleotide primers used for IRES PCR amplification have at each 5′ end restriction 
sites useful for cloning into pBEL and pBELM and subsequently insertion of a reporter gene. 
The 5′ end of the IRES sense has a restriction site for BamHI and a short polylinker (XhoI, MluI 
and HpaI) is present on the IRES antisense primer (Table 2.1 and 2.2) (Fig. 3.2 and 3.3).  
The PCR product was inserted into pCR2.1-TOPO vector (3931 bp) and the recombinant vector 
was transformed into competent E. coli. Several colonies were picked and plasmids were isolated 
and purified from bacterial cultures. In order to identify the recombinant plasmid of interest each 
purified plasmid DNA was subjected at restriction digest with BamHI and XhoI and then 
analyzed on a 1% agarose gel. Only two recombinant plasmids, lanes 2 and 4, have the correct 
IRES sequence inserted (Fig. 3.6).  
 
 
 
Figure 3.6 Analysis of recombinant plasmids TOPO + IRES 
10Kb DNA ladder (M), lanes 1-13 different recombinant plasmids, lane 2 and lane 4 TOPO + 
IRES (4000 bp + 752 bp), lane 14 IRES PCR product band 752 bp. 1% agarose gel ethidium 
bromide-stained. 
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The TOPO vector carrying the IRES gene and pBEL were digested together with BamHI and 
XhoI restriction enzymes. By cutting the two plasmids with the same restriction enzymes, the 
resulting molecular fragments terminate with complementary sticky ends and in order to 
recombine the fragments into recombinant DNA molecules T4 DNA ligase was used. The 
ligation was then transformed into competent E. coli and plasmid DNA was isolated and purified 
from bacterial cultures and recombinant plasmids analyzed as mentioned above. The same was 
repeated for pBELM. The result of this ligation can be the original TOPO-IRES, the original 
pBEL or pBELM, TOPO-L1 and pBEL-IRES or pBELM-IRES. Only two colonies seemed to 
have the right recombinant pBEL + IRES (Fig. 3.7) and pBELM + IRES (Fig. 3.8). These 2 new 
plasmids have the original pBEL and pBELM sequence with part of the L1 gene (approx. 1000 
bp) replaced by the IRES sequence (752 bp). Lane 4 (Fig. 3.7) below appears to have the correct 
pBEL backbone and insert and lane 6 (Fig. 3.8) the correct pBELM backbone and insert. 
High quality plasmid was generated for each correct recombinant and sequenced to confirm the 
clone, (see appendix I for alignment with poliovirus sequence).  
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Figure 3.7 Analysis of recombinant plasmids pBEL + IRES 
10Kb DNA ladder (M), lanes 1-14 different recombinant plasmids, lane 4 pBEL + IRES (10000 
bp + 752 bp). 1% agarose gel ethidium bromide-stained. 
 
 
 
 
 
Figure 3.8 Analysis of recombinant plasmids pBELM + IRES 
10Kb DNA ladder (M), lanes 1-11 different recombinant plasmids, lane 6 pBELM + IRES 
(10000 bp + 752 bp). 1% agarose gel ethidium bromide-stained. 
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In order to generate an easily detected reporter plasmid, 5 different reporter genes were selected 
to replace the L1 gene: chloramphenicol acetyltransferase (CAT), green fluorescent protein 
(GFP), secreted alkaline phosphatase (SEAP), Luciferase and β-galactosidase (LacZ) (Fig. 3.9).  
 
 
 
 
  
Figure 3.9 Schematic representation of the reporter plasmids 
Chloramphenicol acetyltransferase (CAT), green fluorescent protein (GFP), secreted alkaline 
phosphatase (SEAP), Luciferase and β-galactosidase (LacZ) were chosen as reporter gene to 
clone pBEL-IRES and pBELM-IRES. The polylinker is shown in the diagram. 
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CAT was PCR amplified at 65°C with CATs and CATa primers (Table 2.1 and 2.2) resulting in 
a PCR product of 660 bp (Fig. 3.10). SEAP was PCR amplified at 60.2°C with SEAPs and 
SEAPa primers (Table 2.1 and 2.2) resulting in a PCR product of 1530 bp (Fig. 3.10). LacZ was 
PCR amplified at 59°C with LacZs and LacZa primers (Table 2.1 and 2.2) resulting in a PCR 
product of 3141 bp (Fig. 3.10). Each oligonucleotide used for these PCR amplifications has a 5′ 
restriction site required for the cloning into pBEL-IRES and pBELM-IRES. For example as 
shown in Table 2.1 CATs and CATa primers have MluI and XhoI restriction site, respectively. 
SEAPs primer has at the 5′ end restriction site for MluI restriction enzyme and SEAPa for XhoI.  
LacZ primers both have at each 5′ end restriction site for XhoI. 
 
 
 
 
Figure 3.10 PCR amplification of secreted alkaline phosphatase (SEAP), β-galactosidase 
(LacZ) and chloramphenicol acetyltransferase (CAT) reporter genes 
10Kb DNA ladder (M), lane 1 PCR amplification of SEAP gene (1530 bp) using the 
SEAPs/SEAPa primers. Lane 2 PCR amplification of LacZ gene (3141 bp) using the 
LacZs/LacZa primers. Lane 3 PCR amplification of CAT gene (660 bp) using the CATs/CATa 
primers. 
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The CAT PCR product was first ligated with pCR2.1-TOPO vector (3931 bp) and the 
recombinant vector was transformed into competent E. coli. Several colonies were picked and 
plasmids were isolated and purified from bacterial cultures. In order to identify the recombinant 
plasmid of interest each purified plasmid DNA was digested with MluI and XhoI restriction 
enzyme and then analyzed on a 1% agarose gel stained with ethidium bromide-stained. As 
shown in figure 3.11 all recombinant plasmids, except one (lane 2), resulted in TOPO + CAT 
sequence. 
 
 
 
Figure 3.11 Analysis of recombinant plasmids TOPO + CAT 
10Kb DNA ladder (M), lanes 1-11 different recombinant plasmids TOPO + CAT (4000 bp + 660 
bp). 1% agarose gel ethidium bromide-stained. 
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In order to clone the CAT sequence into pBEL-IRES and pBELM-IRES, the TOPO vector 
carrying the CAT reporter gene and pBEL-IRES and pBELM-IRES plasmids were digested 
separately with MluI and XhoI restriction enzymes and then ligated in 2 different reactions: 
pBEL-IRES and TOPO-CAT one, and pBELM-IRES and TOPO-CAT the other. Ligations were 
then transformed into competent E. coli and plasmid DNA was isolated and purified from 
bacterial cultures and recombinant plasmids analyzed as mentioned above. The result of this 
ligation can be the original TOPO-CAT, the original pBEL-IRES or pBELM-IRES and pBEL-
IRES-CAT or pBELM-IRES-CAT. Only two recombinant plasmids showed to have the CAT 
reporter gene inserted into pBEL-IRES (Fig. 3.12, lane 6) and pBELM-IRES (Fig. 3.13, lane 8). 
The CAT reporter gene is inserted downstream of the IRES sequence resulting in pBEL-IRES-
CAT and pBELM-IRES-CAT that for simplification we will call pBELCAT and pBELMCAT, 
respectively. 
 
 
 
 
Figure 3.12 Analysis of recombinant plasmids pBEL-IRES + CAT 
10Kb DNA ladder (M), lanes 1-14 different recombinant plasmids, lane 6 pBEL-IRES-CAT 
(bands 10000 bp + 660 bp). 1% agarose gel ethidium bromide-stained. 
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Figure 3.13 Analysis of recombinant plasmids pBELM-IRES + CAT 
10Kb DNA ladder (M), lanes 1-11 different recombinant plasmids, lane 8 pBELM-IRES-CAT 
(bands 10000 bp + 660 bp). 1% agarose gel ethidium bromide-stained. 
 
 
The SEAP PCR product was first inserted into pCR2.1-TOPO vector (3931 bp) as mentioned 
above. In order to identify the recombinant plasmid of interest each purified plasmid DNA was 
digested with MluI and XhoI restriction enzymes and then analyzed on a 1% agarose gel. Five 
recombinant plasmids resulted in TOPO + SEAP sequence (Fig. 3.14, lanes 10, 12, 14, 15 and 
17).  
 
 
 
Figure 3.14 Analysis of recombinant plasmids TOPO + SEAP 
1 10Kb DNA ladder (M), lanes 1-17 different recombinant plasmids for TOPO-SEAP, lanes 10, 
12, 14, 15 and 17 positive TOPO + SEAP (4000 bp + 1530 bp). 1% agarose gel ethidium 
bromide-stained. 
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The SEAP sequence was then inserted into pBEL-IRES and pBELM-IRES, by digestion with 
MluI and XhoI restriction enzymes of the TOPO vector carrying SEAP reporter gene and pBEL-
IRES and pBELM-IRES plasmids and ligation. Ligations were then transformed into competent 
E. coli and plasmid DNA was isolated and purified from bacterial cultures and recombinant 
plasmids subjected at restriction. As shown in figure 3.15 many recombinant plasmids showed to 
have the SEAP reporter gene inserted into pBEL-IRES (lanes 1, 2) and pBELM-IRES (lanes 10, 
14, 15, 16, 17 and 18), respectively, resulting in pBELSEAP and pBELMSEAP reporter 
plasmids. 
 
 
 
 
Figure 3.15 Analysis of recombinant plasmids pBEL-IRES + SEAP and pBELM-IRES + 
SEAP 
10Kb DNA ladder (M), lanes 1-9 different recombinant plasmids for pBEL-IRES-SEAP, lanes 
10-18 different recombinant plasmids for pBELM-IRES-SEAP (10000 bp + 1530 bp). 1% 
agarose gel ethidium bromide-stained. 
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In order to generate the GFP reporter plasmid a pUC57-tat-LTR-GFP plasmid has been 
generated with restriction sites MluI and XhoI in the GFP gene. The CAT reporter gene from 
pBELMCAT was replaced with the GFP reporter gene by digestion with MluI and XhoI of 
pBELMCAT and pUC57-tat-LTR-GFP and religation. The result of this ligation can be the 
original pUC57-tat-LTR-GFP, pBELM-IRES, pBELMCAT or pBELM-IRES-GFP. As shown in 
figure 3.16 two recombinant plasmids resulted to be pBELM-IRES-GFP (lane 12 and 13) that 
from now on will be called pBELMGFP. We reasoned that GFP levels produced from the pBEL-
backbone would be too low to detect, and therefore constructed only pBELMGFP. 
 
 
 
 
 
Figure 3.16 Analysis of recombinant plasmids pBELM-IRES + GFP 
10Kb DNA ladder (M), lanes 1-14 different recombinant plasmids, lane 12 and lane 13 pBELM-
IRES + GFP (10000 bp + 650 bp). 1% agarose gel ethidium bromide-stained. 
 
 
 
The LacZ reporter gene was inserted into TOPO vector as shown in figure 3.17 (lanes 1, 4, 5 and 
10). Cloning into pBEL and pBELM was unsuccessful, probably due to the considerable size of 
the reporter gene itself (3141bp) and the plasmid which is approximately 10Kb.  
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Figure 3.17 Analysis of recombinant plasmids TOPO + LacZ 
10Kb DNA ladder (M), lanes 1-11 different recombinant plasmids for TOPO-LacZ, lanes 1, 4, 5 
and 10 positive TOPO + LacZ (4000 bp + 3141 bp). 1% agarose gel ethidium bromide-stained. 
 
 
 
 
3.2 Determination of CAT expression in pBELCAT and pBELMCAT 
The pBELCAT and pBELMCAT reporters were chosen as the first constructs to analyse. These 
were transfected into HeLa cells in culture to examine if they behave in a similar manner to the 
L1 gene in previous transfections with pBEL and pBELM (Fig. 3.18). 
pBELCAT and pBELMCAT (Fig. 3.19) were transfected into Hela cells and CAT expression 
was monitored 24 hours posttransfection. Similar to previously Northen blot analysis, pBELCAT 
produced barely detectable levels of CAT (0.13 CAT units), whereas pBELMCAT showed 
higher CAT expression (29 CAT units) as expected, and produced over 200-fold more CAT than 
pBELCAT (Fig. 3.20). However, these levels were relatively low compared to CAT expression 
from the positive control plasmid CMVCAT, which produced 10,600 CAT units (Fig. 3.20). 
These results demonstrated that only a minority of the mRNAs produced by pBELCAT and 
pBELMCAT were late mRNAs, suggesting that late gene expression was relatively inefficient 
from both plasmids. These results demonstrate that the reporter plasmids are functional and 
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express CAT protein. Multiple nucleotide substitutions in the first 514 nucleotides of L1 
enhanced CAT expression as a result of the inactivation of splicing silencers as previously 
described (Zhao et al., 2004). These results also indicate that the pBELCAT and pBELMCAT 
reporters can be used in future studies to examine proteins that regulate L1 gene expression. 
 
 
 
 
 
Figure 3.18 Northen blot analysis on pBEL and pBELM 
pBEL and pBELM in previous transfections produced high levels of the early mRNAs, primarily 
E4 mRNA, whereas late mRNAs are undetectable. pBELM showed to produce late mRNAs 
without interfering on the production of the E4 mRNAs. (Zhao et al., 2004). 
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Figure 3.19 Schematic representation of the subgenomic HPV-16 expression plasmids, 
pBELCAT and pBELMCAT, and the major potential mRNAs that can be produced 
The position of the human cytomegalovirus immediate early (CMV) promoter is shown. 
Numbers refer to nucleotide positions of 5’ splice sites (black circles), 3’ splice sites (white 
circles). The early and late polyadenylation signals pAE and pAL are indicated. Major potential 
mRNAs produced by pBELCAT and pBELMCAT are indicated below plasmids. 
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Figure 3.20 Determination of CAT levels in transient transfection 
Transfection of pBELCAT, pBELMCAT and CMVCAT expression plasmids into HeLa cells. 
Logarithmic scale. Cells were transfected with each plasmid in a minimum of three independent 
experiments. Error bars indicate standard error for each sample.  
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3.3 Adenovirus E4orf4, polypyrimidine tract binding protein, ASF/SF2 and 
SRp30c induce CAT expression from pBELCAT and pBELMCAT reporter 
plasmids 
HPV-16 late gene expression is regulated at the level of RNA processing (Graham, 2008; 
Schwartz, 2008; Zheng & Baker, 2006). Overexpression of some viral and cellular proteins, e. g. 
adenovirus E4orf4 protein (E4orf4), polypyrimidine tract binding protein (PTB), alternative 
splicing factor/splicing factor 2 (ASF/SF2) and arginine/serine-rich SRp30c protein (SRp30c), 
have been shown previously to induce HPV-16 late gene expression from pBEL and pBELM 
(Somberg et al., 2011; Somberg & Schwartz, 2010; Somberg et al., 2009; Somberg et al., 2008). 
In order to validate the functionality of the novel reporter plasmids pBELCAT and pBELMCAT, 
each reporter plasmid was cotransfected with E4orf4, PTB, SRp30c and ASF/SF2 into HeLa 
cells. Overexpression of E4orf4, PTB, ASF/SF2 or SRp30c caused an increase in CAT 
expression from both pBELCAT and pBELMCAT (Fig. 3.21). E4orf4, which regulates the 
switch from early to late gene expression in the adenovirus life cycle (Akusjärvi & Stevenin, 
2003), efficiently induced CAT production from both plasmids but in particular from pBELCAT, 
resulting in a 300 fold induction (Fig. 3.21). A titration of the E4orf4-, PTB-, SRp30c or 
ASF/SF2-plasmids sub-genomic HPV-16 expression plasmid in pBELMCAT, revealed that 
induction of CAT was dose-dependent (Fig. 3.22). While CAT induction caused by PTB and 
SRp30c was increased with higher levels of PTB or SRp30c plasmid, the highest concentrations 
of E4orf4 and ASF/SF2 plasmids inhibited CAT production, suggesting other effects on the cells 
(Fig. 3.22). We concluded that E4orf4, PTB SRp30c and ASF/SF2 induced CAT expression 
from pBELCAT and pBELMCAT in a dose dependent manner and that the reporter plasmids 
respond to known inducers of late gene expression in a manner similar to the native L1 gene. 
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Figure 3.21 Cotransfection of CAT reporter plasmids with E4orf4, PTB, SRp30c or 
ASF/SF2 expression vector 
pBELCAT or pBELMCAT were transfected into HeLa cells in the presence and absence of 
cotransfected expression vectors. Cells were transfected with each plasmid in a minimum of 
three independent experiments. Error bars indicate standard error for each sample. * indicates 
significance in relation to pBELCAT or pBELMCAT cotransfected with the empty vector 
(pUC19) (p<0.05). 
 
 
Figure 3.22 Titration of E4orf4, PTB, SRp30c or ASF/SF2 expression vector in 
pBELMCAT reporter plasmid 
A titration up to 1µg of E4orf4, PTB, SRp30c or ASF/SF2 was carried out in pBELMCAT. 
pUC19 plasmid was used as an empty vector to equalize the concentration in each single 
transfection. 
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3.4 Determination of GFP levels in pBELMGFP 
Green fluorescent protein (GFP) is a reporter gene widely used as a tool to study gene 
expression. It is a reliable reporter of gene expression in individual eukaryotic cells and its 
fluorescence can be measured and quantified from living cells.  
pBELMGFP (Fig. 3.23) and a CMV driven GFP expression plasmid (CMVGFP) were 
transfected into HeLa cells. Analysis of the cells post-transfection revealed that pBELMGFP 
produced low detectable levels of GFP (Fig. 3.24). Quantification of GFP expression in a 
number of different GFP positive cells revealed that GFP levels produced from pBELMGFP 
were approximately 200-fold lower than those produced by CMVGFP (Fig. 3.25).   
 
 
 
Figure 3.23 Schematic representation of subgenomic expression plasmid pBELMGFP 
The position of the human cytomegalovirus immediate early (CMV) promoter is shown. 
Numbers refer to nucleotide positions of 5’ splice sites (black circles), 3’ splice sites (white 
circles). The early and late polyadenylation signals pAE and pAL are indicated.  
 
 124 
 
 
Figure 3.24 Examination of GFP expression after 24 hours posttransfection 
HeLa cells were transfected with (A) CMVGFP plasmid as a control, (B) pBELMGFP reporter 
plasmid and (C) pBELMGFP + E4orf4 (D) pBELMGFP + PTB (E) pBELMGFP + SRp30c (F) 
control HeLa cells. Untransfected cells are shown as a comparison. 
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Figure 3.25 Determination of GFP levels in transient transfection 
Transfection of CMVGFP and pBELMGFP expression plasmids into HeLa cells. GFP 
fluorescence intensities were detected with a fluorescence microscope from the living cells. GFP 
fluorescence intensities were detected and quantitated in 10 randomly chosen cells as described 
in material and methods. Cells were transfected with each plasmid in a minimum of three 
independent experiments. Logarithmic scale. Error bars indicate standard error for each sample.  
 
 
Cotransfection with E4orf4 showed a small but significant induction compared to the other 
cotransfected expression vectors and to the experiments with pBELCAT and pBELMCAT (Fig. 
3.26). However, cotransfection of pBELMGFP with a PTB and SRp30c expression plasmids 
resulted in induction of GFP expression (Fig. 3.24 and 3.26). PTB and SRp30c increased the 
levels of GFP of almost 6- and 30- fold, respectively (Fig. 3.26 B). 
Taken together these results showed that pBELMGFP reporter plasmid is functional and its 
expression is fast and easily detectable when transfected into proliferating cells.  
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Figure 3.26 Determination of GFP levels in pBELMGFP transient transfection 
(A) GFP intensities in transfection of pBELMGFP reporter plasmid into HeLa cells in the 
absence or presence of cotransfected expression vectors. (B) Induction of GFP expression by 
E4orf4, PTB and SRp30c in pBELMGFP. GFP fluorescence intensities were detected and 
quantitated in 10 randomly chosen cells as described in material and methods. Cells were 
transfected with each plasmid in a minimum of three independent experiments. Error bars 
indicate standard error for each sample. * indicates significance in relation to pBELMGFP alone 
(p<0.05). 
 
 
 127 
In order to detect higher levels of GFP expression HeLa cells were transfected with plasmids 
pBELMGFP and E4orf4, PTB or SRp30c and cells were analyzed 48 hours posttransfection. Still 
low GFP expression was detected from cells transfected with pBELMGFP. A moderate increase 
of GFP levels was observed in cells transfected with pBELMGFP and PTB or SRp30c as seen in 
previous experiment (Fig. 3.27). 
 
 
 
Figure 3.27 Examination of GFP expression after 48 hours posttransfection  
HeLa cells were transfected with (A) pBELMGFP reporter plasmid and (B) pBELMGFP + 
E4orf4 (C) pBELMGFP + PTB (D) pBELMGFP + SRp30c. 
 
 
 
C 
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D 
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3.5 Determination of SEAP levels in pBELSEAP and pBELMSEAP 
The secreted embryonic alkaline phosphatase (SEAP) assay is a very simple method to analyze 
gene expression since the SEAP gene product is secreted from mammalian cells and therefore it 
is easily detected in a sample of culture medium. pBELSEAP, pBELMSEAP (Fig. 3.28) and a 
CMV driven SEAP expression plasmids were transfected into HeLa cells. Analysis of SEAP 
expression was performed after 24 and 48 hours post-transfection. Very high background levels 
were observed and only SEAP expression from the CMVSEAP was detected (Fig. 3.29).  
 
 
 
Figure 3.28 Schematic representation of subgenomic expression plasmids pBELSEAP and 
pBELMSEAP 
Numbers refer to nucleotide positions of 5’ splice sites (black circles), 3’ splice sites (white 
circles). The early and late polyadenylation signals pAE and pAL are indicated.  
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Figure 3.29 Determination of SEAP levels in SEAP reporter plasmids transient transfection 
Analysis of SEAP expression in CMVSEAP, pBELSEAP and pBELMSEAP 24 and 48 hours 
post-transfection.  
 
The fetal calf serum (FCS) present in the medium may contain alkaline phosphatase (AP) that 
can interfere with AP quantification, therefore, in order to optimize the assay, samples from 
cultured HeLa cells were analyzed after 24 and 48 hours at room temperature or after a heat-
treatment at 65°C for 30 min to eliminate non-SEAP phosphatase activity (from the FCS used in 
the culture medium) (Fig. 3.30 A). The secreted embryonic alkaline phosphatase (SEAP) is 
insensitive to heat, in contrast to the endogenous alkaline phosphatase (AP). To evaluate the 
presence of alkaline phosphatase in the fetal calf serum, samples of only medium containing 
serum and serum-free medium were also tested at room temperature or after heat-treatment at 
65°C for 30 min (Fig. 3.30 B). The heat-treatment at 65°C reduced the background level, but 
after 48 hours of incubation it resulted still very high. The second experiment demonstrated that 
the medium without serum reduces the background levels when compared with the medium 
containing serum, but heat-treatment had any effect on it. However the serum in the medium is 
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required for the growth of the cell thus the heat-treatment proved to be the best way to reduce the 
background level. 
 
Figure 3.30 Optimization of SEAP assay 
(A) Hela cells were incubated at 37°C for 24 and 48 hours and the medium samples were 
analyzed at room temperature and after a heat-treatment at 65°C for 30 min. (B) Analysis of the 
medium in the presence or absence of serum at room temperature or after heat-treatment at 65°C 
for 30 min. 
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Next, a transfection of the SEAP reporter plasmids in the presence and in the absence of E4orf4 
expression plasmid was carried out and the samples were pre-heated at 65°C but no detection of 
SEAP expression was observed (Fig. 3.31). In this figure it is possible to see the equivalent 
production of SEAP from HeLa cells and the SEAP reporter plasmids. Only the CMVSEAP 
plasmid showed to produce SEAP however, SEAP levels revealed to be much lower when 
compared with the levels of CAT produced by the CMVCAT. In conclusion we were not able to 
detect any SEAP expression from SEAP reporter plasmids due probably to the high background 
levels.  
Since the CAT assay proved to be the most sensitive, reliable and suitable for large scale 
screening, this reporter was chosen for the generation of the stable cell lines and continued study. 
 
 
Figure 3.31 SEAP levels of SEAP reporter plasmids transiently transfected in HeLa cells  
Analysis of SEAP levels in CMVSEAP, pBELSEAP, pBELMSEAP, pBELSEAP + E4orf4, 
pBELMSEAP + E4orf4 and HeLa cells pre-heated at 65°C for 30 min, 24 and 48 hours post-
transfection. Cells were transfected with each plasmid in three independent experiments. 
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3.6 Identification and characterization of cis-acting regulatory RNA elements 
in HPV-16 CAT and SEAP reporter plasmids 
 
Two viral splice sites are used exclusively by HPV-16 late mRNAs: late 5′-splice site SD3632 
(located between the E4 and E5 coding regions) and late 3′-splice site SA5639 (located in the L1 
coding region). Both splice sites are suppressed by multiple splicing silencer elements (Schwartz 
et al., 2007). To further investigate how the reporter plasmids presented here could be used to 
study HPV-16 late gene expression, a set of simpler plasmids were generated containing the late 
region with the CAT reporter gene but only the two late splice sites SD3632 and SA5639, named 
pBSpliceCAT and pBSpliceMCAT (Fig. 3.32). Transfection of these plasmids into HeLa cells 
revealed that pBSpliceCAT failed to produce detectable levels of CAT whereas pBspliceMCAT 
expressed barely detectable levels of CAT (1.3 CAT units) (Fig. 3.33 A). These results 
confirmed that SD3632 and SA5639 are efficiently suppressed in proliferating cancer cells. 
Transfection of pBspliceMCAT in the presence of plasmids expressing E4orf4, PTB or SRp30c 
resulted in an induction of CAT production, but this induction was lower than the induction of 
CAT from pBELMCAT by the same proteins (Fig. 3.33 B). In contrast, deletion of a previously 
described sequence (Rush et al., 2005; Somberg et al., 2008) that suppressed SD3632 as in 
plasmid pMt1sdCAT (Fig. 3.32), resulted in efficient production of high levels of CAT (155 
CAT units) (Fig. 3.33 A), demonstrating that this set of plasmids could be used to study cis-
acting, splicing regulatory elements at the HPV-16 late splice sites.  
 
 
 133 
 
 
Figure 3.32 Schematic representation of subgenomic expression plasmids pBspliceCAT, 
pBspliceMCAT and pMt1sdCAT 
Numbers refer to nucleotide positions of 5’ splice sites (black circles), 3’ splice sites (white 
circles). The early and late polyadenylation signals pAE and pAL are indicated. Major potential 
mRNAs produced by pBspliceCAT, pBspliceMCAT and pMt1sdCAT are indicated below. E4* 
refers to a short mRNA encoding E4 and E5 that is unspliced due to the absence of SD880 and 
SA3358. 
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Figure 3.33 Determination of CAT levels in CAT reporter plasmids  
(A) pBspliceCAT, pBspliceMCAT and pMt1sdCAT were transfected into HeLa cells and levels 
of CAT expression were determined 24h posttransfection. (B) pBspliceMCAT was transfected 
into HeLa cells in the presence and absence of plasmid expressing E4orf4, PTB and SRp30c. 
Transfections were carried out in triplicate. Error bars indicate standard error for each sample. * 
indicates significance in relation to pBspliceMCAT cotransfected with the empty vector 
(pUC19) (p<0.05). 
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Since pMt1sdCAT showed to efficiently induce CAT expression, this experiment was 
reproduced with the SEAP reporter plasmid pMt1sdSEAP (Fig. 3.34). In previous experiments 
the SEAP expression was undetectable from pBELSEAP and pBELMSEAP due to high 
background levels but as shown in figure 3.35 deletion of sequences upstream SD3632 
(pMt1sdSEAP), resulted in a modest production of SEAP (0.5 SEAP units). This result 
demonstrated that these sequences upstream SD3632 strongly suppress this splice site therefore 
inhibiting late gene expression. In conclusion pMt1sdSEAP plasmid could be used to study cis-
acting, splicing regulatory elements at the HPV-16 late splice sites. 
 
 
 
 
 
Figure 3.34 Schematic representation of subgenomic expression plasmid pMt1sdSEAP 
Numbers refer to nucleotide positions of 5’ splice sites (black circles), 3’ splice sites (white 
circles). The early and late polyadenylation signals pAE and pAL are indicated. Major potential 
mRNAs produced by pMt1sdSEAP are indicated below. E4* refers to a short mRNA encoding 
E4 and E5 that is unspliced due to the absence of SD880 and SA3358. 
. 
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Figure 3.35 Determination of SEAP levels in SEAP reporter plasmid 
CMVSEAP, pBELSEAP, pBELMSEAP and pMt1sdSEAP were transfected into HeLa cells and 
levels of SEAP expression were determined 24h posttransfection. Transfections were carried out 
in triplicate. 
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4. Chapter 4 – Results 
Generation and characterization of stable cell lines 
The capability to integrate genes into the full DNA sequence of a mammalian cell has a 
significant impact on biomedical research. Stable transfection of mammalian cells is a widely 
used technique to study gene expression and it ensures long term gene expression.  
 
4.1 Establishment of two novel HPV-16 reporter cell lines that can serve as 
tools to investigate regulation of HPV-16 gene expression 
Having demonstrated the use of transient transfections of the CAT reporter constructs, it was 
decided to generate stable cell lines of the pBELCAT and pBELMCAT constructs to aid in large 
scale screening. To establish stable cell lines containing the reporter plasmids pBELCAT or 
pBELMCAT, these plasmids were separately introduced into HeLa cells in the presence of 
plasmid pSVneo, which encodes the neomycin-resistant gene under control of the SV40 
promoter. The transfected cells were propagated in G418 to select for cells with integrated 
plasmid DNA. More than 100 neomycin-resistant colonies were picked and DNA was first 
extracted and PCR amplified with CAT and IRES set primers (Table 2.2) (Fig. 4.1). The level of 
CAT expression of each positive clone was then monitored with a CAT ELISA assay. Five 
positive clones for pBELCAT (pBELCAT-24, 51, 102, 47 and 67) and two for pBELMCAT 
(pBELMCAT-31 and 25) stable cell lines expressed CAT. As shown in figure 4.2, CAT 
expression was barely detectable in pBELCAT cell lines (between 0.002 and 0.3 CAT units). In 
contrast, significant levels of CAT were detected in both pBELMCAT-derived cell lines (Fig. 
4.2). In particular one, pBELMCAT-31, produced more than 500 CAT units. These results 
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demonstrated that pBELCAT- and pBELMCAT-derived stable cell lines were functional and 
expressed detectable levels of CAT. The expression of CAT from the stable cell lines mimicked 
that seen in transient transfections using pBELCAT and pBELMCAT and also of HPV-16 late 
genes confirm the suitability of the cell lines for further study. 
 
 
Figure 4.1 PCR amplification of DNA extracted from pBELCAT and pBELMCAT stable 
cell lines using CAT or IRES set primers 
(A) 1KB DNA ladder (M), lanes 1-11 PCR amplification of DNA extracted from pBELCAT 
stable cell lines using CAT primers, lane 13 positive control, lane 15 blank.  (B) 1KB DNA 
ladder (M), lanes 1-11 PCR amplification of DNA extracted from pBELCAT stable cell lines 
using CAT primers, lane 13 positive control, lane 15 blank.  (C) 1KB DNA ladder (M), lanes 1-
11 PCR amplification of DNA extracted from pBELMCAT stable cell lines using CAT primers, 
lane 14 positive control, lane 15 blank. (D)  1KB DNA ladder (M), lanes 1-5 PCR amplification 
of DNA extracted from pBELCAT and pBEMCAT stable cell lines using IRES primers, lane 8 
positive control, lane 11 blank.   
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Figure 4.2 Determination of CAT levels in stable transfection 
CAT levels were determined from pBELCAT- and pBELMCAT-derived cell lines. 5 pBELCAT 
stable cell lines produced little CAT, and 2 pBELMCAT produced high levels of CAT. 
Logarithmic scale. 
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4.2 Analysis of overexpression of E4orf4, PTB and SRp30c in pBELCAT and 
pBELMCAT stable cell lines 
 
To evaluate the functionality of these novel stable cell lines we wished to examine if they 
responded to inducers of late gene expression in a similar manner to HPV-16 L1 and to the 
transient transfections of the reporters pBELCAT and pBELMCAT. pBELCAT- and 
pBELMCAT-derived cell lines were screened for functionality by transfecting them  with 
adenovirus E4orf4, PTB or SRp30c expression plasmids (Fig. 4.3). CAT expression was 
observed in three pBELCAT-derived cell lines (pBELCAT-51, -47 and -67) whereas the other 
two (pBELCAT-24 and -102) showed no induction of CAT expression (Fig. 4.3 A). 
Overexpression of E4orf4, PTB and SRp30c resulted in an increase of CAT expression in both 
pBELMCAT-derived cell lines (Fig. 4.3 B). In particular pBELMCAT-31, which showed really 
high level of CAT when untransfected, in the presence of the viral or cellular proteins showed an 
induction of 2.6-, 1.7- and 2.2-fold respectively. These results showed a lower induction of CAT 
compared to the transient transfections, which could be explained in two ways: either the levels 
of CAT produced by the pBELMCAT-derived cell line were too high and expression could only 
be modestly enhanced, or low transfection efficiency resulted in relatively fewer CAT producing 
cells transfected with adenovirus E4orf4, PTB or SRp30c, resulting in a relatively low increase 
in CAT. In order to demonstrate that CAT expression is dependent on the level of these proteins 
a titration up to 4µg of E4orf4 and/or PTB was carried out in each stable cell line. Three 
pBELCAT cell lines (pBELCAT-51, -47 and -67) showed an induction of CAT expression in a 
PTB dose-dependent manner, whereas CAT induction failed in the other two stable cell lines 
(pBELCAT-102 and -24) (Fig. 4.4). Induction of CAT in an E4orf4 dose-dependent manner was 
observed only in pBELCAT-47 and -67 but not in pBELCAT-51 (Fig. 4.5). 
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Figure 4.3 Induction of CAT expression in pBELCAT and pBELMCAT derived-cell lines 
(A) Induction of CAT expression by overexpression of PTB expression plasmid in pBELCAT-
derived cell lines. (B) Induction of CAT expression by overexpression of E4orf4, PTB and 
SRp30c expression plasmid in pBELMCAT-derived cell lines. 
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Figure 4.4 Titration of PTB expression plasmid in pBELCAT stable cell lines 
Titration up to 4µg of PTB expression plasmid into (A) pBELCAT-47, (B) pBELCAT-51, (C) 
pBELCAT-67, (D) pBELCAT-24 and (E) pBELCAT-102 stable cell lines. pUC19 plasmid was 
used as an empty vector to equalize the concentration in each single transfection. 
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Figure 4.5 Titration of E4orf4 expression plasmid in pBELCAT stable cell lines 
Titration up to 4µg of E4orf4 expression plasmid into (A) pBELCAT-47, (B) pBELCAT-51 and 
(C) pBELCAT-67 stable cell lines. pUC19 plasmid was used as an empty vector to equalize the 
concentration in each single transfection. 
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As pBELMCAT-31 produced higher levels of CAT when compared with pBELMCAT-25 and 
showed to respond well to the effect of the viral and cellular proteins, it was used for continued 
study. With a titration up to 4 µg of E4orf4 or PTB plasmid into pBELMCAT-31 higher levels of 
CAT were observed at higher concentrations of transfected E4orf4 or PTB plasmid, 
demonstrating that CAT induction in pBELMCAT cell line was dependent on the amount of 
transfected plasmid (Fig. 4.6). These results also indicated that the relatively low induction of 
CAT in the stable cell lines compared to transient co-transfections with CAT reporter plasmids 
and E4orf4, PTB and SRp30c, was most likely the result of low transfection efficiency. 
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Figure 4.6 Titration of inducers of late gene expression in pBELMCAT stable cell lines 
A titration up to 4µg of (A) E4orf4 or (B) PTB was carried out in pBELMCAT-31 derived-stable 
cell line. pUC19 plasmid was used as an empty vector to equalize the concentration in each 
single transfection. 
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Transfections with 4µg of E4orf4, PTB or SRp30c were then reproduced in pBELCAT-67 and 
pBELMCAT-31 stable cell lines in a minimum of three independent experiments and fold 
induction was calculated. As previously seen in transient transfection, higher levels of CAT were 
observed in the wild type-derived cell line (pBELCAT-67) in the presence of E4orf4 expression 
plasmid resulting in 8 fold induction but also PTB or SRp30c efficiently modulated CAT 
expression inducting 6 and 4 fold, respectively (Fig. 4.7). A lower induction was observed in 
pBELMCAT-31 in the presence of E4orf4, PTB or SRp30c, resulting in 1.7-, 1.6- and 1.5-fold, 
respectively (Fig. 4.7). The results indicate that pBELCAT and pBELMCAT stable cell lines 
respond to inducers of later gene expression in a manner similar to HPV-16 L1 and to that seen 
in transient transfections. 
In conclusion, we have generated functional stable reporter cell lines that will be useful for 
analyzing HPV-16 late gene expression and for the identification of cellular factors that regulate 
HPV-16 gene expression. Much of the further work on the cell lines focussed on pBELCAT-67 
and pBELMCAT-31. 
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Figure 4.7 Induction of CAT expression in pBELCAT-67 and pBELMCAT-31 stable cell 
lines 
Induction of CAT expression by overexpression of E4orf4, PTB and SRp30c expression plasmid 
in pBELCAT and pBELMCAT-derived cell lines. Cells were transfected with each plasmid in a 
minimum of three independent experiments. Error bars indicate standard error for each sample. * 
indicates significance in relation to pBELCAT-67 or pBELMCAT-31 transfected with the empty 
vector (pUC19) (p<0.05). 
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4.3 RT-PCR analysis 
 
To confirm that the integrated pBELCAT and pBELMCAT plasmids produced the expected 
early and late mRNAs, RNA was extracted and subjected to RT-PCR. cDNA was synthesized 
from RNA extracted from pBELCAT or pBELMCAT-derived cell lines using gene specific 
primers: E4a, L1a or L1Ma and CATa primers (Table 2.5). RT-PCR on cDNA from selected 
pBELCAT-67 cell line with primers 757s and E4a (Table 2.5) yielded a single 190bp-band, 
representing E4 mRNAs produced by splicing from SD880 to SA3358 (Fig. 4.8 A), whereas RT-
PCR performed using 757s and L1a or 757s and CATa primers (Table 2.5), revealed that none of 
the late mRNAs could be detected, as expected (Fig. 4.8 A). cDNA synthesized with E4a primer 
from pBELMCAT-31 was then PCR amplified with primers 757s and E4a (Table 2.5) yielding a 
single 190bp-band, representing splicing from SD880 to SA3358 (Fig. 4.8 B), as expected. PCR 
on the cDNA synthesized with L1Ma using primers 757s and L1Ma (Table 2.5) resulted in two 
splice products; one 430bp cDNA representing the L1 mRNA that contains the sequence 
between SA3358 and SD3632 in the E4 coding region, and one 160bp cDNA representing the 
L1i mRNA that is directly spliced from SD880 to SA5639 (Fig. 4.8 C). cDNA synthesized with 
CATa primer was then PCR amplified with primers 757s and CATa primers (Table 2.5) yielding 
a major product at 2000bp. The 2000bp band resulted in a direct splice from SD880 to SA5639, 
representing the PCR product of roughly 500bp (L1) + 752bp (IRES) + 660 (CAT) (Fig. 4.8 D). 
These results demonstrated that correctly spliced HPV-16 early and late mRNAs were produced, 
corroborating the integrity of the reporter plasmids in the stable reporter cell lines. 
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Figure 4.8 Characterization of pBELCAT-67 and pBELMCAT-31 stable cell lines 
Analysis of mRNAs produced by stable cell lines pBELCAT-67 and pBELMCAT-31. (A)  RT-
PCR amplification of the early CMV―> E4 region with 757s-E4a primers and the late region 
CMV―>L1 with 757s-L1a primers and CMV―>CAT with 757s-CATa primers in pBELCAT-
67. (B) RT-PCR amplification of the early CMV―> E4 region with 757s-E4a primers, (C) the 
late region CMV―>L1 with 757s-L1Ma primers and (D) CMV―>CAT with 757s-CATa 
primers in pBELMCAT-31. 
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4.4 Treatment of CAT reporter cell lines with small molecules 
 
(i) TPA 
 
In order to demonstrate that these cell lines could be used to identify small molecules that induce 
HPV-16 late gene expression the cells were treated with TPA (phorbol 12-myristate 13-acetate), 
a small molecule that has been shown to induce HPV-31 late gene expression (Meyers et al., 
1992). A number of pBELCAT or pBELMCAT cell lines were treated with different 
concentrations of TPA and an increase of CAT expression in a dose-dependent manner was 
observed in pBELCAT-67, pBELMCAT-31 and -25 stable cell lines, whereas the others cell 
lines, as an example pBELCAT-47 in figure 4.9, did not show any increase in CAT levels (Fig. 
4.9), further validating the functionality of these stable cell lines.  
 
 
Figure 4.9 Treatment of pBELCAT- and pBELMCAT-derived cell lines with TPA  
Induction of CAT by TPA in (A) pBELCAT-67 (B) pBELCAT-47, (C) pBELMCAT-25, (D) 
pBELMCAT-31 stable cell lines. Error bars indicate standard error for each sample.  
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(ii) Emetine, ceramide and cycloheximide 
In order to identify other small molecules that could be used to treat HPV-16 infections we tested 
a number of substances which have been shown to induce apoptosis by interfering with splicing 
such as emetine, ceramide and cycloheximide (Boon-Unge et al., 2007). First a time course 
experiment up to 6 hours was performed in pBELCAT-67 and pBELMCAT-31 stable cell lines 
but CAT induction was not observed at any time point in the presence of emetine, ceramide or 
cycloheximide (Fig. 4.10). A serial dilution of emetine and ceramide revealed that CAT 
expression is not affected by the presence of these substances at any concentration (Fig. 4.11).  
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Figure 4.10 Treatment of CAT reporter cell lines with emetine, ceramide or cycloheximide 
Time course experiment of pBELCAT-67 and pBELMCAT-31 stable cell lines treated with (A) 
10µM emetine, (B) 20µM ceramide or (C) 400ng cycloheximide. 
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Figure 4.11 Serial dilution of emetine and ceramide 
Serial dilution of (A) emetine or (B) ceramide in pBELCAT-67 and pBELMCAT-31 stable cell 
lines. 
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Treatment of pBELCAT-67 and pBELMCAT-31 with TPA, emetine, cycloheximide or ceramide 
at optimal concentrations was then reproduced and fold induction was calculated. Emetine and 
cycloheximide decreased CAT levels in both stable cell lines possibly due to their inhibition of 
protein synthesis. Any effect on CAT expression was observed in the presence of ceramide in 
both cell lines. Induction of CAT in a TPA-dose-dependent manner was consistent, resulting in 
an increase of CAT expression of 10 and 5 fold in pBELCAT-67 and pBELMCAT-31, 
respectively (Fig. 4.12 A). To control for possible effects of these substances on cellular protein 
synthesis, a western blot for actin was performed and demonstrated that they had no effect on 
actin levels (Fig. 4.12 B). It was concluded that induction of CAT from pBELCAT-67 and 
pBELMCAT-31 was specific for the small molecule TPA and that the cell lines can be used to 
study the effect of small molecules and drugs on late gene expression. 
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Figure 4.12 CAT induction in stable cell lines treated with TPA, emetine, cycloheximide or 
ceramide and Western blot analysis 
(A) CAT induction in pBELCAT-67 and pBELMCAT-31 by TPA, emetine, cycloheximide or 
ceramide. Cells were treated with each small molecule in a minimum of three independent 
experiments. A control of 0.5 µl DMSO was included. Error bars indicate standard error for each 
sample. * indicates significance in relation to pBELCAT-67 or pBELMCAT-31 untreated 
(p<0.05). (B) Expression levels of β-actin were determined in pBELCAT-67 and pBELMCAT-
31 cell lines in the absence and presence of TPA, emetine, cycloheximide or ceramide by 
Western Blot. 
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(iii) Valproic acid 
Since it has been shown that valproic acid (VPA) increases the expression of ASF/SF2, which 
has previously shown to induce CAT levels, we wished to investigate if this small molecule can 
induce HPV-16 late gene expression. First a serial dilution of VPA was performed in pBELCAT-
67 and pBELMCAT-31 cell lines resulting in a moderate increase of CAT at lower concentration 
of VPA in both cell lines (Fig. 4.13). Treatment of pBELCAT-67 and pBELMCAT-31 cell lines 
at optimal concentration of VPA resulted in a high induction of CAT in pBELCAT-67 whereas 
in pBELMCAT-31 CAT induction was only slightly enhanced (Fig. 4.14). These results 
demonstrated that VPA could be a candidate as a novel drug for treatment of HPV infections. 
Western blot confirmed an increase of ASF/SF2 protein expression by VPA and actin levels 
were unaffected in both cell lines (Fig. 4.15). The result showed also a slight increase of PTB 
levels in cells treated with valproic acid (Fig. 4.15).  
 
 
 
Figure 4.13 Serial dilution of valproic acid  
pBELCAT-67 and pBELMCAT-31 stable cell lines were treated with different concentrations of 
valproic acid.  
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Figure 4.14 Treatment of CAT stable cell lines with valproic acid 
Induction of CAT by VPA in pBELCAT-67 and pBELMCAT-31 cell lines. Cells were treated 
with valproic acid in a minimum of three independent experiments. A control of 0.5µl H2O was 
included. Error bars indicate standard error for each sample. * indicates significance in relation 
to pBELCAT-67 or pBELMCAT-31 untreated (p<0.05). 
 
 
 
Figure 4.15 Western blot analysis on stable cell lines treated with valproic acid  
Expression levels of ASF/SF2, PTB and β-actin proteins were determined in both cell lines in the 
absence and presence of VPA by Western Blot. 
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(iv) Scriptaid and amiloride  
Next, we wanted to examine the role of two small molecules scriptaid and amiloride that in 
recent studies have been shown to be useful for treatment of a variety of cancers. pBELCAT-67 
and pBELMCAT-31 were treated at different concentrations of scriptaid or amiloride and CAT 
levels were monitored 24 hours post-treatment. Scriptaid had no effect on late gene expression in 
both cell lines (Fig. 4.16) whereas a slight increase of CAT expression was observed in 
pBELCAT-67 but not in pBELMCAT-31 in the presence of amiloride.  
 
 
 
 
Figure 4.16 Treatment of CAT stable cell lines with scriptaid or amiloride 
Treatment of pBELCAT-67 and pBELMCAT-31 stable cell lines with different concentrations 
of (A) scriptaid or (B) amiloride. Small graphs represent treatment of stables cell lines with 
lower concentration of amiloride or scriptaid. 
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(v) Tannic acid 
 
Since in previous experiments was demonstrated that overexpression of PTB efficiently induces 
CAT expression in transient and stable transfections, it was investigated if the small molecule 
tannic acid, which it is believed to increase levels of polypyrimidine tract binding protein, has 
any effect on CAT expression. A serial dilution of tannic acid was performed in both stable cell 
lines and cells were analysed 24 hours post-treatment. Lower concentrations of tannic acid up to 
1 µM did not modulate CAT expression and at high concentrations (100µM) was toxic to cells 
(Fig. 4.17). However, 10µM of tannic acid showed a significant increase of CAT in both cell 
lines suggesting that this small molecule could be useful to treat persistently HPV infected cells. 
Western blot analysis confirmed an increase of PTB levels by this substance further proving that 
this splicing factor plays a critical role in the regulation of late gene expression in HPV-16 and 
with its overexpression HPV-16 late gene expression can be induced (Fig. 4.18).  
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Figure 4.17 Treatment of CAT stable cell lines with tannic acid 
Serial dilution of tannic acid in pBELCAT-67 and pBELMCAT-31 stable cell lines. Cells were 
treated with tannic acid in a minimum of three independent experiments. A control of 0.5µl H2O 
was included. Error bars indicate standard error for each sample. * indicates significance in 
relation to pBELCAT-67 or pBELMCAT-31 untreated (p<0.05). 
 
 
 
Figure 4.18 Western blot analysis on stable cell lines treated with tannic acid 
Expression levels of PTB and β-actin proteins were determined in both cell lines in the absence 
and presence of tannic acid by Western Blot. 
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4.5 Treatment of pBELCAT or pBELMCAT plasmids transiently transfected 
in HeLa cells with TPA, valproic acid or tannic acid 
Seeing that treatment of pBELMCAT-31 with VPA had very little effect on CAT induction this 
substance was tested in cells transiently transfected with pBELCAT or pBELMCAT. Also TPA 
and tannic acid, which have shown to modulate CAT expression in both cell lines, were analysed 
in transient transfections. HeLa cells were transfected with pBELCAT or pBELMCAT and 24 
hours posttransfection cells were treated with 800ng TPA, 10µM tannic acid or 0.05mM valproic 
acid. An induction of 2 and 3.5 fold was observed in cells transfected with pBELCAT and 
pBELMCAT in the presence of VPA, respectively (Fig. 4.19). Higher levels of CAT were 
observed in cells treated with TPA and also tannic acid showed to greatly induce CAT, 
particularly in pBELCAT (Fig. 4.19). These results suggested that the lower induction observed 
in pBELMCAT-31 by valproic acid could be due to the high levels of CAT produced by this 
stable cell line that can be difficult to increase further. Furthermore, all 3 substances proved to 
induce late gene expression in HPV-16-derived plasmids and stable cell lines suggesting that 
they could be possibly used as drugs for treatment of HPV-16 infections. 
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Figure 4.19 Effect of TPA, valproic acid or tannic acid in cells transient transfected with 
pBELCAT or pBELMCAT plasmids 
Induction of CAT of pBELCAT or pBELMCAT transiently transfected into HeLa cells by TPA, 
valproic acid or tannic acid. Transfections were carried out in triplicates. A control of 0.5µl H2O 
was included.  
 
 
4.6 Treatment of pBELCAT-67 cell line with TPA, valproic acid or tannic 
acid combined 
So far we demonstrated that TPA, valproic acid and tannic acid can induce CAT in transient and 
stable transfected CAT reporter plasmids, possibly due to their effect on cellular factors involved 
in splicing. We speculated that using simultaneously one or more substances on CAT stable cell 
lines the levels of two or more cellular factors would it be induced and, as consequence, higher 
levels of CAT would it been detected. In order to verify that, pBELCAT-67 cell line was treated 
with TPA, valproic acid and tannic acid combined. Best result was observed in cells treated with 
TPA and tannic acid or TPA and valproic acid combined inducing more than 3 and 2 fold, 
respectively (Fig. 4.20). Lower levels of CAT were observed in the cells treated with a mix of 
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valproic acid and tannic acid whereas a combination of all 3 substances together did not 
modulate CAT expression (Fig. 4.20). Taken together these results demonstrated that TPA alone 
or combined with other substances gives the greater CAT induction, except for the mixture of all 
three substances that it might be toxic for the cells.   
 
 
 
 
Figure 4.20 Treatment of pBELCAT-67 stable cell line with TPA, valproic acid and tannic 
acid combined  
Induction of CAT in pBELCAT-67 by TPA, valproic acid (VPA) and tannic acid (TA) 
combined. Treatments of cells were carried out in triplicates. A control of 0.5µl H2O was 
included.  
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4.7 APOPTOSIS-program 
Many cells initiate an apoptosis program which is similar to what can be seen in epithelial cells 
that differentiate. This induction also counteracts proliferation and progression to cancer. In 
order to see if apoptosis could induce CAT production in our cell lines two simple apoptosis-
programs were started on them including serum deprivation and heat shock. Both stable cell lines 
were treated as described in material and methods. None of these treatments seemed to have a 
positive effect on CAT production and after 2 days of serum deprivation (Fig. 4.21 A) and 2 
hours of heat shock (Fig. 4.21 B) the cells looked quite sick and CAT levels start to drop off. 
 
 
 
Figure 4.21 Apoptosis program 
CAT levels in pBELCAT-67 and pBELMCAT-31 after (A) Serum deprivation or (B) Heat shock 
treatments. 
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4.8 Establishment of pBELMGFP reporter cell lines  
Since in previous experiments the GFP assay proved to be very easy and inexpensive it was 
decided next to generate stable cell lines with pBELMGFP reporter plasmid integrated in the 
HeLa cellular genome. This would allow screening of compounds capable of inducing late gene 
expression without the need to use expensive reagents. Transfection was carried out as described 
previously for the establishment of CAT stable cell lines. Over 80 neomycin-resistant colonies 
were picked and DNA was first extracted and then PCR amplified with GFP or IRES set primers 
(Fig. 4.22). Three clones (pBELMGFP-31, -61, -69) resulted positive for both GFP and IRES 
sequences amplifications proving the successful integration of the full reporter plasmid (Fig. 
4.22). Cells from each positive clone were analysed with a fluorescence microscope revealing 
very few glowing cells on each of them. The intensity of these visible positive cells was much 
lower compared to the cells transfected with pCMVGFP in transient transfections (Fig. 4.23). 
Even though GFP expression from pBELMGFP reporter plasmid transiently transfected was 
very low, this result was unexpected considering the high levels of CAT produced by 
pBELMCAT-31 stable cell line, which produces 20 fold more than pBELMCAT plasmid 
transiently transfected.  
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Figure 4.22 PCR amplification of DNA extracted from pBELMGFP-derived cell lines using 
GFP or IRES set primers 
(A) 1KB DNA ladder (M), lanes 1-15 PCR amplification of DNA extracted from pBELMGFP 
stable cell lines using GFP primers, lane 16 positive control, lane 18 blank.  (B) 1KB DNA 
ladder (M), lanes 1-15 PCR amplification of DNA extracted from pBELMGFP stable cell lines 
using GFP primers, lane 16 positive control, lane 18 blank. (C) 1KB DNA ladder (M), lanes 1-10 
PCR amplification of DNA extracted from stable cell lines pBELMGFP using GFP primers and 
lane 11-18 using IRES primers.   
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Figure 4.23 Fluorescence of pBELMGFP stable cell lines   
GFP fluorescence intensities were detected with a fluorescence microscope from the living cells 
in (A) pBELMGFP-31, (B) pBELMGFP-61 and (C) pBELMGFP-69 (CELL^F software, 
Olympus Soft Imaging solutions GmbH).  
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4.9 Treatment of pBELMGFP with TPA 
Since TPA showed to increase levels of CAT in both pBELCAT-67 and pBELMCAT-31 stable 
cell lines we considered that it would be useful to treat all 3 pBELMGFP-derived cell lines with 
TPA to see if GFP intensity can be enhanced by this small molecule. In the presence of TPA 
only the clones pBELMGFP-31 and -61 showed few glowing cells with a relative higher GFP 
intensity whereas in the clone number 69 fluorescence was not detected. 
However, GFP fluorescence intensity from these pBELMGFP-derived cell lines in the absence 
or in the presence of TPA was very low and only detectable in a few cells (Fig. 4.24). We 
reasoned that the fluorescence from these pBELMGFP-derived cell lines might be insufficient to 
be detected under the microscope light. Therefore 2x104 pBELMGFP-derived cell lines were 
plated in a 96 well plate and treated with 0ng, 400ng or 800ng TPA in triplicate. 24 hours post-
treatment cells were analysed with a Luminescence Spectrometer (Perkin Elmer LS55B), but 
GFP fluorescence was not detected. Hence we concluded that these stable cell lines are unusable 
for analysis of HPV-16 late gene expression. 
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Figure 4.24 Treatment of pBELMGFP with TPA 
(A) pBELMGFP-31, (C) pBELMGFP-61 and (E) pBELMGFP-69 stable cell lines untreated and 
(B) pBELMGFP-31, (D) pBELMGFP-61 and (F) pBELMGFP-69 stable cell lines treated with 
800ngTPA. Fluorescence was detected 24 hours posttreatment with a fluorescence microscope 
(CELL^F software, Olympus Soft Imaging solutions GmbH). 
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4.10 Gene Knockdown 
So far we have shown that with overexpression of a number of cellular proteins late gene 
expression is induced in transient and stable transfected subgenomic HPV-16 plasmids. To 
further examine the role of these cellular proteins on the regulation of HPV-16 late gene 
expression, next goal was to see if, decreasing the levels of these cellular proteins in the cells, 
late gene expression would be affected. In order to do that Lentiviruses carrying a shRNA to 
knockdown specific genes were used and the pBELMCAT-31 was selected as a cell line, which 
itself produces high levels of CAT. As genes to be knockdown we opted for ASF/SF2 and PTB, 
which have shown to efficiently induce late gene expression in HPV-16-derived plasmids. The 
lentivirus expressed RNAs were targeted against ASF/SF2, PTB or a scrambled non targeting 
sequence. In these lentiviruses GFP is used as a marker for shRNA expression and thus the use 
of a fluorescence or confocal microscope can be used to follow shRNA expression in the cells. 
Lentiviruses carrying ASF/SF2, PTB or scramble shRNA were transduced at different 
multiplicity of infectivity (MOI) into pBELMCAT-31 stable cell lines and then cells were 
analysed under a confocal microscope. At MOI 0.3 and 1 transduction failed, but at MOI 2, 5 
and 10 more than 90% of the cells were infected by the virus confirming the successful 
transduction (Fig. 4.25, 4.26 and 4.27). Higher intensity of GFP was seen in cells infected with 
lentiviruses at MOI 10. A CAT ELISA was then performed to verify a change in CAT 
production by pBELMCAT-31 in the presence of the lentiviruses. The lentiviruses definitely 
dropped down the levels of CAT compared with the levels of CAT produced by pBELMCAT-31 
untransduced and infection at MOI 10 resulted in a lower induction of CAT by all 3 lentiviruses, 
as expected (Fig. 4.28 A). However, levels of CAT expression in the cells infected with 
lentiviruses carrying shRNA PTB or ASF/SF2 were not significant (p-value>0.05) compared to 
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the levels dropped down by the scramble lentivirus (Fig. 4.28 B). Western Blot analysis showed 
that ASF/SF2 and PTB expression was not knocked down at any MOI utilized for this 
experiment and actin levels seemed to be unaffected by the presence of the lentiviruses (Fig. 
4.29). To assure the highest possibility of modulating gene expression level, multiple shRNA 
constructs each covering a unique region of the target gene should be used. Therefore we 
reasoned that this might be the cause of this unsuccessful knockdown. 
 
 
 
 
 172 
 
Figure 4.25 Detection of infected cells at MOI 2 with confocal microscope 
Detection of GFP expression in cells infected with lentiviruses carrying ASF/SF2, PTB or 
scramble shRNA at MOI 2. The 3 panels in each image represent fluorescence, light and 
combined.  
MOI 2 
pBELMCAT-31_ASF/SF2 pBELMCAT-31_PTB 
pBELMCAT-31 pBELMCAT-31_scramble 
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Figure 4.26 Detection of infected cells at MOI 5 with confocal microscope  
Detection of GFP expression in cells infected with lentiviruses carrying ASF/SF2, PTB or 
scramble shRNA at MOI 5. The 3 panels in each section represent fluorescence, light and 
combined.  
 
 
pBELMCAT-31 pBELMCAT-31_scramble 
MOI 5 
pBELMCAT-31_ASF/SF2 pBELMCAT-31_PTB 
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Figure 4.27 Detection of infected cells at MOI 10 with confocal microscope  
Detection of GFP expression in cells infected with lentiviruses carrying ASF/SF2, PTB or 
scramble shRNA at MOI 10. The 3 panels in each image represent fluorescence, light and 
combined.  
 
 
 
 
pBELMCAT-31 pBELMCAT-31_scramble 
MOI 10 
pBELMCAT-31_ASF/SF2 pBELMCAT-31_PTB 
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Figure 4.28 CAT expression in pBELMCAT-31 stable cell line transducted with 
lentiviruses carrying shRNA ASF/SF2, PTB or scramble 
(A) Induction of CAT expression in pBELMCAT-31 stable cell lines uninfected and infected by 
lentiviruses carrying shRNA ASF/SF2, PTB or scramble. (B) CAT units produced by 
pBELMCAT-31 stable cell lines infected by lentiviruses carrying shRNA ASF/SF2, PTB or 
scramble. 
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Figure 4.29 Western blot analysis on pBELMCAT-31 stable cell line infected with 
lentiviruses 
Expression levels of ASF/SF2, PTB and β-actin proteins were determined by Western Blot.  
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5. Chapter 5 – Results 
Identification and localization of a RNA-binding protein involved in 
the regulation of splicing in normal and neoplastic cervical 
epithelium 
 
RNA processing has a pivotal role in HPV-16 gene regulation (Johansson et al., 2011; Mole, et 
al., 2006; Schwartz et al., 2007). Therefore the identification of novel cellular proteins or RNA 
binding factors that might influence RNA processing events, such as alternative splicing and 
polyadenylation, has a major importance in the study of HPV-16 gene regulation.  
 
 
5.1 Identification of a novel splicing factor involved in HPV-16 late gene 
regulation 
Previous results demonstrated that the small molecule TPA efficiently modulates CAT 
expression in transient and stable transfections. Since it has been shown that TPA induces 
expression of various genes, including the splicing factors arginine/serine 2 (SC35) and hnRNP 
A2/B1 (Zheng et al., 2002), it was investigated if these two cellular proteins are involved in the 
splicing events that can occur in HPV-16. Transient transfections of pBELCAT or pBELMCAT 
plasmids with vectors expressing SC35 or hnRNP A2/B1 were carried out into HeLa cells 
resulting in a considerable increase of CAT levels in both reporter plasmids in the presence of 
hnRNP A2/B1. A small CAT induction was observed in pBELCAT by overexpression of SC35 
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but not in pBELMCAT (Fig. 5.1). These results suggested that the splicing factor hnRNP A2/B1 
might have a role in regulation of HPV-16 late gene expression.  
In order to prove that hnRNP A2/B1 expression is induced by TPA a western blot on pBELCAT-
67 and pBELMCAT-31 stable cell lines treated with TPA, emetine, cycloheximide or ceramide 
was performed resulting in an increase of hnRNP A2/B1 levels by TPA in both cell lines, 
whereas hnRNP A2/B1 levels were unaffected by emetine, cycloheximide and ceramide (Fig. 
5.2).  
 
 
 
Figure 5.1 Co-transfection of CAT reporter plasmids with SC35 or hnRNP A2/B1 
expression vector 
pBELCAT pBELMCAT were transfected into HeLa cells in the presence and absence of 
cotransfected expression vectors. Cells were transfected with each plasmid in a minimum of 
three independent experiments. Error bars indicate standard error for each sample. * indicates 
significance in relation to pBELCAT or pBELMCAT cotransfected with the empty vector 
(pUC19) (p<0.05). 
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Figure 5.2 Western blot analysis on pBELCAT-67 and pBELMCAT-31 stable cell lines 
Expression levels of hnRNP A2/B1 and β-actin proteins were determined in both cell lines in the 
absence and presence of emetine, cycloheximide, ceramide or TPA by Western Blot.  
 
 
To further evaluate the role of this cellular protein, a two-fold serial dilution of hnRNP A2/B1 
was performed resulting in a dose-dependent induction of CAT from both reporter plasmids. A 
lower induction was observed at higher hnRNP A2/B1 concentrations whereas low levels of 
hnRNP A2/B1 efficiently induced CAT expression in both pBELCAT and pBELMCAT 
plasmids (Fig. 5.3). 
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Figure 5.3 Induction of CAT by hnRNP A2/B1 
Co-transfection of (A) pBELCAT and (B) pBELMCAT reporter plasmids with a serial dilution 
of hnRNP A2/B1 expression vector. 
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To establish if this RNA-binding protein targets sequences located upstream SD3632 and 
SA5639, reporter plasmids containing only these two splice sites (Fig. 5.4 A) were tested in the 
presence of hnRNP A2/B1 expressing plasmid. When hnRNP A2/B1 was cotransfected with 
pBspliceMCAT or pMt1sdCAT (Fig. 5.4 A) an induction of CAT was observed in both reporter 
plasmids (Fig. 5.4 B) indicating that this RNA-binding factor acts on the splice sites used 
exclusively by late genes. A lower induction was seen in pMt1sdCAT, in which splicing silencer 
upstream SD3632 have been deleted, whereas higher induction, up to 7 fold, was seen in 
pBspliceMCAT as demonstration that hnRNP A2/B1 binds specifically to these sequences that 
suppress SD3632 (Fig. 5.4 B).  
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Figure 5.4 Induction of CAT in pBspliceMCAT and pMt1sdCAT by hnRNP A2/B1 
(A) pBspliceMCAT and pMt1sdCAT constructs (B) pBspliceMCAT or pMt1sdCAT plasmids 
were transfected into HeLa cells in the presence and absence of plasmid expressing hnRNP 
A2/B1. Transfections were carried out in triplicate. Error bars indicate standard error for each 
sample. * indicates significance in relation to pBspliceMCAT or pMt1sdCAT cotransfected with 
the empty vector (pUC19) (p<0.05). 
 
 
 
 183 
Transfection of plasmid expressing hnRNP A2/B1 in pBELCAT-67 and pBELMCAT-31 stable 
cell lines confirmed that overexpression of hnRNP A2/B1 efficiently modulates CAT expression, 
inducing 6.9 and 1.7 fold in pBELCAT-67 and pBELMCAT-31 cell lines, respectively (Fig. 
5.5).  
In conclusion a novel splicing factor involved in the regulation of HPV-16 late gene expression 
was identified. 
 
 
 
Figure 5.5 Induction of CAT in stable pBELCAT-67 and pBELMCAT-31 cell lines by 
hnRNP A2/B1  
Induction of CAT expression by overexpression of hnRNP A2/B1 expression plasmid in 
pBELCAT-67 and pBELMCAT-31 stable cell lines. Transfections were carried out in triplicate.  
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5.2 Detection of hnRNP A2/B1 protein on cervical tissue arrays 
Since the hnRNP A2/B1 was identified as a novel cellular factor involved in regulation of HPV-
16 late gene expression next it was investigated if the expression level of this RNA-binding 
protein is altered in cervical premalignant and malignant lesions. Thus an immunohistochemistry 
assay was performed on cervical tissue arrays in order to detect and localize this protein. The 
advantage of using tissue microarray slides is that it allows the analysis of multiple histological 
samples in a single slide. The TMA was designed to have 80 cores in total and out of 80 cores it 
was possible to read 54 cores. hnRNP A2/B1 immunostaining in normal cervical (NC) tissue 
cores resulted in high expression of hnRNP A2/B1 protein in the lower layers, especially in the 
basal layer with a predominant nucleoplasmic staining. In the superficial layers no staining was 
observed (Fig. 5.6). The strong staining was detected in eight cores out of eight normal cervical 
tissue cores. In low-grade squamous intraepithelial lesion (LSIL) the staining was also very 
strong in the basal and intermediate layers (Fig. 5.7). Only two cores out of 15 readable LSIL 
cores showed a weaker staining. In high-grade squamous intraepithelial lesion (HSIL) and 
squamous cell carcinoma (SCC) low expression of hnRNP A2/B1 was detected in few scattered 
nuclei of 15 and 16 cores, respectively (Fig. 5.8 and 5.9).  
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Figure 5.6 hnRNP A2/B1 protein expression in NC 
hnRNP A2/B1 protein expression detected by immunohistochemical staining in normal cervical 
epithelium (NC). Images on the left, magnification 20X; images on the right, magnification 40X. 
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Figure 5.7 hnRNP A2/B1 protein expression in LSIL 
hnRNP A2/B1 protein expression detected by immunohistochemical staining in low-grade 
squamous intraepithelial lesions (LSIL). Images on the left, magnification 20X; images on the 
right, magnification 40X. 
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Figure 5.8 hnRNP A2/B1 protein expression in HSIL 
hnRNP A2/B1 protein expression detected by immunohistochemical staining in high-grade 
squamous intraepithelial lesions (HSIL). Images on the left, magnification 20X; images on the 
right, magnification 40X. 
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Figure 5.9 hnRNP A2/B1 protein expression in SCC 
hnRNP A2/B1 protein expression detected by immunohistochemical staining in squamous cell 
carcinoma (SCC). Images on the left, magnification 20X; images on the right, magnification 
40X. 
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5.3 Correlation of RNA-binding protein expression in cervical epithelium to 
p16INK4a, a known marker of differentiation 
An immunohistochemistry assay was performed on the same tissue microarrays using 
p16INK4a, which is a known marker of cervical high-grade lesion and squamous cell carcinoma. 
In normal cervical (NC) core tissue and low grade lesion p16INK4a was not detected (Fig. 5.10 
A and B), whereas in HSIL and SCC it was highly expressed with nuclear and mostly 
cytoplasmic staining, as expected (Fig. 5.10 C and D). 
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Figure 5.10 p16INK4a protein expression  
p16INK4a protein expression detected by immunohistochemical staining in (A) normal cervical 
epithelium (NC), (B) low-grade squamous intraepithelial lesions (LSIL), (C) high-grade 
squamous intraepithelial lesions (HSIL), (D) squamous cell carcinoma (SCC). Magnification 
20X; small image, Magnification 40X. 
 
 
 
 
 
 
 
 
 
A B 
D C 
 191 
In conclusion these results showed that hnRNP A2/B1 is highly expressed in normal cervical 
tissue (NC) and low-grade squamous intraepithelial lesion (LSIL) and decreases from high-grade 
squamous intraepithelial lesion (HSIL) to squamous cell carcinoma (SCC) (Fig. 5.11) (Table 
5.1). Since we have shown that hnRNP A2/B1 is involved in the regulation of late gene 
expression in HPV-16 and late genes are not expressed in cervical cancer these results suggested 
that it might be a correlation with the suppression of late genes and a lower expression of hnRNP 
A2/B1 in cervical cancer. 
 
 
 
 NC LSIL HSIL SCC 
hnRNP A2/B1 +++ +++ + + 
p16INK4a - - +++ +++ 
Table 5.1 Overall expression of proteins in core sections of cervical epithelium 
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Figure 5.11 Comparison of immunostaining with hnRNP A2/B1 or p16INK4a antibodies on 
the same tissue microarray slide 
Expression levels of hnRNP A2/B1 and p16INK4a in normal cervical tissue (NC), low-grade 
intraepithelial lesion (LSIL), high-grade intraepithelial lesion (HSIL) and squamous cell 
carcinoma (SCC). 
hnRNP A2/B1 p16INK4a 
NC 
LSIL 
HSIL 
SCC 
 193 
6.  Chapter 6 - Discussion    
Cervical cancer is the second leading cause of death by cancer in women worldwide after breast 
cancer with approximately 250,000 deaths annually. Persistence of HPV and in particular high 
risk HPV subtype infection is a prerequisite for development of cervical cancer or pre-malignant 
lesions that could progress to cancer (Lowy & Howley, 2001). Although the lifetime risk for 
HPV infection in sexually active women is approximately 80% (Baseman & Koutsky, 2005), 
most infections are cleared spontaneously by the host immune system and only few cases 
develop cervical cancers after a period of persistent infection.  
Two prophylactic vaccines utilizing virus-like particles have been developed to prevent HPV 
infection, Gardasil against HPV-6, -11, -16, -18, and Cervarix against HPV-16, -18. These 
vaccines have proved to be efficacious for individuals who have not been exposed to HPV prior 
to immunization and to prevent up to 70% of all cervical cancer (Batson et al., 2006). 
Nonetheless, vaccination is not efficacious for individuals who are already infected (Ault, 2006), 
the duration of efficacy still needs to be confirmed and only few serotypes of HPV are targeted. 
There are other types not comprised in vaccine, such as HPV-31 and HPV-45, which can become 
dominant within the population and take over as the major cause of cervical cancer. Furthermore 
the high cost of vaccination won’t be afforded by the developing countries where there is the 
highest percentage of cervical cancer cases. Therefore research into how the viruses alter the 
infected cells during infection, what cellular proteins are involved in HPV life-cycle and how 
gene expression is regulated during an infection will possibly help to develop new therapeutic 
agents and prevention methods that could prevent cervical cancer. 
HPV gene expression is strictly dependent on cellular differentiation (Doorbar, 2005). At the 
molecular level, high-grade pre-malignant lesions and cervical cancer are characterised by 
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continued expression of the early viral genes, and a complete shut-down of the late viral genes 
encoding the viral structural proteins L1 and L2. These proteins are highly immunogenic and 
they can induce an immune response, therefore with inhibition of L1 and L2 gene expression in 
the lower layers of the epithelium the virus can escape surveillance by the immune system of the 
host and establish a persistent infection (Scheurer et al., 2005). Thus it was speculated that 
activation of L1 and L2 late gene expression in the persistently infected cells would uncover the 
HPV infected cells for the immune system of the host.  
The overall aim of this study was to elucidate the mechanism of HPV-16 gene regulation, 
primarily regulation of late gene expression. The first goal was to generate a simple reporter 
assay to facilitate the study of HPV-16 late gene expression; second was to establish useful 
stable cell lines for the identification of small molecules and cellular factors that can induce 
HPV-16 late gene expression and third to localize and determine expression levels of identified 
proteins involved in HPV late gene regulation.  
Two HPV-16 genomic constructs were generated where the L1 gene is replaced with an easily 
detectable reporter gene such as chloramphenicol acetyltransferase (CAT), green fluorescent 
protein (GFP), secreted alkaline phosphatase (SEAP), Luciferase or β-galactosidase (LacZ). 
These reporters have different proprieties but all can be easily measured and quantified when 
transfected into proliferating cells.  
The CAT assay resulted to be the most sensitive compared to the others and thus most of the 
experiments in this study were focused on that. The two reporters used most commonly were 
pBELCAT and pBELMCAT where the HPV-16 L1 gene was replaced by the CAT reporter. 
Evaluation of CAT expression levels showed that pBELCAT, as expected, produces very little 
CAT whereas pBELMCAT, in which a mutation that reduces the negative regulation on the 
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splice site present in the late region is introduced, efficiently produce CAT as demonstration that 
the splice site 5639 has a pivotal role in regulation of late gene expression. These results confirm 
that the CAT reporter mimics the expression patterns of the L1 gene in the intact viral genome. 
In the presence of E4orf4, PTB, SRp30c or ASF/SF2 both reporter plasmids induced an 
increased expression of CAT. In particular Ad E4orf4, which regulates the switch from early to 
late gene expression in Adenovirus, showed a higher induction of CAT expression in pBELCAT 
when compared to the pBELMCAT plasmid, although this difference may be due to the high 
CAT levels pBELMCAT produces itself when transfected alone. In addition it has been shown 
that Ad E4orf4 overcomes the negative effect of splicing silencers present in the L1 region 
(Somberg et al., 2009) and since in pBELMCAT these inhibitory elements had been inactivated 
by multiple point mutations, the viral protein can no longer target them and positively influence 
late gene expression as strong as it is observed in pBELCAT. When increasing quantities of the 
inducers cotransfected with pBELMCAT, higher levels of CAT were observed with the higher 
concentration of PTB and SRp30c, respectively. E4orf4 decreased CAT expression at higher 
concentration; this result could be correlated to other studies where adenovirus E4orf4 had 
shown to induce apoptosis (Roopchand et al., 2001). It was previously shown that low levels of 
ASF/SF2 induced HPV-16 late gene expression whereas high levels did not (Somberg & 
Schwartz, 2010). Transfection of pBELMCAT with serially diluted ASF/SF2 plasmid revealed a 
similar effect, further demonstrating that expression of the CAT reporter gene is an accurate 
marker for HPV-16 late mRNA production. Unequal rates of ASF/SF2 levels in low-grade 
lesions and in high-grade lesions have been reported with low and high expression level, 
respectively (Mole et al., 2009b). This could be due to the many roles that ASF/SF2 undertakes 
in pre- and post-splicing influencing expression of genes and metabolic activity in the cell. These 
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data clearly show that induction of CAT expression is dependent on the levels of these proteins, 
suggesting that it will be possible to identify cellular factors or small molecules that induce late 
gene expression. Thus functional reporter plasmids were generated that can be used to study 
HPV-16 late gene expression and that mimic the effect of the viral and cellular proteins on L1 
gene expression as demonstrated in previously studies with the original pBEL and pBELM. It 
was of interest also to investigate the effect of 2 splice sites, SD3632 and SA5639, on these 
novel reporter plasmids. These splice sites are used exclusively by late mRNA and are 
suppressed in proliferating cancer cells (Rush et al., 2005; Zhao et al., 2007; Zhao et al., 2004). 
Deletion of part of the early genes in pBspliceCAT showed no production of CAT whereas 
pBspliceMCAT, which has a mutation in the late region, modestly induced CAT expression 
validating the role of the splice site located in the late region for induction of late gene 
expression. Deletion of sequences located upstream the SD3632, in plasmid pMt1sdCAT 
resulted in an efficient production of CAT expression supporting that these sequences strongly 
suppress this splice site, therefore inhibiting late gene expression, as already shown in other 
studies (Somberg & Schwartz, 2010). Taken together these results demonstrated that these 
reporter plasmids can be used for identification and characterization of cis-acting regulatory 
RNA elements in HPV-16. 
The second reporter gene was used is the green fluorescent protein (GFP), originated from the 
jellyfish Aequorea Victoria, a protein that auto-fluoresces and its expression is easily detected 
and quantifiable. At the same time GFP signals can be weak and hard to detect with a low 
expression. In this study pBELMGFP transfected alone showed low GFP intensities. 
Cotransfection assays revealed that the viral and cellular proteins Ad E4orf4, PTB and especially 
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SRp30c induced late gene production from pBELMGFP. Since the GFP intensities are detected 
from the living cells this assay proved to be very efficient, easy to use and inexpensive.  
In order to find the easiest way to analyse HPV-16 late gene expression it was decided to insert 
the LacZ reporter gene, which encodes for β-galactosidase and seems to be the most versatile 
reporter gene. Unfortunately cloning of LacZ into pBEL-IRES and pBELM-IRES failed several 
times possibly it caused by the size of the reporter gene. In fact LacZ gene is 3141 bp in size, a 
quite big fragment to insert into pBEL-IRES and pBELM-IRES plasmids, which both are already 
approximately 10000 bp in size. Transformation efficiency decreases as the size of the DNA 
being transformed goes up therefore it is more difficult to introduce into bacterial cell larger 
constructs.  
Next two reporter plasmids were generated with the SEAP reporter gene which can be simply 
analyzed in proliferating cells. The SEAP reporter gene product is secreted from mammalian 
cells and is thus easily detected in a sample of culture medium but unfortunately in this study this 
assay was not sensitive enough to analyze late gene expression in subgenomic HPV-16 reporter 
plasmids. Some companies do not recommend HeLa cells as a cell line for experiments with 
SEAP due to high background. In these experiments in each transfection very high background 
levels were observed and SEAP expression from the reporter plasmids was undetectable. Only in 
pMt1sdSEAP plasmid, where sequences that suppress SD3632 are deleted, it is possible to detect 
SEAP expression confirming once again that this splice site is involved and has an important role 
in regulation of late gene expression. Therefore it can be reported that this plasmid could be used 
to study cis-acting, splicing regulatory elements at the HPV-16 late splice sites.  
In conclusion subgenomic HPV-16 plasmids with different and versatile reporter genes such as 
CAT, GFP, Luciferase and SEAP in place of the late L1 gene were generated. 
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These reporter genes are functional surrogate markers for HPV-16 late gene expression. It was 
demonstrated that E4orf4, PTB, SRp30c and ASF/SF2 proteins efficiently induce HPV-16 late 
gene expression and that induction is dependent on the levels of these proteins, confirming the 
idea that it should be possible to identify cellular factors and small molecules that could induce 
HPV-16 late gene expression.  
The second step was to generate stable cell lines with CAT reporter plasmids integrated into the 
chromosomal DNA in order to obtain a model for a large scale screening of small molecules and 
to evaluate levels of CAT expression in these cell lines. Although transient transfections are 
useful tools for fast analysis of genes, a stable cell line ensures reproducible, long-term and 
defined gene expression. 
The stable cell lines were evaluated by PCR amplification of CAT and IRES sequences from 
extracted DNA and evaluation of CAT levels. The pBELCAT-derived cell line resulted in 5 
positive clones and 2 from pBELMCAT-derived cell lines but they have been demonstrated to 
behave differently, producing different amount of CAT units. These results revealed that not all 
the stable cell lines behave at the same way. This may be determined by different integration 
sites in the genome of the target cell that can affect transcription rate of the gene of interest 
(Wurm, 2004). A regular expression plasmid is usually integrated into the cellular chromosomal 
DNA randomly (Murnane et al., 1990). Organization of genomic DNA into euchromatic and 
heterochromatic regions widely alters the expression of sequences contained within these 
regions. Integration into active euchromatin allows transgene expression, whereas integration 
into inactive heterochromatin results in little or no transgene expression and random integration 
often leads to silencing of the transgene. This might explain why it is possible to see such a 
difference in CAT expression from the stable cell lines; in particular in pBELMCAT stable cell 
 199 
lines which, one of them (pBELMCAT-31), produced really high levels of CAT when 
untransfected, whereas in the other one (pBELMCAT-25) much lower levels of CAT were 
observed.  
In the presence of E4orf4, PTB or SRp30c a slightly increase in CAT expression was observed in 
pBELMCAT cell lines but these results, when compared to the induction levels seen in transient 
transfections, showed a lower induction of CAT expression. This could be due to the fact that the 
levels of CAT produced by the pBELMCAT-derived cell line alone were too high and 
expression could only be slightly increased, or low transfection efficiency affected CAT 
production by adenovirus E4orf4, PTB or SRp30c, resulting in a relatively low increase in CAT. 
If only 5% of the stable cells are transfected with the expression vector then the CAT induction 
in these cells would be masked by the levels of CAT produced in the 95% of untransfected cells. 
Two of the five pBELCAT-derived cell lines failed to induce CAT expression in the presence of 
PTB whereas three showed an increase of CAT levels in a dose dependent manner. Also in this 
case a lower induction compared to the transient transfections is observed. The transient 
cotransfection results appear to be more efficient than stable transfection for the demonstration 
of induction of late gene expression. Transfection efficiency could be increased using different 
methods of transfection, such as electroporation which have been shown that 80% of the cells 
can receive the foreign DNA (Nickoloff, 1995). After analysis of CAT expression as described 
above, two stable cell lines (pBELCAT-67 and pBELMCAT-31) consistently reproduced same 
effects seen in transient transfection by viral and cellular proteins in CAT reporter plasmids, 
reliably reproducing L1 gene expression in the original subgenomic HPV-16 plasmids. RNA 
analysis on pBELCAT and pBELMCAT stable cell lines showed that correctly spliced HPV-16 
early and late mRNAs were produced, confirming that we established functional stable cell lines 
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that could be used for the identification of cellular proteins or microRNAs that may regulate 
HPV-16 gene expression.  
Generation of pBELMGFP-derived cell lines was less successful. Low levels of fluorescence 
were detected in each clone that had the IRES and GFP inserted in the cellular genome. Also in 
transient transfection GFP expression from this plasmid was very low and detectable only in few 
cells. It was expected that with a stable transfection all cells should have the transgene inserted in 
the cellular genome and, considering the high levels of CAT produced by the pBELMCAT-31 
stable cell line higher levels of fluorescence were expected from the GFP stable cell lines. 
Although the evidence presented here, using GFP instead of CAT appeared as a step forward to 
update and simplify the system, the signal was too low to be considered a reliable and accurate 
instrument to study HPV-16 gene regulation. Therefore, CAT stable cell lines, which proved 
functionality and authenticity, were chosen for further study and screening of small molecules.  
The major anticipated use of the stable cell lines was in the screening of small molecule libraries. 
Libraries of compounds are increasingly becoming commercially available for the use of 
individual academic laboratories. Small molecules associate with, or bind to, a protein in specific 
ways and in some cases they modulate the protein’s function by inactivating or activating 
it. Therefore it was of interest to look at a number of small molecules that have been shown to 
interfere with cellular proteins involved in the regulation of HPV-16 late gene expression. 
Analysis of compounds on the described stable cell lines could be also useful for the 
identification of novel regulatory elements of late gene expression in HPV. In addition, many 
small molecules have being widely used as drugs for the treatment of many types of cancer 
(Collins & Workman, 2006; Garcia et al., 2008) and for this reason we wished to identify small 
molecules suitable for treatment of HPV infections. Thus diverse substances were tested on CAT 
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stable cell lines with an emphasis on molecules that have been demonstrated to have an effect on 
cellular splicing mechanisms. The system was initially tested with TPA which is a known 
inducer of late gene expression in HPV-31 (Meyers et al., 1992). A consistent CAT induction 
was observed after a treatment of these stable cell lines with TPA, proving the utility of 
pBELCAT-67 and pBELMCAT-31 cell lines as high quality tools to study HPV-16 late gene 
expression. Treatment of pBELCAT and pBELMCAT-derived cell lines with other substances, 
such as emetine, ceramide and cycloheximide had no or an inhibitory effect on late gene 
expression in both cell lines, suggesting that CAT induction was specific for the small molecule 
TPA. This inhibitory effect could be caused by their role in inhibition in protein synthesis 
(Grollman, 1968; Grollman, 1966). 
Induction of CAT was also observed in both cell lines in the presence of valproic acid and tannic 
acid, two substances that have been shown to enhance levels of cellular proteins, such as 
ASF/SF2 and PTB, respectively. Therefore we deduced that this effect is due to the increased 
levels in the cell of these cellular factors that we have demonstrated to induce expression of late 
genes in transient and stable transfected subgenomic HPV-16 plasmids.  
To date, valproic acid it has been used for 45 years as a chronic therapy for epileptic disorders 
showing a good tolerability and safety profile (Loscher, 2002). Tannic acid, which for many 
years has been used to treat burn patients, has been revealed to have hepatotoxic effects (Duffin, 
1942; McClure & Lam, 1940). Evidence of an impaired liver function accompanied by central 
liver necrosis was reported in some cases of patients treated with tannic acid and many other 
studies in different animals provided further support for its toxicity (Clark & Rossiter, 1943; Erb 
et al., 1943; Jackson, 1944; Saltonstall et al., 1945; Wells et al., 1942). A relevant toxicity was 
also seen in our cell lines after treatment with tannic acid at high concentrations. Therefore, we 
 202 
can assume that valproic acid is the safest small molecule identified in this study that could be 
easily used for HPVs infections treatment, but also tannic acid, that is generally present in red 
wine, could potentially be a good candidate to cure persistently HPV infected cells by exposing 
the highly immunogenic L1 protein to the immune system. Indeed, it would be a big 
breakthrough if a glass of red wine per day would help the fight against cervical cancer.  
Two more small molecules, amiloride and scriptaid, were tested in this study. Scriptaid had no 
effect on late gene expression whereas a slight induction of CAT was observed in both cell lines 
after treatment with amiloride, but it was not consistent. This might be due to the various effects 
this substance has on different cellular factors. In fact it has been shown that amiloride treatment 
of cells results in hypo-phosphorylation of SR proteins, in particular SF2/ASF (Chang et al., 
2011), and it has been shown that both phosphorylation and dephosphorylation of ASF/SF2 are 
required for pre-mRNA splicing (Cao et al., 1997). Phosphorylation is essential for SR protein 
nuclear import and for spliceosome assembly (Roscigno & GarciaBlanco, 1995; Xiao & Manley, 
1997; Yeakley et al., 1999; Yun & Fu, 2000; Lai et al., 2001), and partial SR proteins 
dephosphorylation is also essential for progression of the assembled spliceosome to catalysis 
(Mermoud et al., 1994; Cao et al., 1997) and for post-splicing events such as interaction with the 
mRNA transport machinery and SR protein-mediated translational control (Huang et al., 2004; 
Lai & Tarn, 2004; Lin et al., 2005; Sanford et al., 2005). Therefore, both SR protein hypo- and 
hyper-phosphorylation inhibits splicing (Prasad et al., 1999). In addition, amiloride upregulates a 
number of proteins of the hnRNP family, such as hnRNP A1, hnRNP A2/B1 and hnRNP Q1 
(Chang et al., 2011). In this study was shown that hnRNP A2/B1 positively modulates late gene 
expression but in previous studies it has been shown that hnRNP A1 inhibits splicing by 
interaction with HPV-16 L1 3′ splice silencer at 5639 (Zhao et al., 2004). Therefore, even though 
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amiloride overexpresses hnRNP A2/B1, which should induce late gene expression, other factors 
are altered in the cell, that might interfere with the positive effect of hnRNP A2/B1 or, in 
general, with the regulation of late splice sites thereby inhibiting late gene expression. 
Scriptaid, like valproic acid, is a histone deacetylase inhibitor but, while valproic acid efficiently 
induced CAT in both cell lines, scriptaid did not, suggesting that the induction of late gene 
expression by valproic acid is due to the upregulation of ASF/SF2 in the cell by this substance 
and not for the action as HDAC inhibitor. Our findings further authenticate the pivotal role of 
cellular RNA binding factors, like in this particular case ASF/SF2, in HPV-16 gene regulation. 
In fact, it has been demonstrated that late HPV gene expression is regulated at the transcriptional 
and post-transcriptional levels (Schwartz, 2008; Zheng & Baker, 2006) and alternative splicing is 
necessary to produce L1 since the 3′ end of L2 and the 5′ end of L1 overlap. Inhibitory RNA 
elements present in the L1 sequence of HPV-16 prevent production of late mRNAs (Collier et 
al., 2002) and late gene expression is also inhibited in mitotic cells because of a competition 
between early and late splice sites (Rush et al., 2005). Therefore, since this study and others have 
demonstrated that cellular RNA binding factors and viral RNA elements are very important for 
HPV-16 gene regulation (Johansson et al., 2011; Mole et al., 2006; Schwartz et al., 2007) it was 
investigated further the role of these cellular proteins on the regulation of late gene expression in 
HPV-16 by knocking down protein expression using lentivirus delivered RNAi. The target genes 
chosen for knockdown were ASF/SF2 and PTB to better analyse regulation of HPV-16 late 
mRNAs and to see if the expression of late genes would be effected. So far we have shown that 
with overexpression in the cell of these two cellular proteins the expression of HPV-16 late 
genes is increased, therefore with their downregulation it would be expected a decrease of late 
mRNAs production even though more than 90% of cells were infected with lentiviruses carrying 
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ASF/SF2, PTB or scramble shRNA, knockdown of these specific genes failed. In this study only 
one shRNA construct for each gene was used and the possibility of modulating gene expression 
level rises using multiple shRNA constructs each covering a unique region of the target gene. 
This might be the reason for an ineffective knockdown. Forasmuch as HPV-16 late gene 
expression is a complex process that involves many regulatory steps it would be interesting to 
further investigate or to fully knockdown expression of genes on these stable cell lines to 
intimately explore their relationship with HPV-16 gene regulation. It would be also of interest to 
start a screening of antisense oligonucleotides against HPV-16 for ability to induce late gene 
expression in infected cancer cells.  
An interesting finding in this study was the identification of hnRNP A2/B1 as a novel regulator 
of HPV-16 late gene expression. This RNA-binding factor efficiently induced CAT from 
transient and stable CAT reporter plasmids, whereas another common splicing factor, such as 
SC35, had no effect on CAT expression. Sureau et al. reported that SC35 accumulation is 
correlated to changes in the splicing pattern regulating its expression by promoting alternative 
splicing events changing the stability of its own mRNAs (Sureau et al., 2001). They also 
demonstrated that endogenous SC35 mRNA levels in HeLa cells are decreased when SC35 is 
overexpressed and this could be the reason of failure in CAT induction by SC35 in the reporter 
plasmids. When an hnRNP A2/B1 expressing plasmid was cotransfected with pBspliceMCAT 
and pMt1sdCAT, plasmids containing the late region with the CAT reporter gene, part of the 
early region but only the two splice sites SD3632 and SA5639, an induction of CAT was 
observed in both reporter plasmids, suggesting that this RNA-binding factor acts on sequences 
adjacent to these two splice sites. The lower induction observed in pMt1sdCAT by hnRNP 
A2/B1 could either indicate that this splicing factor binds specifically to sequences that suppress 
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SD3632, that have been deleted in this plasmid, therefore hnRNP A2/B1 can no longer target 
them, or also can be caused by the higher levels of CAT produced by this reporter plasmids 
alone, and therefore levels of CAT could be only modestly enhanced. Further studies on hnRNP 
A2/B1 would be useful to identify specific sequences on the HPV-16 genome that this RNA-
binding factor targets. With a serial dilution of hnRNP A2/B1 higher levels of CAT were 
observed at lower concentrations of hnRNP A2/B1, whereas at higher concentrations CAT 
induction was inhibited. This could be due to low transfection efficiency, caused by the 
considerable amount of exogenous DNA and transfection reagent that can be toxic to the cells, or 
to other metabolic activity this RNA-binding factor can trigger in the cell. Recently, hnRNP 
A2/B1 has been designated as a putative proto-oncogene due to its overexpression in 
glioblastoma cells and to its role in the regulation of a number of tumor suppressors and 
oncogenes, such as c-FLIP, BIN1, Wwox and RON (Golan-Gerstl et al., 2011). Despite the fact 
that overexpression of hnRNP A2/B1 in different tumors has been reported by other researchers 
(Tockman et al., 1997; Tockman et al., 1988; Zhou et al., 1996), immunohistochemistry 
analysis, carried out in this study on cervical tissue microarrays, revealed that hnRNP A2/B1 is 
highly expressed in normal cervical tissue and low-grade squamous intraepithelial lesion (LSIL), 
whereas expression levels of this protein decreased form high-grade squamous intraepithelial 
lesion (HSIL) to squamous cell carcinoma (SCC). Our findings are in line with other studies that 
proved a down-regulation of hnRNP A2/B1 in tumors, such as the colon, thyroid, small intestine 
and kidney (Karni et al., 2007). 
Since hnRNP A2/B1 regulates and stimulates the production of late mRNAs, it would be 
expected that in the upper layers of the epithelium, where expression of HPV late genes naturally 
occurs, the levels of hnRNP A2/B1 would be high, inducing late gene expression. In this study in 
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epithelium that was infected with HPV but was histologically normal and in low-grade squamous 
intraepithelial lesion, hnRNP A2/B1 was highly expressed in the basal and intermediate layers, 
but as the cells differentiates no expression was detected. This may suggest that expression of 
HPV late genes in the upper layers of the cervical epithelium is dependent on other factors and 
regulatory steps. In high-grade lesions and tumour samples expression of hnRNP A2/B1 
radically decreased, therefore, considering that HPV-16 late genes expression is suppressed in 
cervical cancer and hnRNP A2/B1 regulates expression of late gene in HPV-16, we suppose that 
it might be a correlation with the lower expression of hnRNP A2/B1 and prevention of late gene 
expression in cervical cancer. Other components of the hnRNP family, such as hnRNP H, 
hnRNP A1 and hnRNP C1/C2, that unlike hnRNP A2/B1 inhibit late gene expression, and 
hnRNP I have been shown to be highly expressed in HSIL and SCC (Fay et al., 2009). 
It was also determined the expression of a known marker of HSIL and SCC (Carozzi, 2007; 
Hairiri & Oster, 2007; Iaconis et al., 2007), such as p16INK4a, on the same TMA, to validate the 
integrity of all tissue cores in the TMA slides and to compare their levels of expression in the 
different cases. As expected p16INK4a expression was not detected in normal cervical tissue 
cores and LSIL, but a very strong staining was observed in HSIL and SCC proving the integrity 
of the tissue cores and therefore authenticating the veracity of the immunostainings performed in 
this study.  
In conclusion, CAT and GFP genes in place of the late L1 gene in subgenomic HPV-16 plasmids 
proved to be functional surrogate markers for HPV-16 late gene expression in HeLa cells. 
Moreover functional stable cell lines useful for the identification of cellular proteins, small 
molecules or microRNAs that regulate HPV-16 gene expression were established. Three small 
molecules such as TPA, valproic acid and tannic acid positively modulated late gene expression 
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in HPV-16-derived cell lines and these substances, in particular valproic acid, could potentially 
be used as antiviral drugs to treat persistent HPV infections. Furthermore a RNA-binding factor 
was identified as a novel regulator of HPV-16 late genes expression and immunohistochemical 
analysis allowed us to detect and localize this protein in cervical epithelium at the different 
stages after HPV infection. 
Since it has been shown that the prevalence of HPV in the oropharyngeal area in men is 
increasing significantly and it is suspected that oropharyngeal squamous cell carcinoma will 
exceed cervical malignancies in women by 2020 (Chatuverdi et al., 2011; Sanders et al., 2012), 
it would be useful to speculate that the results presented in this thesis might have a major 
application in this area in the future.  
It also would be interesting to extend the experiments to other HPV types, such as HPV-6 or 
HPV-18, since they have different pathogenic proprieties and although this study focussed 
exclusively on HPV-16, the most common HPV type found in cervical cancer, the reporters 
presented herein could be easily modified to examine other HPV types and this would it be 
useful for a better understanding of the differences in the gene expression mechanism of HPVs. 
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A. Appendix I - Solution 
 
Agarose gel 
1g agarose (Invitrogen)  
100ml of TBE (Invitrogen) (appendix I) 
boil until dissolved 
let cool to 60 ºC 
add 5µl of GelRed® (Biotium) or 0.5µg/ml ethidium bromide  
mix and pour into gel template 
allow to set 
 
TBE buffer 
1000ml of 10×TBE (Invitrogen) 
mix with 9000ml of distilled water 
 
6×Loading buffer 
0.25% bromophenol blue (BDH) 
0.25% xylene cyanol (BDH) 
30% glycerol (BDH) 
 
5M NaCl 
73g Sodium Chloride (Merck) 
Diluted in 250ml of distilled water and autoclaved 
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Phenol/chloroform/isoamyl alcohol 
49 ml of phenol (Sigma) 
49ml Cloroform (Sigma-Aldich) 
2ml isoamyl alcohol (Sigma) 
Mix and freeze at -20ºC 
 
70% Ethanol 
70ml 100% ethanol (Merck) 
Made up to 100ml with distilled water  
 
1M TRIS 
121.1g Tris (BDH)  
Mix with 1000ml of distilled water and adjust pH to 7 using HCl and autoclave 
 
0.5M EDTA 
181.1g EDTA (BDH) 
Mix with 1000ml of distilled water and adjust pH to 7 using NaOH and autoclave 
 
TE buffer   
10mM Tris (appendix I) 
1mM EDTA (appendix I) 
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LB broth 
5g Tryptone (Lab M Limited) 
5g NaCl (Merck) 
2.5g Yeast extract (Lab M Limited) 
Mix with 500ml distilled water and autoclave 
 
 
0.1M CaCl2 
5.5g CaCl2 (Riedel-de Haën) 
Mix with 250ml distilled water and autoclave  
 
SOC medium 
4g Bacto-tryptone (Lab M Limited) 
1g Yeast extracts (Lab M Limited) 
0,1g NaCl (Merck) 
Mix with 200ml of distilled water and shake it until dissolved  
5ml 1M KCl  
Bring the volume up to 200ml adjust pH to 7 using 10M NaOH (appendix I) 
4ml 1M glucose solution 
 
100mg/ml Ampicillin 
100mg ampicillin (Sigma) 
Mix with 1ml sterile water, filter the solution and freeze at -20ºC 
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LB Agar 
3g Tryptone (Lab M Limited) 
3g NaCl (Merck) 
1.5g yeast extracts (Lab M Limited) 
4.5g Agar (Lab M Limited) 
Mix with 300ml of distilled water and autoclave 
Let cool to 55ºC and add 150µl ampicillin(100mg/ml) 
Pour into Petri dishes and let set  
 
Alkaline Lysis Solution I  
25mM Tris pH8  
10mM EDTA  
50mM Glucose 
 
SDS 10% 
10g SDS (BHD) 
Make up to 100ml with distilled water 
 
10M NaOH 
40g NaOH 
Make up to 100ml in a volumetric flask 
 
 
 243 
Solution II 
1ml 10% SDS (appendix I) 
0.2ml 10M NaOH (appendix I) 
Mix with 8.8ml distilled water (make fresh) 
 
Alkaline Lysis solution III 
60ml 5M potassium acetate 
28.5ml distilled water 
Mix and autoclave then add 
11.5ml glacial acetic acid 
 
TE buffer containing RNase A 
1ml TE buffer 
1µl RNase(22µg/µl) (Sigma)  
Vortex and centrifuge for 3sec at maximum speed three times 
 
Phosphate Buffered Saline (PBS) 
1 PBS tablet (Oxoid) for every 100ml distilled water and autoclave 
 
2.5%Trypsin 
50ml trypsin (invitrogen) 
1 bottle (500ml) Eare’s balance salt (sigma) 
 
 244 
0.02% EDTA in PBS 
7,4g EDTA (BDH) 
Make up to 1 litre with PBS in a volumetric flask 
 
Trypsin with EDTA 
10ml 2.5% Trypsin (appendix I) 
10ml 0.02% EDTA (appendix I) 
Mix by inverting 
 
Sodium phosphate buffer 
68,4ml disodium hydrogen phosphate (Na2HPO4) (141.96g Na2HPO4(BDH) in 1 litre distilled 
water) 
 
2× assay β-galactoside buffer 
1ml IM MgCl2 (appendix I) 
10ml 1M sodium phosphate buffer pH 7.2 (appendix I) 
350µl β-mercaptoethanol (Fluka) 
66.5mg ortho-Nitrophenyl-β-galactoside (ONPG) (sigma) 
Make up to 50ml with distilled water in a volumetric flask  
 
Cell lysis solution  
25mM EDTA  
2% SDS 
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Protein precipitation solution 
10M ammonium acetate 
 
1M Sodium carbonate  
10.5g sodium carbonate (BDH) 
Make up to 100ml distilled water in a volumetric flask  
 
2M Magnesium chloride 
190,4g magnesium (BDH) 
Make up to 1 litre with distilled water in a volumetric flask 
 
0,5M ZnCl2 
68,14g ZnCl2 (Sigma-Aldrich) 
Make up to 1 litre with distilled water in a volumetric flask 
 
2M Diethanolamine 
20ml 9,5M Diethanolamine 
Make up to 100ml with distilled water in a volumetric flask 
 
15% CHAPS 
0.15g CHAPS (Sigma) 
1ml of PBS (appendix I) 
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0,05% CHAPS 
33µl 15% CHAPS (appendixI) 
9.67ml PBS (appendix I) 
 
Coloring substrate 
20ml 2M diethanolamine 
20µl 0,5M ZnCl2 
10µl 2M MgCl2 
Mix and add 1 tablet of 4-nitrophenyl phosphate disodium salt hexahydrate (Sigma-Aldrich) 
 
0.01mol/l Citrate Buffer (pH 6) 
2.1g citric acid 
add approximately 800ml distilled water 
adjust pH to pH 6 using 2mol/l NaOH (79.98g NaOH in 1 litre) 
Make solution up to 1 litre in a volumetric flask 
 
12% polyacrylamide gel 
6.6 ml    H2O                           
5.2 ml    polyacrylamide buffer   (appendix I)            
8 ml      30% Acrylamide (29:1)        
180 µl 10% APS (appendix I) 
40 µl Temed                      
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5% polyacrylamide gel 
2.1 ml H2O                            
0.9 ml Upper buffer (appendix I) 
0.55 ml 30% Acrylamide (29:1)        
40 µl 10% APS                           
4 µl Temed                      
 
10% APS 
0.04g APS  
400µl H2O 
 
Lower buffer 
9.08g   Tris 
0.4% SDS  
Bring the volume up to 50ml H2O and adjust pH to pH 8.8 
 
Upper buffer 
3.03g Tris 
0.4% SDS  
Bring the volume up to 50ml H2O adjust pH to pH 6.8    
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Running buffer  
15g Tris  
72g glycine  
5g SDS   
Bring the volume up to 500ml H2O 
 
Transfer buffer  
6g Tris 
28.82g glycine  
Bring the volume up to 200ml H2O and adjust pH to pH 8.3    
 
10XTBS  
12.1g Tris    
43.8g NaCl    
Bring the volume up to 500ml H2O  
 
5% milk 
5g milk  
100ml H2O (store 4°C)  
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TBS TWEEN 
1/10 TBS  
0.1% Tween  
Make 1L H2O  
 
Laemmli 2X buffer  
4% SDS  
10% 2-mercaptoehtanol  
20% glycerol  
0.004% bromophenol blue  
0.125 M Tris HCl 
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Human poliovirus 2 strain MEF-1 polyprotein gene, complete cds 
Length=7440 
 
 Score = 1308 bits (708),  Expect = 0.0 
 Identities = 718/723 (99%), Gaps = 0/723 (0%) 
 Strand=Plus/Plus 
 
Query  237  TTAAAACAGCTCTGGGGTTGTACCCACCCCAGAGGCCCACGTGGCGGCTAGTACTCCGGT  296 
            ||||||||||||||||||||| |||||||||||||||||||||||||| ||||| | ||| 
Sbjct  1    TTAAAACAGCTCTGGGGTTGTTCCCACCCCAGAGGCCCACGTGGCGGCCAGTACACTGGT  60 
 
Query  297  ATTGCGGTACCTTTGTACGCCTGTTTTATACTCCCTTCCCCCGTAACTTAGAAGCACAAT  356 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   ATTGCGGTACCTTTGTACGCCTGTTTTATACTCCCTTCCCCCGTAACTTAGAAGCACAAT  120 
 
Query  357  GTCCAAGTTCAATAGGAGGGGGTACAAACCAGTACCACCACGAACAAGCACTTCTGTTCC  416 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  GTCCAAGTTCAATAGGAGGGGGTACAAACCAGTACCACCACGAACAAGCACTTCTGTTCC  180 
 
Query  417  CCCGGTGAGGCTGTATAGGCTGTTTCCACGGCTAAAAGCGGCTGATCCGTTATCCGCTCA  476 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  CCCGGTGAGGCTGTATAGGCTGTTTCCACGGCTAAAAGCGGCTGATCCGTTATCCGCTCA  240 
 
Query  477  TGTACTTCGAGAAGCCTAGTATCACCTTGGAATCTTCGATGCGTTGCGCTCAACACTCAA  536 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  TGTACTTCGAGAAGCCTAGTATCACCTTGGAATCTTCGATGCGTTGCGCTCAACACTCAA  300 
 
Query  537  CCCCAGAGTGTAGCTTAGGTCGATGAGTCTGGACGTTCCTCACCGGCGACGGTGGTCCAG  596 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  CCCCAGAGTGTAGCTTAGGTCGATGAGTCTGGACGTTCCTCACCGGCGACGGTGGTCCAG  360 
 
Query  597  GCTGCGTTGGCGGCCTACCTGTGGCCCAAAGCCACAGGACGCTAGTTGTGAACAAGGTGT  656 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  GCTGCGTTGGCGGCCTACCTGTGGCCCAAAGCCACAGGACGCTAGTTGTGAACAAGGTGT  420 
 
Query  657  GAAGAGCCTATTGAGCTACCTGAGAGTCCTCCGGCCCCTGAATGCGGCTAATCCTAACCA  716 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  GAAGAGCCTATTGAGCTACCTGAGAGTCCTCCGGCCCCTGAATGCGGCTAATCCTAACCA  480 
 
Query  717  CGGAGCAGGCAGTGGCAATCCAGCGACCAGCCTGTCGTAACGCGCAAGTTCGTGGCGGAA  776 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  481  CGGAGCAGGCAGTGGCAATCCAGCGACCAGCCTGTCGTAACGCGCAAGTTCGTGGCGGAA  540 
 
Query  777  CCGACTACTTTGGGTGTCCGTGTTTCCTTTTATTTTTACAATGGCTGCTTATGGTGACAA  836 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  541  CCGACTACTTTGGGTGTCCGTGTTTCCTTTTATTTTTACAATGGCTGCTTATGGTGACAA  600 
 
Query  837  TCATTGATTGTTATCATAAAGCAAATTGGATTGGCCATCCGGTGAGAATTTGATTATTAA  896 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  601  TCATTGATTGTTATCATAAAGCAAATTGGATTGGCCATCCGGTGAGAATTTGATTATTAA  660 
 
Query  897  ATTACTCTCTTGTTGGGATTGCTCCTTTGAAATCTTGTGCACTCACACCTATTGGAATTA  956 
            |||||||||||||||||||||||||||||||||| ||||||||||||||||||||||||| 
Sbjct  661  ATTACTCTCTTGTTGGGATTGCTCCTTTGAAATCCTGTGCACTCACACCTATTGGAATTA  720 
 
Query  957  CCT  959 
            ||| 
Sbjct  721  CCT  723 
 
 
 251 
Publications  
 
Orrù B, Cunniffe C, Ryan F, Schwartz S. 
Development and validation of a novel reporter assay for human papillomavirus type 16 late 
gene expression. 
In Press Journal of Virological Methods 2012. 
 
Somberg M, Li X, Johansson C, Orrù B, Chang R, Rush M, Fay J, Ryan F, Schwartz S. 
Serine/arginine-rich protein 30c activates human papillomavirus type 16 L1 mRNA expression 
via a bimodal mechanism. 
J Gen Virol 2011 October; 92: 2411-21. 
 
Orrù B, Schwartz S, Ryan F. 
Novel factors involved in regulation of HPV-16 late gene expression.  
27th International Papillomavirus Conference, Berlin, Germany, September 17-22, 2011. 
 
Li X, Orrù B, Somberg M, Ryan F, Schwartz S.  
RNA element supresses HPV-16 splice site SD3632. 
27th International Papillomavirus Conference, Berlin, Germany, September 17-22, 2011.  
 
Orrù B, Ryan F, Schwartz S.  
Factors influencing HPV-16 late gene expression. 
26th International Papillomavirus Conference, Montreal, Canada, July 3-8, 2010.  
 
Li X, Orrù B, Somberg M, Ryan F, Schwartz S.  
Identification of inhibitory sequences upstream of SD3632 in the HPV-16 genome. 
26th International Papillomavirus Conference, Montreal, Canada, July 3-8, 2010.  
 
Somberg M, Li X, Orrù B, Ryan F, Schwartz S. 
Enhancement of HPV-16 early mRNA splicing by ASF/SF2 is antagonised by SRp30c, a 
specific inducer of L1 mRNA production. 
26th International Papillomavirus Conference, Montreal, Canada, July 3-8, 2010.  
 
 252 
Li X, Orrù B, Somberg M, Ryan F, Schwartz S. 
Upstream sequences suppress HPV-16 late 5’-splice site SD3632. 
Molecular Biology of DNA tumor Viruses Conference, Madison, Wisconsin, USA, July 13-18, 
2010. 
 
Orrù B, Ryan F, Schwartz S.  
A reporter assay for analysis of HPV-16 late gene expression. 
4th European Congress of Virology, Lake Como, Italy, April 7-11, 2010. 
 
Schwartz S, Somberg M, Johansson C, Orrù B, Ryan F, Li X.   
ASF/SF2 regulates HPV-16 early and late mRNA splicing.  
5th Smögen Summer Symposium on Virology, Sweden, August 20-22, 2009. 
 
